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ABSTRACT
Prion diseases are neurodegenerative disorders affecting both animals and humans. They may 
be sporadic, infectious or genetic in origin. Variant CJD (vCJD) is a novel form of human 
prion disease, experimentally proven to be acquired from the consumption o f bovine prion- 
infected material. The causative transmissible agent o f prion disease is thought to consist 
predominantly o f an abnormal isoform o f the host-encoded prion protein (PrP( ), designated 
PrPs\  To date, most prion research has been undertaken in animal models since transmitting 
the disease in cell culture has proved difficult. Nevertheless, a number o f prion-propagating 
mammalian cell lines do exist but despite world-wide effort, no cell lines have shown 
susceptibility to human prion infection. The aim o f this thesis was to develop a cell line that 
stably propagated vCJD prions.
First, a high-throughput screening methodology for detection o f human prions in cells was 
established. This involved subcloning o f vCJD prion-infected cell lines, in order to isolate a 
rare susceptible clone, followed by detection o f PrP^ using the scrapie cell assay or cell blot 
assay. A panel o f cell lines was selected to best mimic in vivo disease and screened for 
susceptibility to vCJD prion infection, but mammalian neuroblastoma, neuroglial, and 
epithelial cell lines were unable to stably propagate human prions. Transient vCJD prion 
propagation (between one and six passages) was observed in two human neuroblastoma lines 
(SKN-SH and SHSY5Y) and a rabbit epithelial kidney line (RK13) overexpressing human 
PrPc. Attempts to prolong prion propagation in a human neuroblastoma cell line with retroviral 
infection, to mimic the intercellular spread o f prions via exosomes, were unsuccessful. The 
second approach involved the humanisation o f a mouse prion-propagating cell line, N2a. To 
eliminate dominant-negative inhibition o f human prion propagation by murine PrPc, the 
endogenous PrPc was knocked-out using RNAi technology. Greater than 90% murine PrPc 
knockout was achieved in several N2a-derived lines and exogenous expression of mouse PrPc 
demonstrated that these cells were still susceptible to mouse prion infection. Human PrPc was 
subsequently expressed in these murine PrPc knockout lines to various levels. Following 
infection with vCJD prions, no long-term vCJD prion propagation was observed in these lines. 
A single murine PrPc knockout line overexpressing human PrP1 (two-fold) transiently 
propagated vCJD prions but this was not stable. The third approach used a v-myc immortalised 
human foetal neural stem cell (NSC) line derived from human ventral mesencephalon 
(ReNcell 197VM). These undifferentiated 197 cells were resistant to vCJD prion infection. 
Upon differentiation, the 197 cultures acquired a neuronal phenotype. Infection with a purified 
vCJD prion-infected brain homogenate yielded propagation o f vCJD prions in these 
differentiated human neurons for >40 days in vitro. This work has improved understanding of 
the complex factors underlying cellular susceptibility to prion infection. The primary human
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neuronal model will be invaluable for the study o f the pathophysiology o f human prion 
disease.
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DNA deoxyribose nucleic acid
DND Department o f Neurodegenerative Disease, UCL
dNTP deoxynucleotide triphosphates
ECACC European Collection of Cell Cultures
ECL enhanced chemiluminescence
EDTA ethylene diamine tetra-acetic acid
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EGF epidermal growth factor
ELISA enzyme-linked immunosorbant assay
ER endoplasmic reticulum
ERAD ER-associated degradation (of proteins)
FBS fetal bovine serum
FGF fibroblast growth factor
FITC fluoroscein isothiocyanate
g gram
GABA gamma-aminobutyric acid
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GPI glycophosphatidylinositol
h hour(s)
HBSS Hank’s Balanced Salt Solution
HIV Human immunodeficiency virus
HRP horseradish peroxidase
HSC haemopoietic stem cell
iCJD iatrogenic CJD
IFN interferon
Ig immunoglobulin
kb kilobase
kDa kilodalton
KO knockout
L or 1 litre
log logarithm to base 10
M molar
m metre
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MM homozygous at codon 129 PRNP for methionine
mRNA messenger ribonucleic acid
MuLV Moloney murine leukaemia vims
MV heterozygous at codon 129 PRNP for methionine and valine
MW molecular weight
NGF nerve growth factor
NGS normal goat serum
NMR nuclear magnetic resonance
NSC neural stem cell
Nt nucleotide
OD optical density
ORF open reading frame
P probability
p- phospho-
PAGF polyacrylamide gel electrophoresis
PBS phospho-buffered saline
PCR polymerase chain reaction
PFA paraformaldehyde
pH hydrogen ion concentration
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PMSF phenylmethylsulphonyl fluoride
PNS peripheral nervous system
PrP prion protein
PrPc cellular prion protein
PrPSc disease-associated prion protein
PRNP gene encoding human prion protein
Prnp gene encoding mouse prion protein
PVDF polyvinylidene difluoride
qRT-PCR quantitative real-time PCR
RML Rocky Mountain Laboratory (mouse-adapted scrapie prion strain)
RNA ribonucleic acid
ref relative centrifugal force
RNAi RNA interference
rpm revolutions per minute
RT room temperature
SCA scrapie cell assay
sCJD sporadic Creutzfeldt-Jakob disease
SD standard deviation
SDS sodium dodecyl sulphate
sec second(s)
SEM standard error o f the mean
STI1 stress-inducible protein-1
TAB Tropix assay buffer
TME transmissible mink encepahlopathy
TSE transmissible spongiform encephalopathy
UCL University College London
UTR untranslated region
V volts
vCJD variant Creutzfeldt-Jakob disease
v/v volume/volume
w/v weight/volume
prefixes
k- kilo
m- milli-
M- micro-
n- nano-
P- pico
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1 Introduction
Prion diseases or transmissible spongiform encephalopathies (TSEs) are fatal, currently incurable 
neurodegenerative conditions affecting both humans and animals. Although these diseases are 
rare, they have attracted much attention due to the unique biology o f the transmissible agent. The 
transmissible agent, designated the prion (PrPSc), is unlike other infectious pathogens since it is 
composed either exclusively or principally o f proteinacious material devoid o f nucleic acid. The 
prion is believed to be a conformational isomer o f the host-encoded prion protein (PrPc), and is 
self-propagating. Neuropathological hallmarks shared by these diseases are spongiform 
vacuolation o f cerebral grey matter, neuronal loss, astrocytic proliferation and often, amyloid 
deposition o f disease-associated prion protein (PrP80). The diseases are characterised clinically by 
long incubation times and a combination o f dementia and neurological symptoms.
1.1 Prion diseases in animals
1.1.1 Scrapie
Scrapie is the prototypic animal prion disease, which naturally affects both sheep and goats. It was 
first described in the UK over 250 years ago but is now present worldwide (with the exception o f 
Australasia). In the 18th and 19th centuries, scrapie was suspected to be hereditary because o f a 
strong genetic element to the disease, for example, scrapie affects only certain breeds (Parry, 
1979). However, the contagious nature o f scrapie was first demonstrated experimentally by 
inoculation into goats (Cuille and Chelle, 1936). Since then it has been experimentally transmitted 
to other species, including mice (Chandler, 1961). The mode o f natural transmission is thought to 
be lateral, perhaps via shedding in faeces and saliva (Ryder et al., 2004).
Scrapie derives its name from one o f the main symptoms, pruritis or itching, which causes animals 
to scrape themselves against objects leading to wool loss and skin damage. Additional early 
symptoms include excitability and apprehension. As the disease progresses, the animals develop 
gait disorders, tremor o f the head and neck and eventual prostration. Death usually occurs six 
weeks to six months after symptom onset.
1.1.2 Transmissible mink encephalopathy
Transmissible mink encephalopathy (TME) was first detected in farmed mink at a ranch in 
Winsconsin in 1947. This outbreak was attributed to a BSE-contaminated food source but it can 
also occur as a result o f scrapie-infected feed (Marsh et al., 1991). The disease has been observed 
in the US, Canada, Russia, Finland and Germany. Symptoms include aggression, loss o f muscle
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coordination and increased tendency to bite. The disease course is rapid, lasting at most six weeks 
before death.
1.13 Chronic wasting disease
Chronic wasting disease (CWD) was first recognised as a clinical syndrome in elk, mule deer and 
white-tail deer in the 1960s. It affects both captive and wild cervid populations across North 
America and Canada and, like scrapie, transmission is thought to be lateral, through saliva and 
blood (M iller and Williams, 2003;Mathiason et al., 2006). Symptoms include weight loss, 
somnolence and excessive drinking (polydypsia). The disease course ranges from days to months. 
Despite considerable concern in the USA and Canada, there is no current evidence o f transmission 
to humans.
1.1.4 Bovine spongiform encephalopathy
The most notorious TSE to emerge to date is bovine spongiform encephalopathy (BSE) or “ mad 
cow disease” . It was probably present in the UK cattle population in the 1970s and early 1980s, 
however, due to long incubation times o f prion disease, the first case was not recognised until 
November 1986. This marked the onset o f an epidemic that devastated the British cattle industry, 
with an estimated one million cows affected (Anderson et al., 1996). The BSE epidemic peaked in 
1992 when 850 cattle were being diagnosed every week; currently (2007) fewer than 4 cattle a 
week are affected by BSE (http://www.BSE review.org.uk). The origin o f BSE remains elusive but 
two theories have been proposed. (1) It arose from the consumption by cattle o f scrapie-infected 
sheep carcasses, though this is unlikely because scrapie and BSE are caused by different prion 
strains (Bruce et al., 1994) or (2) from sporadic BSE as a result o f a stochastic conformational 
change in the bovine prion protein (Weissmann and Aguzzi, 1997). The epidemic was sustained by 
use o f meat and bone meal (MBM) from BSE-infected cattle in their feed. The reason the BSE 
epidemic was confined to the UK may be due to changes in farming practices between 1970 and 
1988. A reduction in solvent concentration was used in the rendering process, which may have 
lead to increased infectivity in MBM. Furthermore, artificially-reared dairy calves were fed MBM 
at a particularly susceptible age; 1-2 weeks (Wilesmith et al., 1988). The epidemic was halted by 
implementation o f stringent control measures in 1988. Affected and at-risk herds were culled on a 
huge scale and a ban preventing the feeding o f ruminant-derived proteins back to ruminants was 
introduced. Since its description in the UK, BSE has been reported in cattle throughout Europe, in 
the US, Canada, Israel and Japan (http://www.BSE review.org.uk).
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1.1.5 Feline and ungulate spongiform encephalopathy
The emergence o f feline spongiform encephalopathy (FSE) in cats, spongiform encephalopathies 
o f exotic ungulates (including nyala and oryx) at zoological parks (Bruce et al., 1994) and new 
variant CJD in humans (Collinge and Rossor, 1996;Bruce et al., 1997;Hill et al., 1997a) has been 
attributed to BSE. The ability o f the BSE prion strain to transmit to several different species has 
identified it as a highly promiscuous prion strain.
1.2 Human prion diseases
Human prion diseases are rare disorders with an incidence o f approximately 1-2 per million 
worldwide per annum, with an equal incidence o f disease in men and women. They have the 
unique characteristic o f being inheritable, sporadic or acquired in origin, and all are transmissible. 
The most common human prion disease is Creutzfeldt-Jakob disease (CJD), named after the two 
doctors who independently first described the disorder; Creutzfeldt in 1920 and Jakob in 1921. 
The disease is characterised clinically by a rapid onset neurological degeneration causing chronic 
decline in motor and cognitive function. Definitive diagnosis o f prion disease across species can 
be made from post-mortem examination o f brain tissue showing spongiform degeneration o f the 
grey matter (resulting from neuronal vacuolation and loss), gliosis and absence o f an immune 
reaction. Although it is by no means a constant feature, some prion diseases including kuru and 
GSS, are characterised by deposition o f amyloid plaques composed o f insoluble aggregates o f the 
disease-associated prion protein, PrP80. Fatal familial insomnia (FFI) is characterised 
neuropathologically by the absence o f PrPSc plaque deposition (Collinge et al., 1995b). The human 
PrP gene (PRNP) exists in two major allelic forms that encode either methionine or valine. There 
is marked genetic susceptibility for the development o f human prion disease at this polymorphic 
codon 129 o f the prion protein. The majority o f human prion disease cases are homozygous for 
either methionine (129MM) or valine (129VV), which occur in 37% and 12% o f the Caucasian 
population, respectively (Owen et al., 1990). Codon 129 heterozygotes (129MV), which make up 
51% o f the Caucasian population, are relatively protected from protecting prion disease (Palmer et 
al., 1991 ;Collinge et al., 1991;Windl et al., 1996). The susceptibility o f methionine homozygotes 
may be explained by increased propensity o f PrP to form PrPSc-like structures in vitro (Tahiri- 
Alaoui et al., 2004). Codon 129 heterozygosity is thought to confer resistance to prion disease by 
inhibiting homologous prion protein-protein interactions (Palmer et al., 1991).
1.2.1 Sporadic prion disease
85% o f human prion diseases are sporadic in origin. The most common is sporadic CJD (sCJD), o f 
which there are 50-60 cases in the UK every year. The cause o f sCJD is unknown but the theory
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favours a spontaneous change in PrP structure or a somatic PRNP mutation that leads to 
production o f the abnormal form o f the prion protein. It remains possible, but less likely, that sCJD 
is an acquired illness due to unidentified environmental prion protein exposure, since two case- 
control studies have reported prior surgery as a risk factor for sCJD (Collins et al., 1999;Ward et 
al., 2002). The disease affects adults mostly commonly aged between 45 to 75 years, with the 
median age o f death being 67 years (W ill RG et al., 2004). The majority o f cases follow a 
relatively uniform and aggressive course. Patients present with a rapidly progressive dementia, 
accompanied by symptoms including myoclonus, cerebellar ataxia and cortical blindness. Median 
duration o f illness is 4 months. The disease culminates in an akinetic mute state and death is 
typically caused by a pulmonary or systemic infection.
1.2.2 Inherited Prion Disease
10-15% o f human prion diseases are Mendelian autosomal dominantly inherited conditions with 
high penetrance, which cause five deaths in the UK per year. Inherited prion diseases are 
associated with mutations in the gene encoding the prion protein, PRNP, o f which more than thirty 
have been described (figure 1.1) leading to a wide range o f clinical syndromes between and within 
kindreds (Collinge, 2001). The fact that a single PRNP mutation can elicit different disease 
phenotypes underscores the importance o f factors additional to the prion protein sequence in prion 
disease pathogenesis, such as environmental and epigenetic factors. Pre-symptomatic genetic 
diagnosis o f inherited prion disease is possible from DNA sequencing o f PRNP from blood 
samples.
Inherited prion disease includes syndromes such as fatal familial insomnia (FFI), a rare disorder 
observed in several Italian kindreds (Medori et al., 1992). It is caused by the substitution o f 
asparagine with an aspartate residue at codon 178 o f the prion protein (D178N). The disease 
affects adults from 30-50 years o f age. It causes focal neuronal degeneration in the thalamus 
resulting in progressive insomnia, panic attacks, hallucinations, weight loss, dementia, and 
eventually ending in an akinetic mute state over the course o f seven months to three years. The 
most common cause o f inherited prion disease is a PRNP point mutation at codon 200, which 
results in the substitution o f glutamate (E) with lysine (K) (Kahana and Zilber, 1991). This E200K 
PRNP mutation has been identified in families from Slovakia (Goldfarb et al., 1990), Chile 
(Goldfarb et al., 1991) and the US (Bertoni et al., 1992). The high incidence o f CJD in a group o f 
Israeli Jews o f Libyan origin was mistakenly attributed to the consumption o f lightly cooked sheep 
brain and eyeballs until the E200K mutation was eventually identified (Kahana et al., 1974).
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Polymorphic variants
OPRI octapeptide repeat insertion 
OPRD octapeptide repeat deletion
Ml 29V
G124G
' V  P68P
P105L
P105T
G142S N171S
V161V
A117V 
G114V B131V
H177H
Q160Stop
R148H
Y145Stop
OPRI pioa
D178N 
V I801
T183A
H187R/
Pathogenic mutations
R228R
Q212Q 
E219K S230S
Q217R
Q212P
E211Q
253aa
P238S
V210I
\
M232T
M232R
R208H
V203I
D202N 
E200K
F198S 
E196K
Figure 1.1 Pathogenic mutations and polymorphic variants of human PrP
Definite or suspected pathogenic mutations are shown below the representation of the prion 
protein. Neutral (green) and disease modifying/susceptibility (blue) polymorphisms are shown 
above. Figure modified from Mead, 2006.
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1.23 Acquired prion diseases
1.23.1 Kuru
Kum represents the largest group o f acquired human prion diseases. It emerged in about 1920 in 
the Fore linguistic tribe in the East Highlands o f Papua New Guinea as a result o f endocannibalism 
(Mead et al., 2003). Kuru derives its name from the Fore word for trembling. The turn o f the 20th 
century saw the introduction o f a feasting mourning ritual in which deceased tribe members were 
eaten as a sign o f respect by their relatives. Kuru is thought to have originated when an individual 
who had developed sCJD was consumed at one o f these feasts. Kuru victims who had died quickly 
were regarded as a delicacy because they carried a layer o f fat that resembled pork. By the 1950s, 
kum had reached epidemic proportions, killing 1% o f the population annually, and in total the 
epidemic (1954-2004) killed over 2700 o f the 36,000-strong tribal population. Eight times as many 
women as men contracted the disease due to selective female exposure; the maternal kin were 
responsible for preparing meat from the corpses and were the main participants in the mortuary 
feasts (Lindenbaum, 1979). The Australian government enforced a ban on cannibalistic practices 
in the East highlands o f Papua New Guinea in the late 1950s, which led to the decline in kuru 
incidence, with no cases o f kuru reported in the subsequent generation (observation reported in 
(Lindenbaum, 1979).
Kum is a cerebellar syndrome progressing through several clinical stages, involving ataxia, 
dysarthria and dementia in terminal stages with a mean clinical duration o f 12 months (Alpers, 
1987). Neuropathologically, the disease is characterised by kuru-like plaques in the brain, which 
are PrP^-positive plaques with a dark eosiniphilic centre and pale periphery. The mean incubation 
period o f kuru is estimated to be 12 years (Collinge, 1999). However, in the most susceptible 
genotype (codon 129 MM), the shortest disease incubation time estimates were between 4 and 5 
years (Collinge et al., 2006), and disease onset was estimated to occur 11 years earlier than in 
heterozygotes (Cervenakova et al., 1999). Some individuals o f the most resistant genotype (codon 
129 MV) exhibited incubation times o f over 50 years (Collinge et al., 2006). Kum is the only 
known example o f a major human prion disease epidemic and therefore serves as an important 
model on which to study acquired human prion disease (see vCJD section -1.2.3.3),
The kum epidemic has had a strong genetic effect on the present-day Fore population, essentially 
eliminating PRNP codon 129 homozygotes (who are most susceptible to prion disease). A study o f 
surviving elderly Fore women (over the age o f 50), found that PRNP codon 129 heterozygotes
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were more common in those who had attended multiple mortuary feasts than those who remained 
unexposed to kuru (Mead et al., 2003). Since heterozygosity at the codon 129 polymorphism in 
PRNP confers resistance to prion disease, there was selection pressure in favour o f these alleles in 
the Fore tribe. Studies o f global haplotype diversity and allele frequency o f coding and non-coding 
polymorphisms o f PRNP (in which there is more variability than expected because o f heterozygote 
advantage) suggest balancing selection pressure at this locus may have been imposed by several 
prion disease epidemics in human prehistory (King et al., 2003).
1.23.2 Iatrogenic CJD
Iatrogenic CJD (iCJD) arises when human prion disease, o f any form, is transmitted from one 
person to another accidentally by medical or surgical intervention. The infectious nature o f CJD 
and kuru was confirmed in the 1960s when both were transmitted experimentally to chimpanzees 
(Gajdusek et al., 1966;Gibbs, Jr. et al., 1968). Over 200 cases o f iCJD have been reported to date, 
most commonly following dura mater implants and human growth hormone injections. Other 
sources o f infection include contaminated human cadaveric comeal transplants and gonadotrophin 
injections. Prions are not inactivated by normal hospital sterilisation procedures, therefore 
inadequately sterilised surgical and medical equipment, such as intracerebral EEG electrodes, can 
also cause iCJD (Brown et al., 2000). Preventative measures include use o f recombinant growth 
hormone and incineration o f surgical instruments from confirmed CJD patients.
1.233 Variant CJD
The most recent TSE to be described is variant CJD (vCJD): a novel clinicopathological form o f 
CJD that emerged in the UK in 1996 as a result o f dietary exposure to BSE (W ill et al., 1996). To 
date there have been 158 deaths from vCJD in the UK, and nearly 30 cases identified overseas, 
including France, USA and Spain (http://www.cjd.ed.ac.uk/figures.htm: March 2007).
The age o f onset o f vCJD varies considerably from 12-74 years and notably affects young 
individuals. The typical presenting symptoms are psychiatric or behavioural in nature, often 
involving depression, social withdrawal and anxiety. Painful sensory symptoms may also be 
present, possibly as a result o f thalamic damage. Cognitive impairment, ataxia and myoclonus, 
often early symptoms in classical CJD, occur towards the later stages o f the disease. Like sCJD the 
disease terminates with an akinetic mute state. Mean survival is 13.5 months, longer than for 
sCJD, and median age o f death is 28.5 years.
Distinguishing neuropathological features o f vCJD are spongiform degeneration, predominantly in 
the basal ganglia and cerebellum, and concentrated PrP510 accumulation in so-called “ florid
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plaques”  (W ill et al., 1996). The florid plaques o f vCJD are similar to dense PrP^-positive kuru 
plaques but they are surrounded by vacuolated tissue (figure 1.2). Unlike other human prion 
diseases, PrP80 can be also detected outside the CNS, most notably in lymphoreticular tissue 
(tonsils, spleen and lymph nodes etc.), but also in ocular tissue and skeletal muscle (Wadsworth et 
al., 2001;Peden et al., 2006). vCJD has also recently been transmitted from human rectal tissue to 
transgenic mice (Wadsworth et al., 2006).
Several lines o f evidence support the fact that vCJD is caused by dietary exposure o f humans to 
BSE. First, epidemiological data demonstrate that those affected by vCJD were resident in the UK 
during the BSE epidemic (W ill et al., 1996;Collinge and Rossor, 1996). Second, transmission 
studies in both humanised transgenic and wild-type mice showed a close correlation in disease 
pathology between vCJD and BSE (Bruce et al., 1997;Hill et al., 1997a). Third, molecular strain 
typing analysis o f the disease-associated prion protein, which involves assessment o f SDS-PAGE 
migration patterns o f PrP following protease digestion (see section 1.5.3.1), demonstrated that 
vCJD prions are a distinct strain o f prion compared to other forms o f CJD; type 1-3 (figure 13). 
The novel vCJD prion strain was designated type 4 and exhibited the same SDS-PAGE signature 
as BSE; with the majority o f PrP being glycosylated at two sites (Collinge et al., 1996). Premortem 
diagnosis o f vCJD is determined from tonsil biopsy by the presence o f type 4 PrPSc on immunoblot 
(H ill et al., 1999).
The incidence o f vCJD remains low and appears to be in decline following control o f the BSE 
epidemic and BSE-infected foodstuff entering the human food chain. The number o f deaths per 
year peaked at 28 in 2000 and fell to 5 in 2005. However, basing estimations o f the eventual size 
o f a vCJD epidemic on the number o f current cases may be misleading for several reasons. First, 
almost all individuals who have developed vCJD to date are o f the most susceptible genotype; 
methionine homozygous at codon 129 o f PRNP (Collinge, 2005). Evidence derived from iCJD 
cases (Huillard d'Aignaux et al., 1999), the kuru epidemic (Collinge et al., 2006) and humanised 
transgenic mice (Poulter et al., 1992;Lloyd et al., 2002) indicates BSE may transmit to other PRNP 
codon 129 genotypes (MV and VV), albeit with longer incubation periods. The mean incubation 
period for human-to-human prion transmission, based on kuru and iatrogenic CJD data, is 
estimated to be around 12 years (Brown et al., 1992;Collinge, 1999). Since human infection with 
BSE prions involves a species barrier (see section 1.5.4), one would expect an increased mean and 
range o f incubation period for vCJD. Based on a three-fold increase in incubation period
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sporadic CJD brain
vCJD brain
Figure 1.2 PrPSc deposition in vCJD and sCJD patient brains
Brains from patients with sCJD and vCJD show abnormal PrP immunoreactivity following 
immunohistochemistry using anti-PrP monoclonal antibody. Top panel: abnormal PrP deposition 
in sCJD most commonly presents as diffuse synaptic staining. Bottom panel: vCJD brain is 
distinguished by the presence of PrP “florid plaques” consisting of a round amyloid core of PrP 
surrounded by a ring of spongiform vacuoles. Scale bar: 50 pm. Figure courtesy of Dr 
J. Wadsworth, MRC Prion Unit
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between cows and mice, a mean vCJD incubation period o f 30 years has been suggested, with a 
maximum incubation period approaching a normal human lifespan (Collinge, 1999). Second, there 
is suggestion from murine strain typing studies that BSE may also transmit as sCJD in humans o f 
129MM PRNP genotype (Asante et al., 2002). Third, secondary iatrogenic transmission o f vCJD 
is o f serious concern because asymptomatic vCJD carriers have been detected within the UK 
population. Studies in transgenic mice suggest vCJD may transmit relatively easily to humans 
because o f the substantially reduced species barrier (Bishop et al., 2006). Already three probable 
cases o f vCJD transmission via blood transfusion have been reported (Llewelyn et al., 2004;Peden 
et al., 2004;Wroe et al., 2006). A recent anonymised study o f human lymphoid tissue (from 
appendicectomy and tonsillectomy) suggested that vCJD was present at a prevalence o f 237 per 
million in the UK population (Hilton et al., 2004). Though it is unclear i f  these individuals w ill 
develop vCJD, they pose a risk for secondary transmission through blood products, surgical and 
medical instruments. Finally, in addition to the prion gene, several other genetic loci have been 
mapped, which affect prion disease incubation times in inbred mouse lines expressing the same 
Prnp allele (Stephenson et al., 2000;Lloyd et al., 2001 ;Asante et al., 2002). Human homologues o f 
these unidentified disease-modifying loci could be important in human susceptibility to prion 
disease. It may be that the most genetically susceptible individuals (those with short incubation 
time alleles and PRNP 129MM) have developed vCJD thus far and the other genotypes are still to 
succumb. As a result, the human vCJD epidemic may be multiphasic.
Due to the possible vCJD infection o f other PRNP codon 129 genotypes, the prevalence o f 
asymptomatic vCJD carriers and risk o f secondary transmission, contrary to some estimations 
(Ghani et al., 2003), vCJD still poses a serious threat to public health in the UK.
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classical CJD vCJD
Figure 1.3 Molecular strain typing of human prions
Immunoblot for PrP in CJD-infected brain homogenates after treatment with Proteinase K. Each 
strain type possesses its own biochemical signature on polyacrylamide gel determined by tertiary 
conformation and glycosylation patterns. PrP has 3 different glycosylation states represented by 
the 3 bands; the top band is diglycosylated, the middle is monoglycosylated and the bottom is 
unglycosylated. vCJD represents a novel prion strain, type 4, since like BSE, it is predominantly 
diglycosylated. Other human prions, such as sporadic CJD and iatrogenic CJD, fall into strain 
types 1-3. Modified from Collinge, 2005.
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1.3 Protein-only hypothesis of prion transmission
For the last hundred years, the nature o f the causative agent o f TSEs has been the subject o f 
substantial research. The unique characteristics o f the diseases defy their placement into any 
existing disease category. In 1954, the experimentally confirmed transmissible nature o f scrapie 
and its associated long incubation time prompted Sigurdsson to propose scrapie was caused by a 
“ slow virus infection”  (reviewed in Carp et al., 1985). However, the slow virus theory was 
seriously challenged by the failure to either detect an immune response, or to inactivate the scrapie 
agent with techniques that modify nucleic acids (such as U V light and nuclease treatment). In view 
o f these findings, Tikvar in 1966, suggested the transmissible agent was devoid o f nucleic acid and 
a year later Griffith proposed that transmission o f scrapie was via a protein-only mechanism. In an 
era when the structure o f DNA had been recently resolved and the “ central dogma”  o f biology 
(DNA encodes RNA, which in turn encodes protein) was in its prime, the theory that proteins 
could be infectious and self-replicating was met with much resistance. Over a decade later, in 
1982, Prusiner and co-workers produced evidence to support a protein-only theory o f the TSE 
agent. The scrapie agent was found to be stable at high temperatures, resistant to nucleases, 
sodium hydroxide and zinc hydrolysis, and sensitive to protein denaturants and proteases (Bolton 
et al., 1982). Experiments involving the progressive enrichment o f infectivity from scrapie brain 
homogenate, allied with lengthy rodent bioassays resulted in the isolation o f a protease-resistant 
glycoprotein o f 27-30 kDa (Bolton et al., 1982). Prusiner coined the term prion to describe this 
novel class o f pathogen, defined as “ a small /?roteinaceous mfectious particle that resists 
inactivation by procedures that modify nucleic acids” . Oligonucleotides derived from the partial 
sequence o f the isolated prion protein27 30 were used to screen cDNA libraries from scrapie- 
infected hamsters. To much surprise, rather than being virally encoded, the prion protein was 
found to be encoded by a single copy host chromosome (Oesch et al., 1985). The normal product 
o f the prion gene is a 33-35 kDa protein called the cellular prion protein, (PrPc). The disease- 
associated isoform o f the prion protein, PrP80, results from a post-translational template-induced 
conformational change o f PrPc and is the central event in prion disease. PrPc and PrPSc do not 
differ in amino acid sequence. There are currently no antibodies that clearly discriminate these two 
isoforms, therefore, PrP80 is currently operationally distinguished from PrPc by its partial 
resistance to Proteinase K (PK) and its insolubility in detergents. PK fully digests PrPc but just 
cleaves 60-70 residues from the amino terminal o f PrPSc to produce PrP27'30
Nowadays, it is almost indisputable that the causative agent o f prion disease is composed primarily 
o f disease-associated PrP80. Some o f the most convincing evidence is the recent generation o f 
synthetic prions: recombinant mouse truncated prion protein (89-230) was polymerised into fibrils
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in vitro and found to be infectious. When intracerebrally inoculated into transgenic mice, these 
fibrils produced neurological dysfunction at 380-660 days, which was further transmissible to both 
transgenic mice and wild-type mice (Baskakov et al., 2004) Nonetheless, investigations are in 
progress to disprove the theory these mice develop spontaneous disease due to overexpression o f 
PrP (16-fold). The fact that mutations in the PRNP gene underlie inherited prion disease further 
substantiates the protein-only hypothesis.
1.4 Cellular prion protein - PrPc
The normal or cellular form o f the prion protein, PrPc, is a sialoglycoprotein o f 30-35 kDa, 
attached to the external surface o f the membrane via a glycosylphosphatidylinositol (GPI) anchor. 
It is ubiquitously expressed, though the highest expression is present in the nervous and immune 
systems (Dodelet and Cashman, 1998a). The prion gene is highly conserved across mammalian 
species and present in other vertebrates including birds, amphibians and marsupials (Windl et al., 
1995;Wopfner et al., 1999;Calzolai et al., 2005;Cotto et al., 2005). In humans, PrPc is composed 
o f 253 amino acids and is encoded by a single exon o f the PRNP gene located on the short arm o f 
chromosome 20 (20p).
1.4.1 Maturation and cellular processing of PrPc
Following translation, PrPc is processed through the endoplasmic reticulum (ER) where the N- 
terminal and C-terminal regions o f the protein are removed. The N-terminal signal peptide is 
cleaved at lysine residue 22 and C-terminal truncation occurs between 2 serine residues at 
positions 230 and 231 for the GPI anchor to be attached (figure 1.4A).
The GPI anchor consists o f a phospholipid chain that spans the cellular membrane and a head 
group composed o f a phosphodiester-linked inositol group attached to the top o f the chain. The 
inositol is linked to a chain o f glucosamine, three mannose sugars and a phosphoethanolamine 
which links sugars to protein. Phosphatidyl inositol-specific phospholipase C (PIPLC) is able to 
selectively cleave PrPc (but not PrPSc) from the cell surface membrane at the GPI moiety (Stahl et 
al., 1990) indicating that the conformation o f PrPSc hinders accessibility o f the enzyme. Sialic acid 
is added to the GPI anchor o f both PrPc and PrPSc in the ER. PrPc contains two asparagine-linked 
glycosylation sites (at Asnl81PheThr and Asnl97 PheThr o f human PrP). Glycosylation occurs as 
PrPc is processed in the Golgi, where neither, either or both sites can be modified with 
carbohydrate so that in vivo PrPc exists as a mixture o f unglycosylated, monoglycosylated and 
diglycosylated moieties. A disulphide bond is formed between the two cysteine residues (174 and 
214 in human PrP) near the C-terminus between the two glycosylation sites in the ER. Finally, 
PrPc is transported to the cell surface where it is tethered to the outer leaflet o f the membrane via
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its GPI anchor. The 3-dimensional conformation o f recombinant mouse PrPc (soluble PrP without 
glycan chain or membrane anchor) was established by NMR spectroscopy (Riek et al., 1996) and 
found to be essentially the same in all mammalian species (figure 1.4B) (James et al., 1997;Lysek 
et al., 2005;Gossert et al., 2005). The C-terminal domain is composed predominantly o f alpha- 
helical structure (three a-helices and a short anti-parallel P-sheet), stabilised by a single disulphide 
bond linking helices 2 and 3. The N-terminal domain is unstructured in solution and contains a 
highly conserved octapeptide repeat region (containing five repeats in mice) with two copper 
binding sites (Jackson et al., 2001).
1.4.2 PrPc function
The amino acid sequence o f mammalian PrPc is highly conserved between mammalian species 
suggestive o f an important cellular function. However, mice lacking PrPc as a result o f gene
knockout show no overt phenotype, probably due to compensatory pathways (Bueler et al.,
1993b;Mallucci et al., 2002). A plethora o f functions for PrPc have been proposed but its precise 
physiological role remains unclear.
Putative functions o f PrPc are based on its localisation and on PrPc-interacting molecules 
generated from in vitro binding assays with recombinant PrP (reviewed in Lee et al., 2003). As a 
GPI-anchored cell surface glycoprotein, PrPc is located in lipid rafts, which are associated with an 
abundance o f signalling proteins. Therefore, PrPc has been proposed to play a role in signal 
transduction. In addition, PrPc is continually cycled from the cell surface through the endocytic 
pathway into endosomes (Shyng et al., 1994). This cycling occurs through the association o f PrPc 
with clathrin-coated pits, invaginations o f the cell membrane that bud o ff into the cytoplasm to 
form endosomes. This aspect o f its cell biology lends credence to the idea that PrPc is acting as a 
receptor o f some kind (Lee et al., 2003). Since PrPc resides on the external surface o f the
membrane, for PrPc to perform the above functions, it would require a binding partner with a
transmembrane domain. It is also proposed PrPc is involved in cellular adhesion since PrPc ligands 
identified have included adhesion molecules: N-CAMS (Schmitt-Ulms et al., 2001), laminin 
receptors (Gauczynski et al., 2001) and glycosaminoglycans (Pan et al., 2002). PrPc has been 
implicated in a numerous physiological processes which are outlined below.
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FIGURE 1.4 (A) Cellular processing of prion protein (PrPc) - Processing of PrP from its genetic 
transcript to the primary protein sequence. Post-translational modifications include cleavage of bl­
and C-terminal signal sequences, attachment of a GPI anchor to residue 231, glycosylation of 
asparagine residues 180 and 196 and disulphide bond formation (S) between cysteines at 178 
and 213 stabilising a-helices 2 and 3. Known regions of secondary structure (a-helix and (3-sheet) 
are also shown in the C-terminal domain. Amino acid numbers refer to mouse PrP but processing 
is essentially the same for the human form. (B) Three-dimensional structure of mouse PrPc - 
Representation of 3D structure derived from data determined by NMR of recombinant mouse 
prp2i-23i (Hosszu et al., 1999) shows the positions of the post-translational modifications, a-helix 
and (3-sheet secondary structure. Globular structure of the protein with the three a-helices (red), 
glycosylations at residues 180 and 196 (blue), disulphide bond (yellow) and GPI anchor (gold).
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1.4.2.1 PrPc in neurite outgrowth and synaptic transmission
There is abundant evidence implicating PrPc in neurite outgrowth and synapse formation in 
neurones. Recombinant PrP induces synaptogenesis in embryonic rat hippocampal neurones in 
vitro (Kanaani et al., 2005). Interaction o f PrPc with N-CAM and stress-inducible protein 1 (ST1) 
mediates neurite outgrowth by activating intracellular signaling pathways (Kanaani et al., 2005), 
which in the case o f NCAM involves Fyn kinase (Santuccione et al., 2005). PrPc binding with 
laminin and its receptor is also important for extension and maintenance o f neurites and neuronal 
adhesion in cultured neuroblastoma and hippocampal cells (Graner et al., 2000a;Graner et al., 
2000b). Thus, it has been proposed that these molecules form protein complexes to guide growing 
neurites to their appropriate destinations making contact with neurones, other cells and the 
extracellular matrix (Caughey and Baron, 2006).
There is strong evidence that PrPc is also important for normal synaptic function (Collinge et al., 
1994;Colling et al., 1996;Spielhaupter and Schatzl, 2001 ;Mallucci et al., 2002). First, PrPc is 
highly expressed at synapses o f adult neurones (Vey et al., 1996;Naslavsky et al., 1997). Second, 
PrP-knockout mice exhibit electrophysiological abnormalities, such as impaired GABAergic fast 
inhibition and reduced long-term potentiation (Collinge et al., 1994). Furthermore, PrPc has been 
implicated in short-term memory formation and long-term memory consolidation via its 
interactions with ST1 and laminin (Coitinho et al., 2006;Coitinho et al., 2007).
PrPc is also crucial in neuronal development; it increases cell proliferation in neurogenic regions 
(dentate gyrus o f the hippocampus and along the rostral migratory stream, adjacent to the 
subventricular zone) and directs multipotent neural precursors to differentiate into neurones 
(Steele et al., 2006).
1.4.2.2 PrPc in copper homeostasis and neuroprotection
The octapeptide repeat m otif at the N-terminus o f PrPc enables it to strongly bind metal ions, 
particularly copper, with high affinity (Brown et al., 1997a). The ability o f PrPc to both bind and 
internalise copper and zinc has lead to the proposal that PrPc is involved in their neuronal 
metabolism or transport (Brown et al., 1997b;Pauly and Harris, 1998;Brown, 1999;Kretzschmar et 
al., 2000;Watt and Hooper, 2003).
Although data are conflicting, there is evidence copper-bound PrPc possesses SOD-1 (super oxide 
dismutase l)-like activity and is neuroprotective against oxidative stress (Brown et al., 
1999;Vassallo and Herms, 2003). For example, PrPc-deficient neurones are more susceptible to
36
Chapter 1 Introduction
oxidative stress and serum deprivation in vitro (Brown et al., 1997b). PrPc is thought to play a role 
in cell survival and neuroprotection through its interaction with STI-1 and apoptotic pathways 
though the exact mechanism remains unclear (reviewed in Roucou and LeBlanc, 2005). PrPc can 
bind the anti-apoptotic factor Bcl-2 (Kurschner and Morgan, 1995) and it can protect neurones 
from Bax-mediated cell death with the same potency as Bcl-2.
1.4.23 PrPc in the immune system
PrPc is highly expressed in cells o f the immune system via its signalling and adhesion properties, 
PrPc is thought to induce cellular differentiation o f leukocytes and follicular dendritic cells 
(Dodelet and Cashman, 1998b) and regulate the immune response by recruitment o f leukocytes to 
the site o f inflammation, T-cell activation and inhibition o f phagocytosis (Cashman et al., 1990;de 
Almeida et al., 2005).
PrPc has also been implicated in long-term renewal o f haematopoietic stem cells (HSC) since 
PrPc-expressing HSCs were significantly more effective at repopulating blood than PrPc-null cells 
when transplanted into irradiated mice. The exact mechanism by which PrPc promotes long-term 
renewal is unclear but it may transduce cell survival signals, act as a co-receptor for hormones 
affecting HSC activity or interact with the extracellular matrix allowing homing o f the stem cells 
to the appropriate environment (Zhang et al., 2006).
Better understanding o f the physiological function and interactions o f PrPc may be important in 
the development o f prion disease therapeutics. Alterations in the structure and expression level o f 
PrPc can cause neurological disease (reviewed in Chiesa and Harris, 2001), suggesting that 
aberrant interactions o f PrP80 with PrPc contribute to pathogenesis in prion disease.
1.5 Disease-associated prion protein - PrPSc
1.5.1 Properties of PrPSc
In contrast to PrPc, which is mainly monomeric, sensitive to proteolysis, readily soluble in mild 
detergents and rich in a-helical structure, PrP80 is detergent and partially protease-resistant 
(carboxyl segment o f about 140 residues), with a propensity to aggregate. Fourier transform 
infrared spectroscopy suggests PrP80 is richer in P-sheet content than PrPc; comprising 45% o f 
PrP8c compared to 3% o f PrPc (Pan et al., 1993). Use o f high-resolution techniques, such as NMR, 
to study the precise atomic structure o f the native conformation o f PrP8c is precluded by its 
insolubility and aggregation state. The nature o f the self-propagating infectious agent is not known
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but a recent study revealed that mid-sized PrP oligomers o f 14-28 molecules were maximally 
infective when compared to monomeric or fibrillar PrP (Silveira et al., 2005).
1.5.2 Conversion of PrPc to PrPSc
The conversion o f PrPc to PrP80 is the central molecular event in prion disease, however the exact 
events involved in this conversion are unresolved. The most current theory proposes that PrP 
fluctuates between a predominant native state, PrPc, and a series o f minor conformations, some o f 
which can self-associate to form a stable supramolecular structure, PrP80, made up o f misfolded 
PrP monomers (P-PrP; figure 1.5). Further aggregation o f (3-PrP occurs until it reaches a critical 
size at which point a stable “ seed”  structure is formed. At this stage, explosive autocatalytic 
formation o f PrP8c ensues involving the recruitment o f unfolded PrP and P-PrP monomers. This 
proposed mechanism o f prion propagation could account for the acquired, sporadic and inherited 
aetiologies o f prion disease. Initiation o f this pathogenic self-propagating conversion reaction with 
accumulation o f aggregated P-PrP may be induced by exposure to a “ seed”  o f aggregated P-PrP 
following prion inoculation, or as a rare stochastic conformational change, or as an inevitable 
result o f expression o f a pathogenic mutant form o f PrPc that is prone to form P-PrP. Whether the 
PrP itself, through its fluctuating conformations can adopt PrP80 conformation, or whether it 
requires other co-factors has not been confirmed. Possible co-factors for conversion include STI1, 
which not only binds to PrPc but also localises in a chaperone complex (Lassie et al., 1997) and 
Hsp60, the bacterial homologue o f which catalyses prion aggregation (Edenhofer et al., 
1996;Stockel and Hartl, 2001). There is evidence to suggest nucleic acids may also play a role in 
prion propagation in vivo. First, PrP avidly binds nucleic acids (Cordeiro et al., 2001;Gabus et al., 
2001a;Gabus et al., 2001b;Moscardini et al., 2002;Nandi et al., 2002) and second, single-stranded 
mammalian RNA molecules (o f about 300 nucleotides) stimulate prion conversion in vitro. This 
work is still consistent with the protein-only hypothesis because the RNA molecules are host- 
encoded and do not form part o f the infectious agent.
The exact sub-cellular site o f prion propagation is also the subject o f debate. Considerable 
evidence points to late-endosome-like organelles or lysosomes (Laszlo et al., 1992;Mayer et al., 
1992;Taraboulos et al., 1992;Arnold et al., 1995). These organelles are favoured because the acidic 
environment induces protein unfolding and may facilitate the conversion o f PrPc to PrP8c
1.5.3 Prion strains
Different prion strains exist and give rise to prion disease that varies markedly in neuropathology 
(presence o f plaques and spongiform degeneration), brain region and cell type affected, incubation
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time and disease length. Prion strains are not encoded by a nucleic acid genome, which 
conventionally encodes strains o f viruses and bacteria. Neither are they encoded by differences in 
PrP primary structure since dinstinct strains can be serially propagated in lines o f inbred mice with 
the same Prnp genotype (Scott et al., 1997). Molecular strain typing studies, in which prion- 
infected material is Proteinase K treated and immunoblotted for PrP, show that different strains o f 
PrP550 display distinctive migration patterns on polyacrylamide gels, reflecting their different 
glycosylation pattern and proteolytic cleavage sites. Therefore, it is a combination o f protein 
conformation and glycosylation that encodes strain diversity.
1.5.3.1 Human prion strains
Four distinct human PrP80 types have been identified (type 1-4), which are associated with 
different phenotypes o f CJD (figure 1.3). An alternative molecular classification system has 
identified six sub-types (Gambetti et al., 2003). As displayed in figure 1.3, following limited 
proteolysis (cleavage o f the N-terminus), CJD isolates show different PrP fragment sizes and ratios 
o f the three glycoforms by immunoblotting. These signatures can be maintained when passaged 
into both human transgenic mice and wild-type mice, fulfilling the definition o f strains. Classical 
CJD is associated with PrPSc types 1-3, while type 4 human PrPSc is uniquely associated with 
vCJD. Molecular strain typing o f prion isolates from tonsil is now used for diagnosis o f vCJD 
(H ill et al., 1997b).
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Figure 1.5 Putative mechanism for prion propagation
Predominantly a-helical PrPc reversibly refolds, via an unfolded state (Hosszu et al., 1999). (i), to a 
largely p-sheet form, 3-PrP (ii), which has a propensity to aggregate under physiological 
conditions. Once p-PrP has aggregated to a critical “seed” size, prion propagation is an essentially 
irreversible process (driven thermodynamically by intermolecular interactions) involving the further 
recruitment of unfolded PrP (iii) or (3-PrP monomers (iv). Modified from (Collinge, 2005).
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1.5.4 Species barrier
When prions from species A are transmitted to species B, not all animals o f species B develop 
disease and those that do have longer and more variable incubation times; this phenomenon is 
referred to as the species barrier o f prion transmission. On secondary passage o f infectivity, as 
intraspecies transmissions, all animals succumb to disease with short and consistent incubation 
periods. Originally, differences in PrP primary structure between species were proposed to 
underlie the species barrier (Palmer et al., 1991 ;Collinge et al., 1991) but more recently it has 
become apparent that prion strains (i.e PrP conformation and glycosylation) affect transmission. 
BSE transmits to a wide range o f species and maintains its transmission characteristics after 
passage through an intermediate species. CJD transmits readily to transgenic mice expressing 
human PrP only, but not to wild-type mice, consistent with the existence o f a species barrier 
(Collinge et al., 1995c). In contrast, vCJD (which has the same primary structure as CJD) 
transmits to both wild-type mice and human PrP-expressing transgenic mice (H ill et al., 1997a). 
Therefore, the term transmission barrier, rather than species barrier, seems more appropriate to 
explain transmissibility o f prion strains. The conformational selection model (figure 1.6) attempts 
to explain the transmission barrier (H ill and Collinge, 2003a).
1.5.5 Neurotoxicity of prions
Prion-induced cell death is caused via an apoptotic mechanism (Hetz et al., 2003;Liberski et al., 
2004;Cronier et al., 2004;Carimalo et al., 2005) but exactly how the accumulation o f PrP80 is 
related to cellular toxicity, neuronal loss and eventual host death in prion disease is the subject o f 
intense research. In order to exert its toxic effect PrPSc requires PrPc since PrP knockout mice are 
resistant to infection with scrapie prions (Bueler et al., 1993a) but regain susceptibility on 
reintroduction o f a murine PrP transgene (Fischer et al., 1996). However, it is unclear i f  PrPSc 
causes cell death due to a toxic gain o f function. On the one hand, PrP80 and PrP80 fragments 
(encompassing residues 106-126) exhibit direct toxicity in primary cultured neurones (Forloni et 
al., 1993). On the other hand, the level o f PrP^ in vivo often does not correlate with disease 
severity. For example, in FFI, there is very little PrP8c deposition observed in patient brains and 
some prion-inoculated mice remain asymptomatic in their lifespan despite high prion titres in their 
brains; a phenomenon termed sub-clinical prion disease (H ill and Collinge, 2003b).
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Figure 1.6 Conformational selection model of prion transmission barriers
Since mammalian PrP genes are highly conserved, this hypothesis proposes that only a limited 
number of different PrP80 conformations or strains are permissible thermodynamically and are 
stable enough to be serially propagated in prion disease. For each species only a certain subset of 
these conformations (or strains) will be allowed. Transmission between species may occur if there 
is an overlap between the subset of permissible PrPSc conformations; red and green strains may 
be transmissible between species A and B, but not the yellow and blue strains. But a large barrier 
to transmission will exist between species with no PrP50 conformations in common, for example, 
species C and species A or B. Modified from (Hill and Collinge, 2003a).
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It seems unlikely that prion-induced cell death is due to loss o f normal PrPc function because PrPc- 
knockout mice develop normally (Bueler et al., 1993a) and the absence o f neuronal PrPc in 
adulthood is also well tolerated; a Prnp conditional knockout mouse, in which PrPc is post-natally 
depleted at 9 weeks o f age using the cre-lox system, shows no neurodegeneration or clinical 
phenotype (Mallucci et al., 2002). Nevertheless, there are in vitro data to suggest that aberrant 
PrPc processing is neurotoxic (H ill et al., 2000;Yedidia et al., 2001;Zanata et al., 2002;Sanchez- 
Valle et al., 2002;Ma and Lindquist, 2002).
Based on these data, a toxic intermediate o f PrP^, designated PrPL (L for lethal), has been 
proposed to cause prion-induced cell death (H ill and Collinge, 2003a). There is growing evidence 
in protein misfolding disorders that smaller intermediate oligomeric species may be more 
biologically active than larger amyloid fibrils (Caughey and Lansbury, Jr., 2003). PrPL may be a 
small, soluble oligomeric, amyloidogenic toxic species akin to A(340 and A(342, in Alzheimer’s 
disease. In this way, the mechanism o f prion toxicity may be shared with other protein aggregation 
diseases (Bucciantini et al., 2002;Kayed et al., 2003).
Like in other neurodegenerative diseases, including Alzheimer’ s disease, Huntingtons’s disease 
and Parkinson’s disease (Ciechanover and Brundin, 2003), impairment o f the ubiquitin- 
proteasome system has also been implicated in the pathogenesis o f prion disease (Hooper, 
2003; Kristian sen et al., 2005). The ubiquitin-proteasome system (UPS) is responsible for the non- 
lysosomal degradation and clearance o f short-lived, misfolded, mutant and damaged proteins in 
eukaryotic cells (Goldberg, 2003). Whether inhibition o f this system by protein aggregates is 
primary or a secondary effect is presently unclear (Hetz et al., 2007).
1.6 Therapeutic strategies for treatment of prion disease
Currently, there are no effective drugs for patients with prion disease but strategies for the 
development o f prion disease therapeutics attempted to-date are presented in a systematic review 
(Trevitt and Collinge, 2006).
As discussed above, although PrP^ is associated with prion disease pathology and infectivity, it is 
unlikely to be the neurotoxic species. Consistent with these observations, therapies aimed at 
preventing PrPSc accumulation, including Congo red, have produced only modest effects in 
experimental models. They often need to be administered at the time o f infection and are only 
effective against peripheral prion inoculation (Aguzzi et al., 2001). Exceptions to this are
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intracerebroventricular pentosan polysulphate for intracerebrally inoculated mice (Doh-ura et al., 
2004) and amphotericin, o f which late administration is effective (Demaimay et al., 1997).
The main thrust o f current prion therapeutic research is to target PrPc and prevent its conversion to 
PrP^. Since the generation o f PrPSc is thought to involve almost complete unfolding o f PrPc 
(Hosszu et al., 1999) one approach under investigation is the prevention o f prion conversion using 
small PrPc binding ligands to stabilise ordered structure o f PrPc. High throughput screening o f 
large compound libraries is being pursued to identify such ligands. Already antibodies that bind 
PrP (mainly at the N-terminus) have been effective in preventing prion propagation in chronically 
prion-infected cell cultures (Enari et al., 2001;Peretz et al., 2001;Gilch et al., 2003) possibly by 
sequestering PrPc and preventing its incorporation into prions. Passive immunisation o f 
peripherally inoculated animals with anti-PrP monoclonal antibodies was very effective in curing 
prion disease; there was reduced splenic infectivity and animals lived over 300 days longer than 
their untreated counterparts (White et al., 2003). Humanised anti-PrP antibodies may have a role in 
post-peripheral exposure prophylaxis to stop neuroinvasion. However, because antibodies do not 
cross the blood brain barrier they would have to be administered intracerebroventricularly to treat 
CNS disease and this would require optimisation; not only is tissue penetration inconsistent, there 
is suggestion that delivery o f high dose antibodies into the CNS may induce extensive neuronal 
apoptosis (Solforosi et al., 2004).
Development o f the Prnp conditional knockout mouse model (Mallucci et al., 2002) strongly 
validates the depletion o f PrPc as a safe and effective therapeutic strategy for prion disease and 
challenges the dogma that neurodegeneration is irreversible. Following prion infection o f this 
model one week after birth, depletion o f neuronal PrPc at 12 weeks, halted neurological disease 
progression and reversed pathology (early hippocampal spongiform changes), allowing animals to 
survive almost to their natural lifespan (Mallucci et al., 2003). For therapeutic purposes PrPc 
would need to be depleted by extrinsic means. The RNA interference (RNAi) technique o f gene 
silencing has been successfully implemented for the inhibition o f PrPc expression in N2a cells 
(T illy  et al., 2003) and curing scrapie-infected cell cultures (Daude et al., 2003). Although 
therapeutic benefit o f RNAi for prion disease has yet to be demonstrated in vivo, the approach has 
been successful for animal models o f Alzheimer’s disease and frontotemporal dementia (Davidson 
and Paulson, 2004).
Active immunisation is, o f course, limited by immune tolerance to PrP but has proved effective in 
animal models (Sigurdsson et al., 2002). Vaccination with recombinant mouse prion protein, 
before or after intraperitoneal inoculation o f prions in mice, demonstrated delayed disease onset in
44
Chapter 1 Introduction
both groups but was more prolonged in animals immunised before prion exposure (Sigurdsson et 
al., 2002). Vaccines may be useful for treatment o f larger scale animal prion diseases, such as 
scrapie. Furthermore, several immunomodulatory approaches are also being pursued for 
prevention o f prion diseases. For example, inhibition o f follicular dendritic cell maturation by 
interference with cytokines signalling prevents splenic PrPSc accumulation and prion 
neuroinvasion (Montrasio et al., 2000).
A key research goal is to develop an early diagnostic blood-based test for PrP80 or specific prion 
biomarkers (Castilla et al., 2005) so that treatment can be offered prior to significant 
neurodegeneration. The prolonged peripheral phase o f prion propagation, characteristic o f many 
forms o f prion disease, which takes place in the lymphoreticular system and/or peripheral nerves 
also offers an opportunity for therapeutic intervention prior to neuroinvasion and precludes the 
need to use drugs that cross the blood-brain barrier.
To-date several drugs have been tested in relatively few patients, with no clear efficacy o f any 
agent demonstrated; controlled clinical trials are desperately needed. However, such trials are 
problematic because prion diseases are very rare, the use o f placebo is unethical due to the fatal 
nature o f the disease, the disease course is rapid and there is an absence o f biomarkers with which 
to monitor disease progression. A clinical trial protocol for prion disease has been developed and 
quinacrine, an anti-malarial acridine derivative, is currently being assessed in an MRC-funded 
trial.
1.7 Cell models of prion disease
Early studies into prion disease were conducted in experimental rodent models o f scrapie 
(reviewed in Collinge et al., 1995a;Weissmann C, 1999). However, in view o f the long prion 
disease incubation times (between 3 months and >2 years in mice), cell culture models represent a 
faster and cheaper alternative to rodent models, and entail fewer ethical constraints. Moreover, the 
easier manipulation o f the genome and proteome o f cells facilitates the study o f cellular and 
molecular disease pathogenesis. Cellular models are also more physiologically relevant than the 
available cell-free in vitro assays o f mammalian prion propagation (Kocisko et al., 1994;Saborio et 
al., 2001;Lucassen et al., 2003).
In light o f the benefits o f cell culture, attempts to propagate prions from animal models in cultured 
neuronal cells began in the 1960s, with the first cell models reported in the 1970s (Clarke and 
Haig, 1970b;Gajdusek et al., 1972). The last two decades has seen the emergence o f a number o f
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cell culture models o f infectious and inherited forms o f prion disease, in which prions are stably 
propagated (reviewed in Solassol et al., 2003).
1.7.1 Methods for development of prion-propagating cell lines
The simplest procedure for development o f a cell line stably replicating prions is first to expose a 
PrPc-expressing line to PrP^, usually in the form o f brain homogenates from prion-infected 
animals. Next, cell cultures are washed and passaged extensively in order to remove the original 
inoculum and are then assayed for the presence o f de novo infectivity over numerous passages 
(Beranger et al., 2001). Prior to the discovery o f PrPSc, the gold-standard surrogate marker for 
prion infection, successful prion transmission to cell culture was assessed by the presence o f 
infectivity using the mouse bioassay (prion-susceptible strains o f mice). Nowadays, the presence 
o f PrP80 is assessed by biochemical methods, including immunoblotting, or the 10-fold more 
sensitive cell blot assay (CBA; Bosque and Prusiner, 2000). These methods involve the detection 
o f protease-resistant PrP using antibodies targeting the carboxyl terminus o f PrP. To further verify 
infectivity, infected cells are homogenised and inoculated into either prion-susceptible mice or 
identical uninfected cells (Cronier et al., 2004). Culture medium o f infected cells often harbours 
infectivity and can also be used to test i f  the cell line is infectious (Schatzl et al., 1997;Cronier et 
al., 2004;Baron et al., 2006). An alternative approach for the development o f cell models o f prion 
disease is the isolation o f primary cultures from prion-susceptible mouse models (see section 
1.7.4).
Mutant PrP molecules have been expressed in cells to improve understanding o f the pathogenic 
process occurring in inherited prion disease. Expression o f octapeptide repeat mutations, 
associated with CJD, have revealed an altered membrane association o f PrP that is resistant to 
PIPLC cleavage (Lehmann and Harris, 1995) and has an increased tendency to aggregate and gain 
PK resistance (Priola and Chesebro, 1998). Expression o f the D178N mutant PrP, associated with 
both FFI (codon 129MM) and CJD (codon 129VV), indicates only glycosylated forms o f this 
mutated protein are attached to the cell membrane (Petersen et al., 1996).
1.7.2 Increasing susceptibility of cells to prion infection
The refractory nature o f most cell lines to prion infection has prompted strategies to increase 
likelihood o f cell infection with the transmissible agent. One such strategy is the use o f sub­
cloning. Using techniques such as the CBA (Bosque and Prusiner, 2000) and the post-embedded 
method (Vilette et al., 2001), it is apparent that not all cells within a susceptible cell line become 
infected. N2a mouse neuroblastoma cells are permissive to the RML mouse-adapted scrapie strain
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(Race et al., 1987), though only 1% o f these cells appear to be susceptible and become infected 
(Race, 1991). More efficient cell culture models do exist; 47% o f L929 cells become infected with 
22L mouse-adapted scrapie (Vorberg et al., 2004a) and 30% o f Rov cells become infected with 
sheep scrapie (Vilette et al., 2001). Dilution subcloning o f the parent N2a population, prior to 
RML infection, allows the isolation o f the most susceptible clones, producing the highest amounts 
o f PrPSc (Bosque and Prusiner, 2000). This work validates subcloning as a method for isolating the 
most prion-susceptible cells in a population and has subsequently been used to isolate a cell line 
propagating CWD (Raymond et al., 2006).
Increasing PrPc expression levels reduces disease incubation times in animal models (Prusiner et 
al., 1990;Raeber et al., 1998). In accord with this finding, PrPc overexpression can also improve 
prion transmission to cells. In their endogenous state N2a neuroblastoma cell lines are only 
permissive to RML prions but up to six-fold overexpression o f PrPc renders them permissive to 
two further mouse-adapted scrapie strains; 22L and 139A (Nishida et al., 2000). Mouse embryonic 
neurosphere cultures overexpressing mouse PrPc (four- to eight-fold) are more susceptible than 
wild-type cultures to RML prion infection, establishing high PrP,Sc levels much sooner than the 
wild-type cultures. Indeed, overexpression o f PrPc has been important for successful development 
o f many o f the cell models o f prion disease (Archer et al., 2004;Giri et al., 2006). However, it is 
clear that cellular susceptibility to prion infection is dependent on factors other than PrPc levels. 
When attempting to render N2a cells more susceptible to prion infection by transfection o f PrPc, 
Enari et al. found that it was the vector-only clone (with wild-type PrPc expression level) that was 
most susceptible to prion infection (Enari et al., 2001).
A further strategy for improving prion infection efficiency in cells is to use different PrPSc 
preparations. First, microsomal preparations o f scrapie-infected brain homogenate (Baron et al.,
2002) have recently been identified as a very efficient way o f initiating prion infection in cultured 
cells (mouse cholinergic septal neurones and N2a neuroblastoma cells) compared to detergent 
purified PrPSc (Baron et al., 2006). Microsomal fractions contain PrPSc associated with membrane 
vesicles (from all types o f cellular membrane). These preparations may be more infectious because 
the PrP^ aggregates appear more diffuse than detergent-purified preparations, providing a greater 
number o f seeds for replication. Alternatively, PrPSc microsomes may improve uptake o f PrP& into 
target cells, either by membrane fusion or association o f microsomal molecules with target cell 
ligands. Second, scrapie-associated fibrils (SAFs), prepared by treatment o f prion-infected brain 
homogenate with proteinase K. and sarkosyl, are often used to improve efficiency o f prion 
infection in cells (Race et al., 1987).
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1.73 Immortalised cell lines supporting prion propagation
There are only a limited number o f cell lines permissive to mammalian prion propagation, 
reflecting the inefficiency o f prion infection o f cells and the lack o f knowledge regarding cellular 
susceptibility factors. Moreover, there is restricted strain propagation for each cell line. O f the 
available cell models o f prion disease, the majority are permissive to mouse-adapted scrapie 
strains, but there are some cell models o f sheep scrapie, hamster scrapie and CWD (table 1.1). 
Most notably, no cell lines have been reported that can stably propagate human prions. Any claims 
o f cell lines replicating human prions have proved unfounded (Ladogana et al., 1995;Kikuchi et 
a l„ 2004).
In order to eliminate the prion species barrier, the majority o f cell models o f prion disease are 
homologous; that is, the species origin o f the cells and PrPc expressed are the same as the PrPSc in 
the inoculum. In addition, the development o f prion cell models originally focussed on cell lines o f 
neural origin since prion disease targets the central nervous system and neuronal cells highly 
express PrPc. Thus, the most extensively studied cell lines in prion research are the N2a mouse 
neuroblastoma cell line (Race et al., 1987) and the ScGTl cell line (Schatzl et al., 1997), 
developed from a T-antigen immortalised mouse hypothalamic (gonadotropin hormone-releasing 
hormone) neuronal line. Unfortunately, these two lines are only able to stably propagate the RML 
mouse-adapted scrapie strain in their endogenous state. Like most other cell culture models o f 
prion disease, scrapie-infected N2a cells (ScN2a) do not exhibit a disease phenotype. Minor 
changes have been reported in ScN2a cells, including increased intracellular catecholamine levels 
and increased proliferative rate (Markovits et al., 1983) but these may be due to clonal differences 
or factors in the inoculum (Solassol et al., 2003). The chronically prion-infected ScGTl line was 
the first prion-infected cell line to exhibit a pathological phenotype. The cultures exhibit apoptosis, 
signs o f vacuolation (Schatzl et al., 1997) and reduced viability in response to oxidative stress 
(Milhavet et al., 2000). Prion infection o f cell lines is not restricted to those o f neuronal origin, 
non-neuronal cells derived from fibroblast and epithelial lines are reported to support prion 
replication (table 1.1). Although PrPSc has not been detected in fibroblasts in vivo (Meiner et al., 
1992), several fibroblast cells lines can replicate prions in vitro (Vorberg et al., 2004b;Raymond et 
al., 2006). The murine L929 fibroblast cell line is a highly prion permissive line. Despite its low 
PrP expression, it can propagate three strains o f mouse-adapted scrapie (ME7, RML and 22L; 
Raymond et al., 2006).
There are several heterologous cell models o f prion propagation, in which there is a mismatch 
between the species origin o f PrP80 and the species origin o f either the PrPc expressed or the cell
48
Chapter 1 Introduction
line. The first cross-species transmission o f prions in culture was reported in 1984 when a NGF- 
diflferentiated PC 12 rat phaeochromocytoma line was found to support replication o f the mouse- 
adapted scrapie strain, 139A (Rubenstein et al., 1984). A rabbit epithelial kidney cell line (RK13) 
was rendered susceptible to sheep scrapie by heterologous overexpression o f ovine PrP 
(homozygous for the most susceptible V 136 R 154 Q171 polymorphism; Vilette et al., 2001). Most 
commonly, cell models propagate prions which have been passaged through rodents but this Rov 
model propagates naturally-occurring prion disease (scrapie from a VRQ homozygous sheep) and 
clearly demonstrates the importance o f PrP polymorphisms in disease susceptibility and in 
establishing prion infection. It has been suggested that although the epithelial cells (like Rov) are 
non-neuronal, they may share some susceptibility factors o f neurones because the nervous system 
is developmentally derived from an epithelium and both cell types are polarised. Moreover, the 
presence o f PrPc-expressing epithelial cells in skin, the digestive tract and reticuloendothelial 
system suggests this cell type may be important in the prion disease pathogenesis and transmission 
(Vilette et al., 2001).
1.7.4 Primary cultures supporting prion propagation
Cell models o f prion disease have been derived by primary culture from either prion-infected or 
prion-susceptible animal models. The first such model, and first ever model o f prion disease, was 
the scrapie mouse brain cell line (SMB) derived from the brain o f a RML prion-infected mouse 
(Clarke and Haig, 1970a). Recently, primary culture has been employed to establish a number o f 
prion-propagating cell lines. These evidently represent a more accurate disease model than tumour 
cell lines and allow the role o f different cell types in prion disease pathogenesis to be assessed.
Two prion-propagating peripheral neuroglial cell lines have been developed: Schwann cells 
isolated from transgenic mice overexpressing ovine PrPc (Mov) can sustain mouse-adapted sheep 
scrapie prion propagation (Archer et al., 2004) and a mouse Schwann cell line (MSC-80) 
propagates RML prions (Follet et al., 2002). These cell lines suggest Schwann cells play a role in 
peripheral prion disease pathogenesis and their study may allow better understanding o f prion 
neuroinvasion. Furthermore the recent development o f a microglial cell line from PrP- 
overexpressing mice may allow the role o f microglia in prion disease pathogenesis to be elucidated 
(Iwamaru et al., 2007).
Sheep scrapie-propagating primary cerebellar cultures derived from a transgenic mouse line 
(overexpressing ovine PrPc on a mouse Prnp knockout background) have been established 
(Cronier et al., 2004). This system demonstrated that both neuronal and astrocyte cultures could 
sustain prion propagation. Prion disease was faithfully recapitulated since the accumulation o f de
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novo PrPSc was neurotoxic to cerebellar granule neurones, which underwent delayed apoptotic cell 
death, but the cerebellar astrocyte cultures remained healthy.
Until very recently, a cell line permissive to CWD was lacking. An SV40-immortalised brain 
fibroblast line was cultured from a mule deer brain with the most common and susceptible PrP 
genotype (Raymond et al., 2006). It was isolated by dilution cloning and stably propagates CWD 
prions o f the same genotype, following infection with a microsomal preparation o f homogenate. 
Due to the widespread nature o f CWD in the USA and Canada, treatment for the disease is o f 
utmost importance. This model w ill be useful for the screening o f potential CWD therapeutics.
RML prion-propagating embryonic neurospheres have been isolated from prion-susceptible mice 
overexpressing mouse PrPc (Giri et al., 2006). Neurospheres are free-floating spherical aggregates 
o f proliferating neural stem cells. The close-packed nature o f cells in neurospheres is proposed to 
facilitate cell-to-cell transmission o f prions in this model. The prion susceptibility o f these 
neurosphere cultures reflects that o f the mice from which they were derived, suggesting this 
system may be useful for the development o f cellular prion models o f different species, with a 
range o f genotypes. Due to their stem cell component, neurospheres also have the potential to 
differentiate into the three brain cell types, neurones, astrocytes and oligodendrocytes, to allow the 
study o f prion neuropathophysiology (Giri et al., 2006). Differentiated embryonic and adult mouse 
neural stem cells have been found to propagate several mouse prion strains (Milhavet et al., 2006). 
The close resemblance o f this in vitro model to the brain environment has been suggested as the 
basis for its prion susceptibility.
1.7.5 Applications of cell models of prion disease
These prion-propagating cell lines have been valuable in the study o f o f PrP80 biology and the 
putative molecular mechanisms o f prion conversion (Lehmann and Harris, 1997), subcellular 
localisation and neurotoxicity o f PrP80 (Vey et al., 1996;Naslavsky et al., 1997;Cronier et al., 
2004;Carimalo et al., 2005;Kristiansen et al., 2005) and the species barrier o f prion transmission 
(Priola et al., 1994;Kaneko et al., 1997). They have also contributed to the evaluation o f putative 
therapeutic agents (Caughey and Raymond, 1993;Doh-ura et al., 2000). For research purposes, a 
quantitative infectivity assay for mouse RML prions has been developed from highly susceptible 
N2a clones as a cheaper and faster alternative to mouse bioassay o f prion infectivity (Klohn et al.,
2003).
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Cell line Species Cell type / Prion strain Reference
of cell tissue origin propagated
NEURAL
N2a mouse neuroblastoma RML (Race et al., 1987)
N1E-115 mouse neuroblastoma RML (Race et al., 1987)
GT1 mouse hypothalamic neurone RML (Schatzl et al., 1997)
HaB hamster brain hamster strain (Taraboulos et al., 1990)
Mov mouse + ovine PrP dorsal root ganglia sheep scrapie (Archer et al., 2004)
SN56 mouse cholinergic septal RML/ 2 2 U  ME7 (Baron et al., 2006)
neurone
Neurosphere mouse embryonic NSC RML (Giri et al., 2006)
Differentiated mouse embryonic NSC 22L/ RML/ C506M 3 (Milhavet et al., 2006)
neurone
CGN mouse + ovine PrP cerebellar granule mouse-passaged (Cronier et al., 2004)
neurone sheep scrapie
NON-NEURAL
SMB mouse brain-mesodermal origin RML (Clarke and Haig, 1970b)
L929 mouse fibroblast RML/ 22L/ ME7 (Vorberg et al., 2004b)
NIH-3T3 mouse fibroblast 22L (Vorberg et al., 2004b)
NS1 mouse fused spleen & scrapie- RML (Elleman, 1984)
infected NS1 cell
MG20 mouse microglia RML/ME7/Obihiro/BSE (Iwamaru et al., 2007)
PC12 rat phaeochromocytoma 139A/ME7 (Rubenstein et al., 1984)
Glial cell rat gasserian ganglia RML (Roikhel et al., 1987)
Rov rabbit + ovine PrP kidney epithelial sheep scrapie (Vilette et al., 2001)
CAS mouse + ovine PrP cerebellar astrocyte mouse-passaged (Cronier et al., 2004)
sheep scrapie
MDB deer mule deer brain CW D (Raymond et al., 2006)
fibroblast
M SC-80 mouse Schwann cell RML (Follet et al., 2002)
Schwann cell mouse Schwann cell mouse-passaged (Archer et al., 2004)
sheep scrapie
Table 1.1 Cell lines capable of stably propagating animal prion strains
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1.8 Aims of this project
The principal aim o f this project was to develop a cell line stably propagating human vCJD prions. 
Currently, only primates and transgenic mouse models are available for the study o f human prion 
disease (Telling et al., 1994;Brown et al., 1994;Telling et al., 1995;Collinge et al., 1995a;Asante et 
al., 2002;Korth et al., 2003) because despite worldwide effort, no cell model o f human prion 
disease exists. Human prion-propagating cell lines are criticially needed for both basic and applied 
research o f human prion disease. Progress in prion biology made by mouse prion cell models may 
not be relevant to human prion disease and would need to be verified in human prion-propagating 
cell lines.
Stable human prion-propagating cell lines w ill allow the study o f cellular and molecular aspects o f 
human prion disease in an efficient manner. Fundamental questions o f prion cell biology remain to 
be answered. Human cell models may facilitate the elucidation o f PrPc function, the mechanism o f 
PrP80 conversion, the identification o f cellular factors conferring susceptibility to prion infection, 
the mechanisms o f prion-induced cell death and the basis o f prion strain cell tropism. Better 
understanding o f these aspects o f prion biology w ill improve prospects for therapeutic research 
specific to human prion disease.
A human prion-propagating cell line w ill also be a rapid, cost-effective bioassay for detection o f 
human prions in tissue, not only for research purposes but also for diagnosis. Pre-mortem early 
diagnosis o f human disease would allow early therapeutic intervention prior to any significant 
neurodegeneration. With the more recent emergence o f vCJD and the fact that it is clearly 
transmitted by blood transfusion (Llewelyn et al., 2004; Peden et al., 2004; Wroe et al., 2006), 
identification o f anti-prion therapeutics for human disease is all the more urgent. A human prion- 
propagating cell line w ill be a powerful tool for screening potentially therapeutic agents.
In the attempt to develop a cell line stably propagating human prions, the following strategies were 
pursued:
•  The development o f methodology to assay human prion infectivity in cells.
• The investigation o f human PrPc -expressing immortalised mammalian cell lines, ofboth 
neuronal and non-neuronal origin, for susceptibility to human prion infection.
• Humanisation o f existing N2a mouse prion-propagating cell lines and the investigation 
o f their susceptibility to human prion infection.
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• The investigation o f human foetal neural stem cells for susceptibility to human prion
infection.
Here I present evidence to support the fact that transmission o f human prions to cells in vitro is 
more difficult than in vivo. The cellular expression o f human prion protein (PrPc) o f the same 
sequence as the disease-associated prion protein (PrPSc) in the vCJD inoculum was insufficient to 
establish human prion propagation in immortalised mammalian cell lines. From work on the 
humanisation o f a mouse prion-propagating cell line, it is also evident that cell lines are permissive 
to restricted strains, and that perhaps cellular prion propagation factors are prion strain-specific. 
This thesis describes the first report o f a cell line able to propagate human prions. The finding that 
a differentiated human foetal neural stem cell is able to propagate human vCJD prions suggests a 
human neuronal phenotype is critical for the propagation o f human prions in vitro.
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2.1 Materials
2.1.1 Equipment
•  Biomat class I microbiological safety cabinet (medical air technology.com)
• Biomat class II microbiological safety cabinet (medical air technology.com)
• Nuaire™ DH autoflow CO2 air-jacketed incubator
• Zeiss Axiovert 25 inverted light microscope
• Zeiss Axioplan 2 MOT fluorescence microscope
• Zeiss Con focal microscope LSM510 META
• Zeiss KS ELISPOT system (Stemi 2000-C stereomicroscope with KL1500 LCD scanner, 
Hitachi HV-C20A colour camera, WELLSCAN software (Imaging Associates, UK)
• Tecan Spectra Image spectrophotometer
• Universal 32R Hettich benchtop centrifuge
• Eppendorf centrifuge 5415 D
• Biorad power pac 200
• Eppendorf comfort thermomixer
2.1.2 Laboratory reagents
Unless stated otherwise, chemicals were supplied by Sigma (UK) and cell culture reagents by 
Invitrogen (UK).
2.2 Mammalian cell culture
2.2.1 Cell lines
Cell lines were acquired from ATCC (via LGC promochem), ECACC or as gifts as detailed 
below.
2.2.1.1 BE(2)M17
BE(2)M17 (ATCC) is a human neuroblastoma cell line derived from a bone marrow metastasis
with neuroblast morphology.
2.2.1.2 H4
H4 (ATCC) is a human neuroglioma cell line with epithelial morphology.
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2.2.1.3 HEK293
HEK293 (ECACC) is a human embryonic kidney cell line with epithelial morphology.
2.2.1.4 iPKl
iPK l was a kind gift from Dr Peter Klohn (MRC Prion Unit, London). It is a chronically RML 
prion-infected PK1 cell line derived from the RML infection o f PK1 cells as described in (Klohn 
et al., 2003).
2.2.1.5 L929
L929 (ECACC) is a mouse fibroblast cell line derived from adipose tissue.
2.2.1.6 Mink lung retroviral producer cell line (mink-ampho)
Mink-ampho was a kind gift from Professor Robin Weiss (University College London, UK). This 
is a Moloney murine leukaemia virus (MuLV) producer cell line that generates competent 
amphotropic retroviral particles.
2.2.1.7 N2a
N2a (ATCC) is a mouse neuroblastoma cell line with neuronal and amoeboid morphology.
2.2.1.8 N2aG
N2aG cell line was a kind gift from Dr Peter Klohn (MRC Prion Unit). It is an RML prion- 
susceptible cell line, derived from N2a cells by one round o f subcloning and exhibits more than 
100-fold susceptibility to RML compared to parent N2a cells (Klohn et al., 2003).
2.2.1.9 NP2
NP2 was a kind gift from Dr Hiroo Hoshino (Gunma University, Maebashi, Japan). It is a human 
glioma cell line.
2.2.1.10 PhiNX- ecotropic and PhiNX-amphotropic packaging cell lines
These were a kind gift from Professor Parmjit Jat. PhiNX-eco and PhiNX-ampho cell lines are 
second-generation retroviral producer lines (MuLV-based) for the generation o f helper-free 
ecotropic and amphotropic retroviruses.The lines are based on the 293T cell line; a human 
embryonic kidney line transformed with adenovirus El a, carrying a temperature sensitive T 
antigen co-selected with neomycin (Pear et al., 1993). These were used for gene transfer into cells. 
Virus packaging lines express genes required for the formation o f viral particles (gag-pol-env), 
which are deleted from the retroviral vectors. PhiNX-eco cells produce virus particles able to
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infect mouse cells whereas PhiNX-ampho cells package virus particles that can infect all species 
o f cells.
2.2.1.11 PK1
PK1 (N2aPKl) was a kind gift from Dr Peter Klohn (MRC Prion Unit). It is an RML prion- 
susceptible cell line, derived from N2a cells by successive rounds o f subcloning and exhibits more 
than 1000-fold susceptibility to RML prions compared to parent N2a cells (Klohn et al., 2003).
2.2.1.12 PrP null embryonic neurospheres
Primary neurosphere cultures were isolated at embryonic day 13.5 from the brains o f FVB mice 
with a targeted null mutation in the PrP gene (F5_FVB/PrP null) as outlined in section 2.2.5.1,
2.2.1.13 ReNcell 197VM
ReNcell 197VM (referred to throughout as 197 NSC) was acquired via a collaboration with 
ReNeuron Ltd. (Guildford, UK). It is a human foetal neural stem cell line (NSC) derived from the 
ventral mesencephalon o f a 10-week foetus, immortalised by the retroviral transduction and 
overexpression o f v-myc oncogene.
2.2.1.14 RG6
RG6 was a kind gift from Dr Miratul Muqit (Institute o f Child Health, London). It is a rat 
neuroglial cell line with fibroblast morphology.
2.2.1.15 RK13
RK13 (ECACC) is a rabbit epithelial kidney cell line with epithelial morphology.
2.2.1.16 SHSY5Y
SHSY5Y (ATCC) is a human neuroblastoma line o f epithelial morphology, cloned from SKN-SH.
2.2.1.17 SHSY5YA
SHSY5Y A was a kind gift from Dr Konstantin Chumakov (FDA, Maryland, USA). It was 
derived from the retroviral transduction o f SHSY5Y with the human prion gene (PRNP), encoding 
the methionine allele at codon 129, with CD25 as a selective marker.
2.2.1.18 SKN-SH
SKN-SH (ATCC) is a human neuroblastoma cell line derived from a bone marrow metastasis with 
epithelial morphology.
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2.2.1.19 U87 MG
U87 MG was a kind gift from Professor Robin Weiss (UCL). It is a human astrocytoma cell line.
2.2.2 Cell culture maintenance
Cell cultures were handled as potentially bio-hazardous material under BioSafety Level 2 
containment, and incubated in a humidified 37°C incubator aerated with 5% CO:. Cells were 
cultured in tissue-culture treated plasticware; 10 cm dish (Falcon), T25 and T75 vented flasks 
(Nunc), 6-well plates, 24-well plates or 96-well plates (Costar).
Details o f culture conditions for each cell line, including culture medium, freeze medium and 
passage details, are outlined in table 2.1. All cell lines grew as adherent monolayers and were 
passaged twice a week, when confluent, either by trituration or trypsinisation, as described below. 
Prior to passaging, reagents were pre-warmed to 37°C. Spent medium was aspirated and cells 
washed with 5 ml PBS (volumes are provided for a 10 cm dish). For trituration, PBS was replaced 
with 5 ml fresh medium and cells gently triturated with a 1 ml Gilson pipette tip until all cells were 
detached from the dish. For trypsinisation, PBS was replaced with 1 ml lx  trypsin-EDTA (0.25% 
trypsin-EDTA.4Na in HBSS) and cells incubated at 37°C until all cells had rounded up and 
detached (2-15 minutes). As soon as cells had detached, the trypsin was neutralised with 4 ml 10% 
FBS-containing medium. Following detachment, cells were harvested and pelleted at 160 ref for 5 
minutes. The cell pellet was resuspended in fresh medium and passaged at the appropriate ratio.
197 NSC and PrP null neurospheres required modified culturing procedures, which are outlined in 
sections 2.2.4 and 2.2.5, respectively.
2.2.3 Freezing and defrosting cell cultures
Cells were harvested as described for passaging (section 2.2.2) and pelleted at 160 ref for 5 
minutes at 4°C. The pellet was resuspended in ice-cold DMSO-containing freeze medium (table
2.1) at 1-2 xlO6 cells/ml. 1 ml aliquots o f this cell suspension were dispensed into cryovials with 
an O-ring (Coming) and placed directly into an isopropanol-containing freezing vessel (Nalgene), 
which slowly cools cells by 1°C per minute to prevent cell lysis. The cells were frozen at - 80°C 
overnight and then deposited into liquid nitrogen for long-term storage.
Cells were defrosted by rapidly thawing vials in a 37°C water bath, resuspending in 14 ml pre­
warmed culture medium and pelleting at 160 ref for 5 minutes. The cell pellet was resuspended in 
fresh culture medium, deposited in tissue-culture plates and placed in a humidified incubator at 
37°C, with 5% C 02 overnight. The culture medium replaced the following day to remove dead 
cells from the culture.
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2.2.4 197 neural stem cell culture
2.2.4.1 Laminin coating of tissue culture plasticware
197 NSC were grown on lam in in-coated tissue culture plastic. 1 mg/ml mouse laminin-1 
(Trevigen) was thawed at 4°C and diluted in cold DMEM/F12 to 20 pg/ml final concentration. The 
appropriate volume o f laminin (table 2.2) was used to generously cover the bottom o f the culture 
vessels and vessels were coated for 2-24 hours at 37°C. The laminin was aspirated and the vessels 
washed with double the original laminin volume o f DMEM/F12. Flasks were used immediately or 
stored at 4°C for 2-3 days.
culture volume of laminin to
vessel coat
T75 5 ml
T25 2.5 ml
6-well 2 ml
96-well 60 pi
Table 2.2 Volumes of laminin required to coat tissue culture vessels
2.2.4.2 Passage of 197 NSC
Cells were passaged at 80-90% confluency. Spent medium was aspirated from a T25 and cells 
washed with 5 ml Hank’s balanced salt solution (HBSS) for 2 minutes. 1 ml trypsin was added to 
the flask and incubated at 37°C until cells were detached. The trypsin was neutralised with 2.5 ml 
trituration solution (see appendix 1.3). Cells were harvested and pelleted at 160 ref for 5 minutes. 
The cell pellet was resuspended in fresh NSC culture medium (see appendix 1.1) supplemented 
with 20 ng/ml EGF (Sigma) and 10 ng/ml bFGF (Peprotech) and passaged lx lO 6 into a T75 flask, 
2.5x105 into T25 flask, 5x l04 in 6-well, 5x l03 in 96-well. Culture medium, with fresh growth 
factors (see appendix 1.2), was replenished every other day and cells passaged 2-3 times a week.
Reagents were not kept for more than 2 weeks at 4°C. 197 NSC were frozen as described in 2.2.3
in 90% NSC culture medium supplemented with 10% DMSO.
2.2.4.3 Differentiation of 197 NSC
Differentiation o f 197 NSC cultures was initiated at 50% confluency by removal o f growth factors, 
EGF and bFGF, from the culture medium. 50% o f culture medium was replenished every 5-7 days.
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2.2.5 PrP null neurosphere culture
2.2.5.1 Neurosphere isolation
Isolation o f neurosphere lines used methods similar to those described previously (Reynolds et al., 
1992;Reynolds and Weiss, 1992). Embryos from F5_FVB/PrP null mice were harvested at 
embryonic day 13.5. The brains were removed, transferred to a 35-mm plate containing F1BSS and 
mechanically dissociated roughly with a scalpel. The tissue was then enzymatically dissociated to 
a single cell suspension with 3% collagenase II-S (Sigma) for 10 minutes at 37°C, followed by 
trituration with a 200 pi Gilson pipette, and a further 3 minutes incubation at 37°C. The 
collagenase was neutralised with 10% FBS-containing NSC culture medium. The cells were 
centrifuged at 100 ref for 5 minutes and the pellet resuspended in 10 ml NSC culture medium 
supplemented with EGF, bFGF and lx  antibiotic/antimycotic (Sigma; containing lOOU/ml 
penicillin, lOOug/ml streptomycin, 250 ng/ml amphotericin). The cells were cultured in a T25 flask 
placed vertically in a humidified incubator at 37°C with 5% CCE. After 2 days, non-adherent cell 
aggregates were harvested and placed into a new T25 flask. After 4-7 days o f culture, distinct 
spheres o f cells containing CNS stem cells (neurospheres) were observed.
2.2.5.2 Neurosphere maintenance
Neurosphere cultures underwent a 50% media change every 3-4 days. Neurospheres were passaged 
every 7-10 days with 0.3% collagenase II-S at a ratio o f 1:4. Neurospheres from a T25 were 
pelleted at 100 ref, resuspended in 200 pi 0.3% collagenase II-S and incubated at 37°C for 10-15 
minutes. Neurospheres were gently triturated with a 200 pi Gilson pipette, and the collagenase 
neutralised with 10% FBS-containing NSC culture medium. The cells were centrifuged at 100 ref 
for 5 minutes and the pellet resuspended in NSC culture medium supplemented with EGF and FGF 
and passaged. To prevent attachment o f neurospheres to the culture vessel, the flasks were gently 
tapped every other day. Neurospheres were harvested and frozen, 2-3 days after passage as small 
neurospheres, in NSC culture medium supplemented with 30% FBS and 8% DMSO.
2.2.5.3 Growth of PrP null neurospheres as adherent stem cells
PrP null cells were cultured as adherent stem cells and could be differentiated as described for 197 
cells (section 2.2.4.3),
2.2.6 Determining plating efficiency for cell lines
10 cells per well were seeded in a 96-well plate and colonies counted under the microscope 3-4 
days later. The plating efficiency was calculated by taking the average number o f colonies per well 
divided by 10 and expressing as a percentage.
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2.3 Genera! molecular biology
2.3.1 Preparation of agar plates
For growth o f transformed E.coli, Luria Bertani (LB) agar was prepared (see appendix 2.2) in 
ddFLO, autoclaved and cooled to 50°C before the addition o f filter-sterilised ampicillin to 100 
pg/ml final concentration. The warm LB agar was poured carefully into 10 cm petri dishes and 
allowed to set overnight.
2.3.2 Transformation of competent E.coli
JM109 competent E.Coli cells (Promega) were thawed on ice; 100 pi was mixed quickly with 50 
ng plasmid DNA in a 12ml round-bottomed tube and placed on ice for 10 minutes. Control mock- 
transformation was performed using JM109 cells alone. Transformation was achieved by heat- 
shock at 42°C for exactly 50 seconds, after which cells were transferred back to ice for a further 2 
minutes. 900 pi filtered pre-warmed LB medium (see appendix 2.1) without antibiotics was added 
and the suspension incubated at 37°C for 45 minutes, whilst shaking at 150 rpm. Cells were 
concentrated by pulsing for 5 seconds and 100 pi and 400 pi o f transformed cell suspension were 
spread onto LB agar-ampicillin plates (section 2.3.1). These plates were inverted and incubated 
overnight at 37°C. The resultant transformed colonies were prepared for plasmid DNA extraction 
(section 2.33).
2.3.3 Maxi-prep of plasmid DNA
5 ml LB ampicillin medium was inoculated with a successfully transformed E.Coli colony from 
plates prepared above (section 2.3.2) and the culture grown for 8 hours at 37°C, whilst shaking at 
180 rpm. 1 ml o f this E.Coli starter culture was used to inoculate 500 ml LB-ampicillin medium 
and grown overnight on a shaker at 37°C. Plasmid DNA was extracted using QIAGEN maxi-prep 
kit according to manufacturer’s instructions. This system employs a modified alkaline lysis in 
conjunction with patented QIAGEN anion-exchange resin, which selectively binds plasmid DNA 
under appropriate low salt and pH conditions. Saturated overnight LB cultures were centrifuged 
for 15 minutes at 4°C at 6000 ref. The supernatant was discarded and the bacterial pellet 
resuspended completely in buffer PI (50 mM Tris-HCl, pH 8, 10 mM EDTA, 100 pg/ml RNase 
A). Cells were lysed under alkaline conditions by addition o f buffer P2 (1 % SDS, 200 mM NaOH) 
at RT for 5 minutes. To precipitate genomic DNA, chilled buffer P3 (3 M potassium acetate, pH 
5.5) was added and incubated on ice for 20 minutes. The lysate was centrifuged at 4°C, at 20,000 
ref for 30 minutes and the supernatant promptly removed and loaded onto an equilibrated 
QIAGEN 500-tip. Any residual impurities were removed by washing the tip twice with buffer QC 
(1 M NaCl, 50 mM MOPS). Pure plasmid DNA was eluted in high salt buffer QF (1.25 M NaCl,
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50 mM Tris-HCl pH 8.5), precipitated and desalted by mixing with 0.7 volumes o f isopropanol, 
followed by centrifugation at 15000 ref at 4°C for 30 minutes (the cold temperature encourages 
flocculation o f DNA). The DNA pellet was washed in 15 ml 70% ethanol, re-centrifuged, air-dried 
and resuspended in molecular biology grade H20.
2.3.4 Preparation of glycerol stocks
For long-term storage, 1ml fresh log-phase E.coli cultures (from starter cultures) were mixed with 
sterile glycerol to a final concentration o f 20% (v/v) glycerol. The glycerol culture was transferred 
to cryotubes, snap frozen in dry ice and stored at -70°C.
2.3.5 Spectrophotometric determination of DNA concentration and purity
DNA in solution has an absorption spectrum at 260 nm wavelength o f light (OD2<so), which can be 
used to calculate its concentration with the following formula:
DNA concentration (pg/ml) = OD26o x dilution factor x 50pg/ml
The ratio o f absorbance readings at 260 nm and 280 nm (OD26o/OD2xo) can be used to estimate the 
purity o f DNA in solution. 500 pi ddH20  was transferred to a clean quartz cuvette to set the 
reference point to zero on the spectrophotometer at both 260 nm and 280 nm. 5 pi o f the DNA 
sample solution was diluted in ddH20  to a total volume o f 500 pi and transferred to a second 
cuvette. Absorbance readings were taken at 260 nm and 280 nm. (OD26o and OD28(l). OD26<) 
readings o f less than 0.15 were considered unreliable. I f  this occurred, the dilution factor was 
reduced and a repeat measurement taken. The ratio o f OD26(>/OD2x<) for pure DNA preparations is 
from 1.8. Only sufficiently pure DNA, with an OD26o/OD2xo ratio o f between 1.8 and 2, was used 
for transfection.
2.3.6 Ethanol precipitation of DNA
This procedure was used to remove contaminants (e.g. protein) from the DNA preparation to 
ensure it was o f sufficient purity for transfection. To equalise the ion concentration, 1:10 volume 
3M sodium acetate (pH 5.2) was added to the DNA solution. 3 volumes o f cold 100% ethanol 
were added, the mixture vortexed and incubated at -80°C for 1 hour or -20°C overnight. The DNA 
was pelleted at 13,000 ref at 4°C for 15 minutes. The supernatant was fully removed with a pipette 
and the DNA pellet washed with 70% ethanol. The DNA was repelleted at 13,000 ref at 4°C for 5 
minutes, the supernatant removed and the pellet left to dry on a tissue before resuspending in 
molecular biology grade H20.
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2.3.7 DNA sequence analysis
This technique was kindly carried out by Gary Adamson, James Uphill and John Beck, to 
determine siRNA and human PRNP sequence. Human PRNP primers for PCR and sequencing are 
shown in appendix 5. SiRNA sequences were determined using pSuper.retro vector-specific 
primers (Oligoengine).
2.3.7.1 Polymerase chain reaction (PCR)
PCRs were carried out in 15 pi reactions containing 13.7 pi MegaMix Blue (Microzone), 0.15 pi 
forward primer (50 pM/pl), 0.15 pi reverse primer (50 pM/pl) and 1 pi template (genomic) DNA 
(-50 ng/pl). Cycling conditions on the Tetrad thermal cycler were polymerase activation step o f 
95°C for 3 minutes and then 34 cycles o f DNA template denaturation at 95°C for 30 seconds, 
primer annealing at 55°C (or relevant temperature) for 40 seconds, 72°C extension step for 45 
seconds, and a final extension step o f 72°C for 5 minutes and 15°C for 2 minutes.
23.1.2 Purification of PCR amplicons for sequencing
PCR products were purified using w/croCLEAN (Microzone), to remove reaction buffers, 
enzymes, primer dimers and unincorporated primers and dNTPs, following the manufacturer’s 
protocol. Briefly, an equal volume o f w/troCLEAN was added to a 96-well plate containing PCR 
products and incubated at RT for 5 minutes. The plate was centrifuged at 3000 ref for 40 minutes 
and then inverted onto absorbent paper and pulsed at 100 ref to discard the supernatant. The 
purified DNA pellet was then resuspended in 20 pi sterile distilled water.
23.13  Sequencing of purified templates and vectors
Automated fluorescent sequencing was carried out with the BigDye Terminator Ready Reaction 
K it (Applied Biosystems) and internal PRNP sequence primers. For the BigDye Terminator Ready 
Reaction Kit, a sequencing master-mix was made containing (per reaction) lp l BigDye 
terminators, 5pl BetterBuffer (Microzone), 0.5 pi forward/reverse primer (1 pM), and 7 pi sterile 
distilled water. A Gilson Distriman repeater-pipette was used to aliquot 13.5 pi BigDye master- 
mix into wells o f a skirted 96-well plate, to which 1.5 pi purified PCR products were added, for a 
total reaction volume o f 15 pi. Cycling conditions were 96°C for 30 seconds, followed by 30 
cycles o f 50°C for 15 seconds and 60°C for 3 minutes and a final hold step o f 15°C for 5 minutes.
2.3.7.4 Post-reaction clean-up with ethanol/salt precipitation
Sequencing products were precipitated to remove reaction buffers and unincorporated terminators 
to avoid tall early peaks, often termed “ terminator blobs” . 55 pi 100% absolute ethanol and 1 pi
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3M sodium acetate was added to 20 pi reaction and the mixture was chilled on ice for 15 minutes. 
The plate was centrifuged at 3000 ref for 45 minutes to pellet the DNA and the supernatant 
discarded by inverting onto absorbent tissue paper and pulse-centrifuging at 100 ref for 1 minute. 
150 pi 70% ethanol was added to wash the pellets and the plate was centrifuged at 3000 ref for 10 
minutes. Again, the plate was inverted onto absorbent tissue paper, pulse-centrifuged at 100 ref for 
1 minute to remove the supernatant and the pellet was allowed to air dry for 10 minutes.
2.3.7.5 DNA sequencing on the MegaBACE 1000 DNA Analysis System
The automated MegaBACE 1000 DNA Analysis System (Amersham Pharmacia) was used to 
sequence DNA. The MegaBACE uses capillary array electrophoresis to perform fragment size 
separation o f fluorescently labelled DNA samples with a confocal optical system to collect data. 
The manufacturer’s guidelines and protocols were followed unless otherwise stated. Precipitated 
DNA with fluorescently labelled terminators, was resuspended in 10 pi MegaBACE Loading 
Buffer (Amersham Pharmacia), vortexed thoroughly to ensure the complete solubilisation o f the 
DNA and then pulse-centrifuged to return the liquid to the bottom o f the 96-plate wells.
MegaBACE Long Read Sequencing Matrix (Amersham Pharmacia) was used to pressure-fill the 
capillary array with sieving matrix to separate DNA fragments o f varying sizes. Sequencing 
products were electrokinetically injected into the capillary array by a potential difference o f 3 kV 
for 40 seconds and electrophoresis was carried out in lx  LPA Buffer (Amersham Pharmacia) at 9 
kV for 100 minutes. Laser excitation o f the fluorescently-labelled samples yielded data as an 
electropherogram for each capillary/sample which were analyzed in forward and reverse directions 
using the Sequence Analyser v3.0 package (Molecular Dynamics), and inspected by eye.
2.4 Human PrP expression
2.4.1 Human PrP expression vectors
Human PRNP 1 kb open reading frame (ORF) was cloned into BamHl and Notl restriction sites 
o f pcDNA3.1(+).neo (Invitrogen, UK; appendix 4.1A) and into Bgl II and Notl o f retroviral 
vector, pLNCX2.neo (Clontech, USA; appendix 4.1 B), by Professor Parmjit Jat. Following 
cloning, the human PrP ORF was checked for mutations by DNA sequence analysis (2.3.7),
2.4.2 Plasmid DNA transfection of human PrP
BE(2)M17, H4, HEK293, RG6 and N2aG cells were transfected with pcDNA3.1 human PrP 
expression vector using GeneJammer transfection reagent (Stratagene), according to 
manufacturer’s instructions. The reagent is a cationic polyamine which binds negatively charged
65
Chapter 2 Materials and Methods
DNA in micelles, the non-polar lipids on the outer layer o f the micelles allow DNA entry into the 
cell by fusion with the plasma membrane. Briefly, cells were seeded in 6-well plates, 24 hours 
prior to transfection to reach exponential growth phase (-50% confluency). 100 pi 
unsupplemented, serum-free medium was incubated with 6 pi GeneJammer reagent for 10 minutes 
at RT. 3 pg plasmid DNA was added to the transfection mix and incubated for a further 10 
minutes. 900 pi FBS-containing culture medium was added to cells in a 6-well, the transfection 
mix added dropwise to the cells and the plate rocked back and forth gently to mix. Control wells 
without DNA were set up. Cells were incubated overnight and the transfection mix replaced with 1 
ml fresh culture medium in the morning. 24 hours later, cells were passaged; each 6-well 
transferred to three 10 cm dishes. About 12 hours later, cells were selected with the appropriate 
concentration o f G418 (table 2.1) until stable colonies became visible (after 2-3 weeks in vitro). 
The appropriate G418 selection concentration for each cell line was determined by performing a 
G418 kill curve (section 2.4.5). Either stable clones were pooled to produce “ mixed clones”  or 
single cell clones were isolated by picking colonies or by lim iting dilution subcloning (as 
described in 2.4.2.1).
2.4.2.1 Isolation of single cell clonal lines
Two methods were used for the isolation o f single cell clones: colony picking and lim iting dilution 
subcloning. For colony picking, medium was removed from the 10 cm dish and single discrete 
colonies expressing sequence o f interest were picked from 10 cm dishes with a sterile 200 pi 
Gilson tip and transferred to 96-well plate containing culture medium (150 pi per well). For 
dilution subcloning, the stable mixed transfected population, expressing the sequence o f interest, 
was seeded at 3 cells per well in a 96-well plate. 24-48 hours after plating, wells were examined 
and those with 1 cell or a small colony derived from one cell were marked and expanded.
2.4.3 Packaging of human PrP into retroviral producer cell line
Human PrP expression vector, pLNCX2, was transiently transfected into the PhiNX cell line to 
produce retroviral particles containing human PRNP ORF. PhiNX-eco cells were used to produce 
supernatant to infect mouse lines and PhiNX-ampho for infection o f cell lines o f other species. 
PhiNX cells were seeded at lx lO 6 cells per 10 cm dish 24 hours prior to transfection to achieve 
exponential growth phase. Transfection was performed with FuGene 6 (Roche) according to 
manufacturer’s instructions; 10 pg plasmid DNA and 12 pi FuGene were used per transfection 
reaction. 10 ml retroviral human PrP supernatant was harvested from each culture dish 48 hours 
and 72 hours after transfection and passed through a 0.45 pm filter to remove cells. Supernatant 
was used fresh or 5-10 ml aliquots made for storage at -80°C.
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2.4.4 Retroviral transduction of human PrP
Retroviral transduction is more efficient than plasmid transfection because the gene o f interest 
becomes integrated into the genome and it is also less harsh on the cells (Blanton, Jr. et al., 2000). 
Cells for human PrP transduction (RK13, L929, N2a and Prnp knockout PK1 clones) were seeded 
in 6-well plates to achieve exponential growth phase 24 hours later. In 72 hours, three rounds o f 
human PrP retroviral transduction were performed. Cells were incubated overnight with 50% 
retroviral supernatant (prepared as described in section 2.4.3) in culture medium, supplemented 
with 8 pg/ml polybrene (a cationic polymer, which improved viral infection efficiency by 
facilitating membrane fusion). Cells were also transduced using pLNCX2 vector-only control 
supernatants. Cells were allowed to recover for 24 hours before plating at a low density (25,000 
cells per 10 cm dish in quintuplicate) and allowed to adhere. Cells successfully transduced with the 
human PrP expression vector were selected with the appropriate concentration o f G418 (see table
2.1). Stable human PrP-expressing clones (mixed and single) were isolated as described in 2.4.2.1, 
PrPc expression level was assessed by immunoblotting.
2.4.5 Antibiotic kill curves
Selection antibiotics used were G418, puromycin, and hygromycin, which all k ill cells not 
expressing the relevant resistance gene by inhibiting different stages o f protein synthesis. The 
antibiotic selection concentration for each cell line was determined by performing a “ k ill curve”  as 
follows. Two 6-well plates, with cells at 40% confluency, were treated with a titration o f selection 
antibiotic in culture medium. Five concentrations o f antibiotic were added to wells in duplicate, 2 
control wells were set up with no antibiotic. Selection medium was replenished every 3-4 days and 
the percentage o f surviving cells assessed by direct visualisation with light microscopy. The 
optimum selection concentration was the one resulting in 100% cell death after 3-14 days 
(depending on antibiotic). K ill curves for G418 lasted for 7-10 days, for puromycin for 3-4 days 
and for hygromycin B for 10-14 days. For G418, 200, 400, 600, 800 and 1000 pg/ml were tested, 
for puromycin, 1, 2, 5, 7.5 and 10 pg/ml were tested and for hygromycin B 50, 100, 250, 500 and 
1000 pg/ml were tested
2.4.6 Isolation of human PrP-expressing single cell clones for vCJD prion infection
Prnp knockout PK1 clones were transduced with human PrP as described in section 2.4.4 and 
single cell clones isolated by colony picking (2.4.2.1). Clones were grown to confluency and 
passaged 1:8 to two replica 96-well plates. One plate o f the pair was infected with vCJD prion- 
infected brain homogenate (section 2.7.2), the other plate was grown to confluency and frozen in 
100 pi freeze medium, wrapped in tissue and aluminium foil and stored at -80°C. I f  the infected
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plate revealed any vCJD prion-infected clones, it was planned the replica plate would be thawed 
and the vCJD prion-susceptible clones expanded and re-infected.
2.5 Knockout of Prnp using RNA interference
2.5.1 SiRNA sequence design for mouse Prnp knockout
Short hairpin RNAs were designed to selectively knockdown mouse Prnp expression but not 
human PRNP expression. Eight 19-mer siRNA duplexes were designed to exactly targeting mouse 
Prnp mRNA and contained a 3'UU overhang (to prevent nuclease digestion; table 2.3). Sequences 
#1, #2, #3 and #4 were designed by Professor Parmjit Jat using a set o f empirical design rules (see
4.4.1.1). Briefly, these included targeting sequences 50-100 base pairs upstream o f Prnp, starting 
with an AA dimer and using the next 19 nucleotides, avoiding stretches o f more than four A and T 
(a termination signal for polymerase 111) and ensuring the GC content was between 30 and 50%. 
Sequences #5, #6, #7 and #8 were designed by Dharmacon Inc. (USA) using SMART Selection™ 
technology, which employs an algorithm to select functional siRNAs (Reynolds et al., 2004). 
siRNA #1 targeted the mouse Prnp open reading frame (containing four mismatches with human 
cDNA sequence) and siRNA #2 to #8 targeted the 3'UTR o f mouse Prnp.
SiRNA
number
Location in mouse 
prion protein mRNA Base pair Sequence
1 coding region 470 - 490 AACCAACCTCAAGCATGTGGC
2 3' UTR 1072- 1092 AATGTACAGTAGACCAGTTGC
3 3‘ UTR 1392- 1412 AACGATAGCTGATTGAAGGCA
4 3' UTR 2039 - 2059 AATCTGCATGTACTTCACGTT
5 3’ UTR 1693- 1711 GAGAGACAATCTAAACATT
6 3' UTR 1695- 1713 GAGACAATCTAAACATTCT
7 3' UTR 1760- 1778 GAAATTCTGCTAGCATTGT
8 3' UTR 1512- 1530 TAGGAGATCTTGACTCTGA
Table 2.3 Location of siRNA target sequences in mouse Prnp mRNA
siRNAs #1-4 (black) were designed by Professor Parmjit Jat using empirical design rules. 
Dharmacon Inc (blue) designed siRNAs #5-8 using in silico technology.
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2.5.2 Cloning of siRNA into pSuper.retro.puro expression vector
SiRNA oligonucleotides #l-#8 were cloned into the pSUPER.retro.puro expression vector 
(OligoEngine Inc., USA; appendix 4.2A) by Professor Parmjit Jat, according to the 
manufacturer’s instructions. Briefly, 64-mer duplexes (comprising the siRNA target sequence in 
sense and anti-sense orientations, separated by a 9-nucleotide spacer sequence) were ligated into 
the vector cloning site between Bgl II and Hind III, under control o f the RNA polymerase III HI 
promoter. This system transcribes a short hairpin RNA, which is processed intracellularly by the 
enzyme, Dicer, to functional siRNA (figure 2.1). This system allowed stable expression o f siRNA 
and the potential for long-term knockdown o f target Prnp gene expression. Vector-specific 
primers were used to verify the correct sequences o f siRNA #1 -#8.
G A C U C C A G U G G U A A U C U A C U U  
U U C U  G A G G U  C  A C  C A U U A G A U  G
4  Dicer cleavage
TTU C AG A C U C C A G U G G U A A U C U A C u  \  
U U C U G A G G U C A C C A U U A G A U G  A G
a g a
A transcription of 
I short hairpin
(Bgl II) Target sequence: sense (Hairpin) Target sequence: antisense
5 '  -GATCCCCGACTCCAGTGGTAATCTACTTCAAGAGAGTAGATTACCACTGGAGTCTTTTTA-3'
3 ' -GGGCTGAGGTCACCATTAGATGAAGTTCTCTCATCTAATGGTGACCTCAGAAAAATTCGA-5 '
(Hind III)
------------------------------------------------------  Oligonucleotides  '
T
Figure 2.1 Shorthairpin RNA processing
60-nucleotide sequences are transcribed to form to hairpin RNA and processed intracellularly by 
Dicer to functional siRNAs. Figure modified from www.oligoengine.com.
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2.5.3 Cloning of siRNA into pM SCV.hyg expression vector
To allow for co-expression o f two siRNA sequences in the same cell, siRNAs #2-#5 expression 
cassettes were cleaved from the pSuper.retro vector, at the Xho I and EcoRl sites, and cloned into 
another retroviral vector: pMSCV, with a hygromycin B selectable marker (Clontech, USA; 
appendix 4.2B).
2.5.4 Packaging of siRNA expression vector into retroviral producer cells
siRNA expression vectors (pSUPER.retro.purosiRNA or pMSCV.hygsiRNA) were transiently 
transfected into the PhiNX-eco retroviral producer line to produce ecotropic retroviral supernatant. 
Cells were seeded at lx  106 cells per 10 cm dish, 24 hours prior to transfection to achieve 
exponential phase o f growth. Transfection was performed with FuGene 6 (Roche) according to 
manufacturer’s instructions; 10 pg plasmid DNA and 12 pi FuGene were used per transfection
reaction. 10 ml ecotropic retroviral siRNA supernatant was harvested from each dish o f cells 48
hours and 72 hours after transfection, and passed through a 0.45 pm filter to remove the cells. 
Supernatant was used fresh or 5-10 ml aliquots made for storage at -80°C.
2.5.5 Retroviral transduction of N2a and PK1 cells with shRNA targeting Prnp
N2a and PK.1 cells were seeded at 70,000 cells per well in 6-well plates to achieve exponential 
growth phase for retroviral transduction 24 hours later. In 48 hours, 2 rounds o f retroviral 
transduction were performed. Cells were incubated overnight with 50% retroviral siRNA 
supernatant in OptiMEM culture medium, supplemented with 8 pg/ml polybrene. Vector-only and 
no vector control supernatants were used as controls. Fresh medium was replenished and cells 
were allowed to recover for 24 hours before plating at a low density (25,000 cells per 10 cm dish 
in quintuplicate) and allowed to adhere. Cells successfully transduced with the siRNA expression 
vector were selected with puromycin at 4 pg/ml (for pSuper.retro.puro) and hygromycin B at 50 
pg/ml (for pMSCV.hyg). Both stable mixed clones and single cell clones expressing siRNA were 
established. Single cell clones were isolated as described in 2.4.2.I. The effect o f stable Prnp- 
specific siRNA expression on PrPc expression levels was assessed by immunofluorescence and 
immunoblotting o f both clonal and mixed populations.
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2.5.6 Quantitation of Prnp mRNA in cell lines
2.5.6.1 RNA extraction from cell lines
Cells were harvested from 6-well plates at 80% confluency. Culture medium was aspirated from 
the plates and cells washed with PBS. 750 pi Trizol reagent (Invitrogen) was added per well and 
plates placed on a shaker for 5 minutes at RT. Each well o f Trizol-lysed cells was transferred to 
one 1.5ml eppendorf tube, shaken vigorously by hand for 15 seconds and left to stand at RT for 5 
minutes. 200 pi chloroform was added to each tube, shaken for 15 seconds and left to stand at RT 
for 5 minutes. Tubes were then centrifuged at 12,000 ref for 10 minutes at 4°C to separate into
aqueous and organic phases. Transfer the upper colourless aqueous phase (containing RNA) into a
fresh eppendorf tube. RNA was precipitated by addition o f 750 pi isopropanol to each tube. Tubes 
were shaken for 15 seconds and left to stand at RT for 10 minutes. RNA was pelleted by 
centrifugation at 12,000 ref for 15 minutes at 4°C and tubes placed on ice. The RNA pellet was 
washed with 180 pi 100% ethanol, vortexed and re-pelleted by centrifugation 13,000 ref for 5 
minutes at 4°C. The ethanol was carefully aspirated, the pellet air-dried for 10 minutes and 
dissolved in water. RNA concentration and purity were determined spectrophotometrically in a 
similar way to DNA, as described in section 2.3.5. RNA was diluted 300-fold and absorbance 
readings taken at 260 nm and 280 nm. The RNA concentration o f the solution was calculated 
using the following formula:
RNA concentration (pg/ml) = OD26o x dilution factor x 40pg/ml
Only RNA o f purity (OD26o/OD2xo ratio) greater than 1.9 was used for PCR reactions.
2.5.6.2 cDNA synthesis
A ll reagents obtained for the cDNA synthesis step were acquired from Invitrogen. The cDNA 
synthesis assays were performed in 20 pi reaction volumes, as described. First, 1 pg RNA was 
combined with 2.5 pi random primers (100 ng/ul) and RNAse-free water to a total reaction volume 
o f 11 pi, and denatured by heating to 70°C for 10 minutes. The tube was immediately cooled on 
ice and briefly centrifuged (30 seconds at 13,000 ref). The following mixture was added to each 
reaction and heated to 25°C for 10 minutes: 4 pi 5X First Strand Buffer, 2 pi 0.1 M DTT, 1 pi 
dNTP and 1 pi RNAase out. Finally 1 pi Superscript II reverse transcriptase was added to the 
reaction mix and stirred with a pipette tip. The reverse transcriptase reaction conditions were as 
follows: 25°C for 10 minutes, 42°C for 10 minutes and 70°C for 10 minutes.
2.5.6.3 Quantitative real-time PCR (qRT-PCR)
Prnp mRNA expression levels in Prnp knockout PK1 and N2a clones were quantified compared to 
wild-type by qRT-PCR and data normalised against GAPDH house-keeping gene. The mouse
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P rnp  FAM-labeled probe and primer set (ABI# Mm00448389_ml) and rodent GAPDH VIC- 
labeled probe and primer set (ABI# 4308313) used were acquired from ABI and made up 
according to the manufacturer’ s instructions. The multiplex qRT-PCR assay was performed in 25 
pi reaction volumes. A qRT-PCR master mix was prepared on ice consisting o f 12.5 pi QuantiTect 
Probe PCR master mix (2x), 1 pi mouse P rnp  probe/primer, 1 pi GAPDH probe/primer and 8.5 pi 
ddHiO. The 23 pi qRT-PCR master-mix was aliquoted using a Gilson Distriman repeater-pipette 
into a MicroAmp Optical 96-well reaction plate on ice and 2 pi cDNA added (~50 ng/pl; prepared 
as described in 2.5.6.2), Plates were sealed using MicroAmp optical adhesive seals with particular 
attention paid to sealing around the edges o f the plate to prevent evaporation. Plates were then 
vortexed briefly at medium speed for 2 seconds and pulse centrifuged at 3000 ref. Plates were run 
on an ABI 7000 detection system, following the manufacturer’s protocol. A rubber evaporation 
mat supplied with the machine was used to prevent evaporation. Cycling conditions were as 
follows: 95°C for 10 minutes, 40 cycles o f 94°C for 15 seconds and 60°C for 1 minute. Data were 
analysed using ABI sequence detection software vl.3.1 (Applied Biosystems)
2.5.6.4 Quantitation of relative Prnp gene expression using the comparative threshold 
method
Comparative threshold (A A C t) method was used to determine relative P rnp  gene expression levels 
o f knockout clones (Heid et al., 1996). In order to apply the A A C t method, it was necessary to 
determine that the amplification efficiencies o f both target (P rn p )  and normaliser (GAPDH) 
probes were equal. This was done by generating a standard curve: five 1:2 serial dilutions (1:2 -  
1:32) o f PK1 wild-type template cDNA were prepared and run in quintuplicate on qRT-PCR (as 
described in 2.5.6.3), A plot o f log dilution o f cDNA against cycle threshold (Ct; cycle number at 
which fluorescence emission exceeds a fixed threshold) for each probe was drawn and slopes o f 
the lines determined. Equal slope values (within 0.1 o f each other) indicated the probe efficiencies 
were equal and that the A A C t method could be applied.
Briefly the A A C t method involved the following calculations:
•  The difference in CT values between target and normaliser were calculated 
ACt= Ct  (sample) - CT (GAPDH)
•  The comparative AACT calculation found the difference between the samples ACT and a 
baseline ACT
AACj = ACt (sample) - ACT (PK1 wild-type)
•  These values were then transformed to absolute values with the following formula:
2  AA C T
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2.6 Protein detection techniques
Table 2.4 shows anti-PrP monoclonal antibodies and the detection technique in which they were 
used.
antibody epitope (human PrP) PrP species detected technique
ICSM18 143-153 mouse, human, ovine, 
bovine, hamster
immunofluorescence, SCA, 
curing of prion-infected cells
ICSM35 93-102 mouse, human, ovine, 
bovine, hamster
immunoblotting, FACS
3F4 1 0 9 - 1 1 2 human, hamster, feline immunoblotting
Table 2.4 PrP-specific monoclonal antibodies
2.6.1 Protein quantitation assay
A ll protein assays were performed using the Pierce BCA™ protein assay reagent. This system uses 
the reaction o f protein with Cu2" in an alkaline environment to form Cu‘\  which is then detected 
by the reagent bicinchoninic acid (BCA). The purple reaction product o f BCA and Cu1* is water- 
soluble and exhibits a strong absorbance at 562 nm. For each assay a set o f protein standards was 
made using dilutions o f bovine serum albumin (BSA) in the same diluent as the unknown samples 
( lx  sample buffer or PBS). The BSA standards were made at the following protein concentrations 
to cover expected concentration o f samples: 0, 25, 125, 250, 500, 750, 1000, 1500, 2000, 3500, 
5000 pg/ml. The assays were performed in a microplate format according to the manufacturer’s 
instructions. 10 pi o f each sample was pipetted into a 96-well plate to which 200 pi working 
reagent (50 parts BCA reagent A to 1 part BCA reagent B) was added. The plate was kept in the 
dark and incubated at 37°C for 30 minutes. The plate was cooled to RT before reading absorbance 
at 570 nm. Each assay was performed in duplicate and 2 dilutions o f each sample were used. The 
protein concentration o f each sample was determined from the BSA standard curve, using the 
regression feature o f GraphPad Instat software.
2.6.2 Protein extraction for immunoblotting
2.6.2.1 Extraction of protein from cell culture for PrPc detection
A confluent 10 cm dish o f cells was washed in ice-cold PBS (without Ca2+ and Mg2+) and the cells 
harvested using a cell scraper. The cells were collected by centrifugation at 160 ref for 5 minute at 
4°C and the cell pellet washed a further two times in ice-cold PBS to remove all traces o f serum.
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The cell pellet was then resuspended in 100-250 pi o f ice-cold lx  Complete EDTA-free protease 
inhibitor cocktail (Roche), supplemented with 1 mM MgCl2 and 50 units/ml Benzonase (VWR). 
The cells were then lysed by three ffeeze-thaw cycles in liquid nitrogen. Samples were incubated 
on ice for 15 minutes to allow Benzonase to digest nucleic acids and reducing sample viscosity. 
Samples were solubilised by boiling for 10 minutes at 100°C in final concentration lx  sample 
buffer (final concentration; see appendix 3.1 for 2x recipe), without bromophenol blue or P- 
mercaptoethanol, which would interfere with the subsequent BCA assay. Samples underwent 
centrifugation at 16,000 ref for 10 minutes and the supernatant was collected. A BCA protein 
quantitation assay (section 2.6.1) was performed using lx  sample buffer as the diluent. Samples 
were subsequently adjusted to 1 mg/ml protein with PBS, supplemented with 0.013% 
bromophenol blue and 2% P-mercaptoethanol reducing agent and boiled for 10 minutes at 100°C 
to fully denature the protein. Samples underwent centrifugation at 16,000 ref for 2 minutes to 
pellet any insoluble material prior to SDS-PAGE.
2.6.2.2 Deglycosylation of PrPc
Protein extraction from cells was performed (section 2.6.2.1) and cell lysates adjusted to 2 mg/ml 
protein concentration. Following the protein denaturation step and clarification o f the lysate with a 
short spin, 30 pg o f sample was taken for deglycosylation. Cell lysates, originally containing 4% 
SDS, were diluted in fresh deglycosylation buffer (see appendix 3.2) to a final 0.1% SDS 
concentration and treated with 30 units/ml /V-glycosidase F (PNGase; Roche) for 4 hours at 37°C 
in a thermomixer. Protein precipitation o f samples was achieved by adding 6 volumes o f ice-cold 
methanol and centrifugation at 16,000 ref for 30 minutes. The supernatant was removed and 
pellets air-dried before dissolving in lx  sample buffer and analysis by immunoblotting.
2.6.2.3 Extraction of protein from cultured cells for PrPSc detection
Cell lysates were prepared in a similar way to those for PrPc detection (section 2.6.2.1). However, 
after harvesting the cell pellet was resuspended in ice-cold PBS instead o f the protease inhibitor 
cocktail, which would have interfered with subsequent proteinase K (PK) digestion. Two wells o f 
a 6-well plate were harvested and resuspended in 30 pi ice-cold PBS. The BCA protein 
quantitation assay (section 2.6.1) was performed prior to boiling in 1 x sample buffer, using PBS as 
the diluent. Cell lysates were adjusted to 2.5 mg/ml with PBS prior to PK digestion.
2.6.2.4 Proteinase K digestion of cultured cells and brain tissue
Cell lysates (as prepared in section 2.6.2.3) were digested with Proteinase K (PK; Roche) at 5 
pg/mg protein for 30 minutes at 37°C on a thermomixer. 10% brain homogenate was first treated
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with 50 units/ml Benzonase for 30 minutes at 37°C, followed by 10 pg/mg PK digestion for 1 hour 
at 37°C. To halt PK digestion, samples were mixed 1:1 with 2x sample buffer (see appendix 3.1) 
supplemented with 4 mM AEBSF protease inhibitor (from lOOmM stock in DMSO) and 2% (3- 
mercaptoethanol. Samples were boiled for 10 minutes at 100°C, centrifuged at 16,000 ref for 2 
minutes to pellet any insoluble material prior to SDS-PAGE.
2.6.2.5 PrP** precipitation from cell lysates with sodium phosphotungstic acid (NaPTA)
Sodium phosphotungstic acid (NaPTA) is a lead containing compound, which is used in this 
protocol to pull down aggregated material, i.e PrPSc and not monomeric PrPc (Safar et al., 1998). 
The protocol is adapted from Wadsworth and colleagues (Wadsworth et al., 2001). vCJD prion- 
infected cell lysates were prepared using the same protocol described in 2.6.2.3 and diluted 1:1 
with 4% (w/v) sarkosyl in PBS (pH 7.4), followed by incubation at 37°C for 10 minutes on a 
thermomixer. Following centrifugation at 500 ref for 1 minute, pre-warmed 4% (w/v) 
NaPTA/170mM MgCl2 (prepared in ddH20  titrated to pH 7.4) was added to the sample to a final 
concentration o f 0.3% NaPTA. The sample was incubated at 37°C for 30 minutes on a 
thermomixer, followed by centrifugation at 15,000 ref for 30 minutes. The supernatant was 
discarded and the pellet resuspended in 20 pi final volume with 0.1% sarkosyl in PBS (pH 7.4). 5 
pg/mg PK (final concentration) was added to the 20 pi resuspended NaPTA pellet and the sample 
incubated at 37°C for 1 hour on thermomixer. Centrifugation o f the sample at 15,000 ref for 1 
minute was followed by addition o f AEBSF and boiling in lx  sample buffer as described in 
2.6.2.4,
2.6.2.6 Immunoblotting
2.6.2.7 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) of protein extracts
Protein samples (prepared as in section 2.6.2) and 10 pi SeeBlue pre-stained markers (Invitrogen, 
UK) were loaded onto pre-cast 16% Tris-Glycine 1.5 mm SDS-PAGE mini-gels (Novex, UK) set 
up in an XCell Surelock™ mini-cell tank (Invitrogen, UK) containing running buffer (see 
appendix 3.4). Unless stated otherwise, 25 pg protein was loaded per lane. Gels were 
electrophoresed at 200 V for 80 minutes.
2.6.2.8 Protein transfer
Following SDS-PAGE, gels were electroblotted onto Immobilon PVDF membrane (Millipore). 
The hydrophobic membrane was first wet in 100% methanol (BDH), followed by a 5 minute soak 
in blotting buffer (see appendix 3.5). Three pieces o f Whatman No.l filter paper (Whatman Ltd,
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Kent) and 5 sponges were also soaked in blotting buffer. A piece o f filter paper was laid on top o f 
a sponge, followed by the gel. The membrane was laid onto the gel, taking care to exclude air 
bubbles, followed by two sheets o f filter paper. This was then sandwiched between 5 sponges and 
laid inside a Novex blot module and placed into an XCell Surelock™ mini-cell tank (Invitrogen, 
UK). The tank was filled with blotting buffer. Electroblotting was performed at 35 V for 90 
minutes.
2.6.2.9 Immunodetection of PrP
After electroblotting, membranes were transferred to square tissue culture dishes (Falcon) and 
washed in PBST (see appendix 3.7) to remove excess blotting buffer. The membrane was blocked 
for 1 hour at RT with gentle agitation in 5% non-fat milk powder (Marvel Premier Brands, UK) in 
PBST and washed 4 times in PBST. Overnight incubation at RT o f the membrane in anti-PrP 
primary antibody (biotinylated-lCSM35; D-Gen Ltd., UK, or 3F4; Covance) diluted as appropriate 
in PBST (0.25 pg/ml or 1:5000, respectively) was followed by 5 washes in PBST over 45 minutes. 
An avidin-biotin alkaline phosphatase (AP)-conjugated complex (DAKO) was used for secondary 
labeling o f the biotinylated primary antibody. The complex was prepared according to 
manufacturer’s instructions in PBST. AP-conjugated goat anti-mouse IgG and IgM secondary 
antibody (Biosource) was used in conjunction with 3F4 primary antibody. The membrane was 
incubated for 45 minutes at RT with secondary antibody and then washed for 1 hour in PBST, 
followed by two 5 minute washes in Tropix Assay Buffer (see appendix 3.8). It was developed 
using Tropix CDP-Star chemiluminescent AP-substrate (Applied Biosystems). The membrane was 
placed between 2 pieces o f acetate paper and visualized by exposure to Biomax MR film  
(Anachem) before development and fixation. Western blots presented in this thesis are 
representative o f at least 3 replicates.
2.6.2.10 Coomassie staining of protein on tris-glycine gel
Following SDS-PAGE, gels were stained for 30 minutes with 0.1% (w/v) Coomassie brilliant blue 
R in 30% (v/v) methanol and 10% (v/v) acetic acid. Subsequently gels were washed with destain 
(40% [v/v] methanol, 10% [v/v] acetic acid) until protein bands were visible. Bands were 
visualised on a light box and photographed using 677 Polaroid gel cam (Sigma). This procedure 
was used to check successful protein transfer and equal protein loading in PK-digested samples 
when reprobing with P-actin was not possible.
2.6.2.11 Densitometric analysis of imrminoblot for quantitation of PrPc expression levels
Densitometry analysis was performed from film  using a Kodak Image Station 440CF with Kodak 
ID  3.6 image analysis software. The net intensity values for the PrPc bands were determined for
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Prnp PK1 KO clones transduced with human PrPc and then expressed as a fold increase in PrPc 
expression compared to the wildtype PK1 cell line.
2.6.3 Immunofluorescence staining
2.6.3.1 Preparation of coverslips for immunofluorescence
Poly-L-lysine is a non-specific attachment factor for cells and functions to enhance electrostatic 
interaction between negatively charged ions o f the cell membrane and the culture surface. When 
adsorbed to the culture surface, poly-L-lysine increases the number o f positively charged sites 
available for cell binding. For immunofluorescence experiments, sterile 22 mm glass coverslips 
(BDH) were coated with 1 mg/ml poly-L-lysine hydrobromide (Sigma P I399; in sterile water). 
Briefly, one coverslip was placed in each well o f 6-well plates. 400 pi poly-L-lysine was pipetted 
onto the coverslip surface and left to coat for at least 30 minutes at RT. Coverslips were then 
washed three times in sterile distilled water and air-dried in a laminar flow hood before use. 
Depending on cell lines, 30-50,000 cells were seeded onto each coverslip and grown to 75% 
confluency before immunocytochemistry. Sufficient coverslips were set up to allow for secondary 
antibody-only controls and for each condition to be tested in duplicate.
2.6.3.2 Immunofluorescence staining protocol
Cells were fixed onto glass coverslips (prepared as in section 2.6.3.1) using 4% (w/v) 
paraformaldehyde (pH 7.4) for 20 minutes at RT, washed three times with PBS, and then 
permeabilised in 100% methanol at -20°C for 15 minutes. Following another three PBS washes, 
cells were incubated in 10% normal goat serum (NGS) for 30 minutes at 37°C in a humidified 
chamber. The primary antibody for the desired target protein (see table 2.5) was diluted to the 
appropriate concentration in 1% NGS in PBS and applied to coverslips for 1 hour at 37°C in a 
humidified chamber. The secondary antibody-only controls were incubated in 1% NGS in PBS 
during this period to determine i f  primary antibody binding was specific for the target protein. 
After washing with PBS, cells were incubated for 45 minutes with the desired fluorescent-tagged 
goat anti-mouse or anti-rabbit secondary antibody (Molecular Probes Inc), diluted to the 
appropriate concentration in 1% normal goat serum in PBS (see table 2.5) at 37°C in a humidified 
chamber. The coverslips were then washed three times in PBS and mounted in antifade medium 
(DAKO) containing either 1 pg/ml 4',6-diamidino-2-phenylindole (DAPI) or 1 pg/ml Hoechst for 
nuclear counterstaining.
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Primary
antibody
Antibody
host
Supplier Concentration Secondary
antibody
Concentration
anti-PrP mouse D-Gen UK, Ltd 10 ug/ml AlexaFluor 488 1:1000
ICSM18
nestin mouse Chemicon 1:500 AlexaFluor 555 1:500
Bl I l-tubulin mouse Sigma 1:1000 AlexaFluor 488 1:200
GFAP rabbit DAKO 1:5000 AlexaFluor 568 1:2500
Table 2.5 Antibodies used for immunofluorescence
2.6.3.3 Immunofluorescence image acquisition and analysis
Images were obtained using a Zeiss Axioplan 2 MOT microscope and Plan Neofluar 10x/0.30 Phi 
objective at RT. A Zeiss AxioCam MRm camera controlled by Axiovision Control software was 
used. Dr Mark Kristiansen helped to obtain fluorescent images using a confocal microscope (Zeiss 
microscope LSM510 META). The microscope was equipped with a “ plan-Apochromat”  63x/1.40 
Oil DIC objective and is controlled by Zeiss LSM software. Fluorescence was recorded at 488 nm 
using 30 mW argon laser for excitation. Zeiss immersol™ 518 F was used as imaging medium. At 
least 5 random fields o f view were studied from duplicate coverslips and assessed for target 
protein expression, specificity was determined by comparison with secondary antibody only 
controls. Results were corroborated blind by a second operator.
2.6.4 Fluorescence activated cell sorting (FACS)
FACS was used for isolation o f human PrPc over-expressing cells. Stable human PrPc clones were 
transduced with human PrPc by three overnight rounds o f retroviral infection (section 2.4.4). 
FACS sorting was performed 48 hours later.
2.6.4.1 Harvesting cells and PrP immunostaining for FACS
Cells were maintained on ice and kept in sterile conditions throughout the procedure. Cells were 
washed twice in ice-cold PBS, harvested by trituration and counted. Cells were pelleted by 
centrifugation at 160 ref for 5 minutes at 4°C and resuspended at 2 x 106 cells per ml. 400,000 
cells o f each cell line were set aside for secondary antibody-only controls. The remaining cells 
were incubated for 45 minutes at 4°C with ICSM35 anti-PrP antibody diluted to 2.5 pg/ml in PBS 
containing 0.01% sodium azide preservative. Following two washes in PBS, cells were incubated 
for 45 minutes at 4°C in the dark with FITC-conjugated anti-mouse IgG Fab (Sigma) diluted 1:50 
in PBS containing 0.01% sodium azide. Following a wash with PBS, cells were resuspended in 3
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ml OptiMEM medium with 5% serum, placed in capped sterile FACS tubes (Falcon) and 
maintained on ice until sorting.
2.6.4.2 Isolation of cells with high human PrPc expression by FACS
Sorting was perfomied on a Beckman Coulter Epics Altra sorter with Expo2 software (Institute o f 
Child Health, London) with FACS technician, Joanne Buddie. Cells were excited by a 488 nm 
argon laser, and PrP FITC-positive cells collected using 525 nm +/- 20 nm bandpass filter. 
Forward scatter and side scatter characteristics were used to gate out dead cells, debris and clumps. 
Cells expressing greater than endogenous PrP( levels (outside secondary antibody-only control 
and wild-type gates) were sorted. Cells were sorted on the basis o f purity. Human PrPc over­
expressing cells were sorted into culture medium with 20% FCS and pelleted by centrifugation, 
resuspended in conditioned medium as quickly as possible after the sorting procedure (to increase 
viability). They were plated at about 50,000 cells per 6-well and left in the 37°C incubator to 
recover for at least 24 hours.
2.7 Prion infection of cells
Prion-infected material was handled as biohazardous under Biosafety level 3 containment. Work 
with prion-infected material was performed in a containment level 111 facility within a Biomat 
class I microbiological safety cabinet, which protects the user from air-borne particulate 
contamination by inward air flow at the front aperture o f the cabinet and filtration o f exhaust air.
2.7.1 Homogenisation of prion-infected brain tissue
This task was performed by assigned members o f staff, Dr Jonathan Wadsworth and Katie Fox. 
Prion-infected brain specimens in sealed pots were partially thawed from -80°C and transferred to 
a petri dish. A suitable quantity o f tissue was excised using a disposable scalpel and forceps, 
sealed in a disposable plastic pot and weighed. A 10% (w/v) brain homogenate was prepared in 
sterile Dulbecco’s PBS (without Ca2~ and Mg2+). The tissue was disrupted by repeated aspiration 
through disposable needles o f decreasing diameter (commencing with 19-gauge needle, through 
21-gauge and 23-gauge needles) until homogenate eventually passed easily through 25-gauge 
needle without blocking. Brain homogenate aliquots were stored in sterile screw-top tubes at - 
80°C.
2.7.1.1 Human prion-infected brain homogenate
Appropriate consent and ethical approval were obtained for use o f vCJD prion-infected brain 
material in the development o f a cell model o f human prion disease (LREC refs: 03/N113 and
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03/N006). Tissue from the frontal cortex o f vCJD donors, PDG 2946, PDG 3140 and PDG 5063, 
was used to prepare 10% vCJD brain homogenate (as described in 2.7.1 above) and assigned 
inocula numbers 12811, 13139 and 14618, respectively (see table 2.6). 12811 vCJD inoculum was 
used for infection o f cells unless stated otherwise. 12811 transmissibility was demonstrated in 
wild-type mice (appendix 6).
patient identifier inoculum number
PDG 2946 12811
PDG 3140 13139
PDG 5063 14618
Table 2.6 vCJD inocula
2.7.1.2 Mouse prion-infected brain homogenate
Brains from scrapie-sick CD-I mice infected with Rocky Mountain Laboratory (RML) prions 
were used to prepare 10% RML brain homogenate (as described in 2.7.1),
2.7.2 Standard method for prion infection of cell lines
Cells were seeded in 96-well plates to yield 50% confluency the following day. 10% (1 0 1) prion- 
infected crude brain homogenate (prepared as described in 2.7.1) was diluted in pre-warmed 
culture medium to the desired concentration (0.0001% and 2%), mixed thoroughly by vortexing 
and added to cells for 72 hours. After 72 hours, the prion-infected inoculum was removed and cells 
washed with PBS. Cells were either sib-selection subcloned (see 2.7.2.1), or passaged normally, 
and assayed for the presence o f PrPSc by cell blot assay or scrapie cell assay (sections 2.7.5.1 and
2.7.5.2) after at least the equivalent o f 1:1000 passage to dilute out the original inoculum. Cells 
exposed to culture medium only were used as uninfected negative controls. Prion-resistant cell 
lines with similar doubling times to candidate lines were exposed to prion-infected brain 
homogenate in parallel to monitor the presence o f original inoculum in the cultures. These were 
called “ particle monitor”  cell lines and they allowed the detection o f PrPSc in the cultures, which 
derived from inoculum. Once these cultures were clear o f PrP^, it was concluded de novo (newly 
produced) PrPSc was being produced in candidate cells.
2.7.2.1 Sib-selection subcloning of prion-infected cells
Following 72 hour prion infection (section 2.7.2), cells from four 96-wells were resuspended, 
pooled and viable cells counted using a haemocytometer. 150-400 cells per well (depending on 
plating efficiency o f cell line) were distributed into three 96-well plates to yield 100 colonies and
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grown to confluency. Cells were passaged normally and assayed for PrP^ by SCA (section
2.7.5.2) after the first passage.
2.7.3 vCJD prion infection of differentiating 197 NSC
197 NSC were seeded to yield approximately 60% confluency the following day (-3000 cells per 
96-well; -  80,000 cells per 6-well). Cells were differentiated by removal o f growth factors (EGF, 
bFGF) from the culture medium. 197 NSCs were prion-infected at day 0 or day 4 differentiation 
with 0.1% (unless otherwise stated) or 0.01% semi-purified vCJD prion-infected brain 
homogenate (preparation o f which is described in 2.7.3.2.2), In parallel, they were mock-infected 
with semi-purified normal human brain homogenate. Differentiating NSCs were exposed to brain 
homogenate for 96 hours, followed by a wash with FIBSS and replacement o f the differentiating 
culture medium. 50% media changes were subsequently performed every 5-7 days.
2.7.3.1 Anti-PrP antibody treatment of differentiated 197 NSC as particle monitor 
control for prion infections
Anti-PrP antibody treatment cures prion-propagating cells, this is thought to be due to antibody 
binding to cell surface PrPc and preventing its conversion to PrP80 (Enari et al., 2001). 
Differentiated neurons cannot be passaged, therefore, prion-infected inoculum cannot be diluted 
out in this way. In order to determine i f  the PrP80 signal detected in cells was derived from the 
active replication o f PrP8c or from the original inoculum, actively prion-propagating cells were 
cured with anti-PrP antibody treatment. Cells were treated for five days with 5 pg/ml ICSM18 
antibody diluted in culture medium before being assayed for PrP^ by immunoblotting.
2.13.2 Inoculum preparation for infection of cell lines
2.7.3.2.1 Washed vCJD inoculum
This procedure was carried out to remove soluble toxic factors from brain homogenate. 10% (w/v) 
brain homogenate (see section 2.7.1) was pelleted by centrifugation at 16,000 ref for 30 minutes in 
an eppifuge. The supernatant was removed and the wash step involved the pellet being 
resuspended in 1 ml sterile PBS. The inoculum was then re-pelleted at 16,000 ref for 30 minutes 
and the pellet resuspended in culture medium to the appropriate concentration for infection
2.13.2.2 Semi-purification o f vCJD prion-infected brain homogenate with detergent
A 10% (w/v) brain homogenate was thawed and diluted 1:10 in sterile lysis buffer (see appendix
3.9), vortexed and centrifuged at 16,000 ref for 15 minutes. The supernatant was discarded. The
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pellet was resuspended by vortexing in warmed cell culture medium, to a final concentration o f 
0.1%, and then directly added to cells.
2.7.3.2.3 Sonication ofprion-infected brain homogenate
Semi-purified inoculum was prepared as described in section 2.13.2.2. Following the final spin o f 
the semi-purified inoculum, the pellet was roughly resuspended in culture medium to final 
concentration o f 1% and transferred to a 15 ml tube. This volume was sonicated for a continuous 1 
second pulse at 40% power output, using a MS73 probe. Inoculum was immediately diluted to the 
desired concentration in pre-warmed culture medium and added to cells.
2.7.4 Replication-competent Moloney M uLV retroviral infection of cells
MuLV supernatant was harvested from milk lung amphotropic retroviral producer cells and passed 
through a 0.45 pm filter to remove cells. Cells were incubated overnight with 33% amphotropic 
MuLV viral supernatant in culture medium, supplemented with 4 pg/ml polybrene. Cells were 
replenished with fresh culture medium the following day. Cells were cultured normally in the 
presence o f 2 pg/ml polybrene to enhance retroviral infection within the population. MuLV 
infection o f cells was determined by immunoblotting for viral capsid protein (CAp30) with anti- 
Rauscher p30 goat polyclonal antibody (1:10,000; a kind gift from Dr Peter Klohn) and anti-goat 
HRP secondary antibody (1:5000; DAKO). Antibodies were diluted in 1% non-fat milk and 1% 
normal goat serum. Blots were developed with ECL reagent (West Pico Supersignal, Pierce).
2.7.5 Assaying for PrP5* in cells
2.7.5.1 Cell blot assay (CBA)
The CBA procedure, developed by Bosque (Bosque and Prusiner, 2000), is briefly described in 
(Klohn et al., 2003). Following prion infection, 80,000 cells were seeded onto 25 mm Thermanox 
coverslips (Nunc) in 6-well plates. After growth for 4-5 days at 37°C with 5% CO2, cells were 
blotted onto nitrocellulose membrane (0.45 pm Bio-Rad) soaked in lysis buffer (see appendix
3.9). This involved placing lysis buffer-soaked Whatman filter paper onto a glass plate and placing 
coverslips on top cell-side up. Nitrocelluose membrane, first wet with water and then soaked for 5 
minutes in lysis buffer, was laid on top o f the coverslips followed by dry filter paper. The 
sandwich was pressed together for 2 minutes using a second glass plate. The nitrocellulose 
membrane, to which the cells had adhered, was peeled away carefully and dried for 1 hour at 
37°C. The membrane was then incubated with 5 pg/ml PK (specific activity 30millianson 
units/mg, Merck Pharmaceuticals) in lysis buffer for 90 minutes at 37°C, rinsed twice with ddH20 ,
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and incubated in 2 mM phenyl methyl sulfonyl fluoride (PMSF) for 10 minutes. The membrane 
was placed into denaturing buffer, 3 M guanidinium thiocyanate (GSCN) in 10 mM Tris-HCl (pH 
8.0), for 10 minutes, rinsed five times with water, incubated in Superblock (Pierce) for 1 hour. The 
membrane was shaken with 0.3 pg/ml 1CSM18 monoclonal anti-PrP antibody in TBST (see 
appendix 3.6) with 1% non-fat milk powder (Marvel, Premier Brands, UK) for 1 hour and washed 
in TBST four times for 5 minutes. The membrane was then incubated with HRP-conjugated anti­
mouse IgGl antibody (Zymed; 1:30,000 in TBST 1% non-fat dry milk) for 45 minutes. After 
washing five times for 5 minutes with TBST, membranes were dried at RT on filter paper (protein 
side up), soaked for 3 minutes with ECL reagent (West Pico Super Signal, Pierce) and exposed to 
X-ray film (Hyperfilm ECL, Amersham Pharmacia).
2.7.5.2 Scrapie cell assay (SCA)
The SCA is an ELISA-based assay that was developed in the MRC Prion Unit as a quantitative, 
highly sensitive in vitro assay for RML mouse prions (Klohn et al., 2003). It can detect single 
PrP^-positive cells. It was used to detect infectivity in cells following infection with both the 
RML strain o f mouse-adapted prions and human prions. Unless otherwise stated all steps were 
carried out at RT. A ll steps were undertaken in class I microbiological safety cabinet in 
containment level III laboratory. Solutions were aspirated by a vacuum pump into trap containing 
sodium hypochlorite (20% final concentration) for decontamination (figure 2.2A). GSCN- 
containing solutions were decontaminated with 2N NaOH because GSCN-containing solutions 
react with sodium hypochlorite to produce chlorine gas.
Prion-infected cells were transferred to an Elispot plate (Enzyme-Linked Immunospot Multiscreen 
Immobilon-P 96-well Filtration Plates, Millipore; figure 2.2B). Elispot plates were activated by 
wetting the 0.45 pm PVDF membrane o f each well with 70% ethanol, aspirating and washing once 
with PBS. 100 pi PBS was added to keep the membrane moist. An average cell number per well 
was calculated from five wells o f 96-well prion infection plate and 25,000 cells were transferred to 
the membrane o f an Elispot plate. SCA controls were always seeded onto the same plate: 
uninfected cells as negative controls (25,000 cells per well) and chronically RML prion-in fee ted 
PK1 cells (iP K l) as positive controls (5000 and 15,000 cells per well). Cells were seeded onto the 
membrane by applying a vacuum and drying them onto the membrane in a 50°C oven in 
biocontainment boxes. PK concentration to digest PrPc was determined for each cell line. 50 pi PK 
(Roche) diluted in lysis buffer was added to each well for 90 minutes at 37°C before it was 
aspirated. The plate was washed twice with PBS, exposed to 160 pi per well 2 mM PMSF for 10 
minutes to inhibit the action o f the PK, washed once with PBS before incubation with 160 pi o f 3
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M guanidinium thiocyanate (GSCN) in 10 mM Tris-HCl (pH 8.0) for 10 minutes to expose the 
PrP50 epitopes. GSCN was discarded into 2N NaOH and the wells washed five times with PBS.
a trap with
M  vacuum sodium hypochlorite
pump for waste
B
vacupipette for 
wash of 
SCA reagents
m
Elispot
plate
vacuum
manifold
tubing 
leading 
to trap
Figure 2.2 SCA equipment
A Vacuum pump and trap containing 100% sodium hypochlorite for decontamination of SCA 
solutions
B Vacuum manifold holding Elispot plate
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For immunoprobing o f PrP80, 160 pi per well Superblock blocking buffer (Pierce) was added to 
plates for 1 hour and aspirated. 50 pi per well anti-PrP ICSM18 monoclonal anti-PrP antibody was 
added at 0.6 pg/ml in lx  TBST (see appendix 3.6) with 1% non-fat milk powder (Marvel, Premier 
Brands, UK) and incubated for 1 hour. The primary antibody was discarded into 2N NaOH and the 
wells were washed seven times with TBST. 50 pi per well alkaline phosphatase (AP)-conjugated 
anti-IgGl (Southern Biotechnology Associates) diluted in TBST/1% non-fat milk powder 
(appropriate dilution was established for each new vial o f secondary antibody by titration) was 
added and plates incubated for 1 hour. The secondary antibody was discarded and the plate washed 
eight times with TBST. The underdrains o f the plates were removed and plates dried under airflow 
and taken to containment level II laboratory.
50 pi per well AP-conjugate substrate (prepared as recommended by Bio-Rad) was added until 
there was a clear colour change in the positive controls (approximately 20 minutes). The AP- 
substrate was discarded and the plates were washed twice with de-ionised water before being dried 
under airflow. Plates were stored in the dark at -20°C until analysed. PrP^-positive cells were 
counted using the Zeiss KS Elispot system and each well was assigned a SCA value (figure 2.3): 
Stemi 2000-C stereo microscope equipped with a KL 1500 LCD scanner, Hitachi HV-C20A 
colour camera and WELLSCAN software from Imaging Associates (Bicester, UK). Detection 
settings were optimised to give a maximal signal to noise ratio (PrPSc-positive sample counts 
relative to negative control sample counts). Parameters were adjusted by using the training feature 
o f the software program according to the manufacturer’ s instructions. Prion-infected wells were 
defined as those for which SCA value (counts per well) was significantly greater than background 
(particle monitor):
SCA value of vCJD prion-infected wells > mean particle monitor SCA value + 5x standard deviation
2.8 Electrophysiology of differentiated 197 NSC
Electrophysiology studies on 197 NSC were undertaken by Dr Roberta Donato in the Department 
o f Physiology at UCL in collaboration with Dr Erik Miljan (ReNeuron Ltd., UK). Briefly, 197 
cells were plated on 13 mm diameter laminin-coated Thermanox coverslips (Nalge Nunc 
International) in growth medium for 3-4 days. Cells were then differentiated by removal o f 
growth factors from the medium for 7-14 days. At specified times (days o f differentiation), 
coverslips were placed in a recording chamber on an upright microscope (Olympus). Cells were 
perfused with an extracellular solution containing (in mM): 125 NaCl, 2.4 KC1, 2 CaCI2, 1 MgCl2, 
26 NaHCOs, 1.1 NaH2P0 4 , 10 glucose, and bubbled with 95% 0 2, 5% C02. The conventional
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Figure 2.3 Zeiss KS Elispot system
Stemi 2000-C stereo microscope equipped with a KL 1500 LCD scanner, Hitachi HV-C20A colour 
camera and WELLSCAN software from Imaging Associates (Bicester, UK).
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whole cell patch clamp technique was employed by using an Axopatch 1-D patch-clamp amplifier 
(Axon Instruments, Foster City, CA) both for current clamp and voltage clamp recordings. 
Electrodes were pulled from thick walled borosilicate glass (World precision Instruments, Herts, 
UK) to a tip resistance o f 4-6MQ (PP-83 microelectrode puller; Narishige, Tokyo, Japan) when 
filled with an intracellular solution containing (in mM); 130 KGluconate, 10 NaCl, 10 HEPES, 10 
EGTA, 2 MgATP, and 1 MgCU, pH7.4 with NaOH and osmolality 298 mOsm with 25 glucose. 
Voltage and current pulse generation and data acquisition were performed with a PC running with 
WCP software (University o f Strathclyde, Scotland). Data were sampled at 10 kHz with an A/D 
interface (Digidata 1200). Voltage clamp experiments used voltage steps o f 10 mV (from -60 mV 
to + 30 mV) o f400 ms duration.
2.9 Transmission electron microscopy (T E M )
This procedure was performed by Dr Alison Wood-Kaczmar at the Institute o f Neurology. 
Undifferentiated 197 cells were plated on 13 mm Thermanox coverslips coated with laminin at 
20,000 cells per coverslip. When confluent, cells were differentiated using the standard 
differentiation protocol for 47 days and fixed using 3% glutaraldehyde in 0.1 M sodium cacodylate 
buffer and 5 mM CaC12, pH 7.4. Specimens were dehydrated through a graded series o f Analar 
ethanol (70%, 90%, 100%), embedded in araldite resin mixture and sectioned using a Richert 
Ultracut S microtome diamond knife. Sections were stained using 25% uranyl acetate in methanol 
and Reynolds lead citrate. Images were taken on a Philips CM 10 transmission electron microscope 
at 3800X and 9800X magnification. Images were taken using the KeenView system from SIS and 
processed in Adobe Photoshop.
2.10 Statistical analysis
Data were expressed as mean plus standard error o f mean (SEM; sd/Vn). Data were compared by 
2-tailed /-tests and considered significantly different when P<0.05. Degree o f significance was 
expressed as follows: *P<0.05, **P<0.005, ***P<0.0005, unless stated otherwise.
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3.1 Introduction
As outlined in chapter 1, cell lines replicating several non-human mammalian prion strains 
have been developed (table 1.1) but a much needed cellular model o f human prion disease is 
still lacking. Since a number o f the existing mammalian prion cell models are derived from 
immortalised tumour cell lines (Rubenstein et al., 1984;Race et al., 1987;Vilette et al., 
2001b;Vorberg et al., 2004b;Baron et al., 2006), this chapter describes how this strategy was 
pursued for the development o f a cellular model o f human prion disease. There is considerable 
evidence supporting a principal role for neurones in prion propagation and disease 
pathogenesis (Race et al., 1995;Jeffrey et al., 2003), particularly the fact that disease 
progression can be halted by neuronal depletion o f murine PrP1 in adulthood (Mallucci et al.,
2003). Glia also play a consistent role in prion disease in the form o f gliosis and there is also 
evidence they actively propagate prions (Mallucci et al., 2003;Cronier et al., 2004). Existing 
prion permissive cell lines suggest that non-neural cells also have the capacity to propagate 
prions in vitro. As a result, in this project human and other mammalian tumour cell lines, of 
both neural and non-neural origin, were screened for susceptibility to human prion infection. 
Non-human cell lines were transfected with human PrPc to eliminate the species barrier of 
prion transmission. An ovine scrapie-propagating cell line, in which ovine PrPc was 
overexpressed in a rabbit cell line, set a precedent for this heterologous approach (Vilette et al., 
2001b).
The criterion for a prion-propagating cell line is the persistent detection o f de novo PrP^ (the 
gold-standard surrogate marker for prion infection) in cells following exposure to prion- 
infected brain homogenate. In the development o f the majority o f prion-propagating cell 
models, immunoblotting was used for the detection o f PrP^ in cells but other techniques do 
exist (Butler et al., 1988;Schatzl et al., 1997;Nishida et al., 2000;Mange et al., 2000;Cronier et 
al., 2004;Vorberg et al., 2004b;Milhavet et al., 2006). The cell blot assay (CBA), developed by 
Bosque and Prusiner, is 10-fold more sensitive than immunoblotting for the detection o f PrP^- 
positive cells and requires fewer cells to be assayed (Bosque and Prusiner, 2000). The assay 
involves growing prion-infected cells on thermanox coverslips, blotting them onto 
nitrocellulose membrane and immunodetection o f PK-resistant PrP (see 2.7.5.1), PrPSc-positive 
colonies are visualised and counted relative to the number o f plated cells. The CBA was used 
in combination with immunoblotting in the development an ovine scrapie-propagating 
Schwann cell line and the murine prion-propagating cholinergic neuronal cell line (Archer et 
al., 2004;Baron et al., 2006). A more recent innovation for the detection of PrPSc in cell culture 
was the scrapie cell assay (SCA;Klohn et al., 2003), which was developed as a faster, cheaper,
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in vitro alternative to the mouse bioassay for the quantitation o f prion infectivity. The assay is 
a high-throughput version of the CBA in a 96-well format. Prion-infected cells are transferred 
to an Elispot plate and immunoprobed for PK-resistant PrP (see 2.7.5.2). The proportion o f 
PrPSt-containing cells is determined using automated counting equipment (figure 2.3 and 3.1). 
The SCA was used to isolate a highly RML prion-susceptible N2a subclone, called PK1, 
which is greater than 1000-fold more sensitive to RML prion infection than the N2a parent 
population (Klohn et al., 2003). In my research project, both the CBA and SCA were 
employed for the detection of vCJD prion infection in cells.
Figure 3.1 Example SCA well showing PrPSc-positive RML prion-infected PK1 cells
1000 chronically RML prion-infected PK1 (iPK1) cells have been spiked into 24,000 uninfected 
PK1 cells and assayed for PrP^ by SCA. (A) PK-resistant PrP^-positive cells are detected as 
purple spots by the SCA. (B) The Elispot plate is read by a scanning microscope associated 
with WELLSCAN software, which quantifies the PrPSc-positive cells per well (yellow circles); in 
this case 514. Figure courtesy of Dr P.Klohn.
90
Chapter 3 vCJD prion susceptibility of cell lines
3.2 Aims of this study
• To select candidate cell lines based on cell types involved in vCJD pathogenesis or
cell types o f existing prion-propagating cell lines.
• To determine the status o f PRNP codon 129 polymorphism in selected human cell
lines and to ectopically express human PrP ORF (129 MM) in non-human cell lines.
• To optimise methodology for vCJD prion infection and PrPSc screening to isolate
vCJD prion-susceptible clones from candidate cell lines.
• To screen candidate cell lines for susceptibility to vCJD prion infection.
• To infect a vCJD prion-susceptible cell line with retrovirus to prolong vCJD prion
propagation.
33 Methods
The data presented in this chapter were produced using methods described in chapter 2. 
Human PrPc (methionine homozygous at codon 129; 129 MM) was expressed in non-human 
cell lines or overexpressed in human cell lines by either plasmid DNA transfection 
(pCDNA3.1) or retroviral infection (pLNCX2) as described in section 2.4. The PRNP ORF 
sequence was checked for mutations and codon 129 status by DNA sequence analysis (2.3.7), 
Cellular expression levels o f human PrPc were assessed by immunoblotting (2.6.2) and 
immunofluorescence (2.6.3), respectively. Cell lines were infected with vCJD prion-infected 
brain homogenate and then subcloned as described in section 2.7.2. Following prion infection 
and passaging, the presence of PrP& in cell lines was determined using either the cell blot 
assay (CBA; 2.7.5.1) or the scrapie cell assay (SCA; 2.7.5.2), In some experiments, cell lines 
were infected with amphotropic murine leukaemia virus (MuLV) to test whether prion 
propagation could be enhanced (2.7.4),
3.4 Results
3.4.1 Selection of candidate cell lines to screen for vCJD prion susceptibility
A panel o f eleven candidate cell lines was selected on the basis o f cell types involved in vCJD 
pathogenesis and cell lines susceptible to non-human prion strains in vitro (see table 3.1). 
Since prions target the central nervous system, where PrPc is highly expressed, six human and 
two non-human neuroblastoma and neuroglial cell lines were selected. The human 
neuroblastoma cell lines selected were BE(2)M17, SHSY5Y and SKN-SH; the human 
neuroglial lines selected were, H4, U87 and NP2; the mouse neuroblastoma line, N2aG, and 
rat neuroglial line, RG6, were also selected. The CNS is not the only target of prions and non- 
neural cell types are also permissive to non-human prions in vitro. Therefore, one human and
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one rabbit epithelial cell line, and a mouse fibroblast were also selected: HEK293, RK13 and 
L929, respectively. Some existing non-human prion-propagating cell lines were included 
within this panel o f candidate cell lines (asterisked in table 3.1): the mouse neuroblastoma 
N2aG cell line is highly susceptible to RML prions, the mouse fibroblast L929 cell line is 
permissive to three mouse-adapted scrapie strains (Vorberg et al., 2004b), the rabbit epithelial 
kidney RK13 cell line is permissive to sheep scrapie (Vilette et al., 2001b) and a mouse- 
adapted CJD strain, FU-1 (A.Hill, Melbourne University, unpublished data).
cell type human cell line non-human cell line
neuroblastoma BE(2)M17 N2aG*
SHSY5Y -
SKN-SH -
neuroglial H4 RG6
U87 -
NP2 -
epithelial HEK293 RK13*
fibroblast - L929*
Table 3.1 Candidate cell lines selected for vCJD prion susceptibility screening
* indicates cell lines permissive to non-human prion strains
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3.4.2 Suitability of candidate cell lines for vCJD prion infection
As previously mentioned, factors conferring susceptibility to prion infection are poorly 
characterised. However, it is apparent that susceptibility to prion infection absolutely requires 
PrPc expression (Bueler et al., 1993). On occasions, overexpression o f PrPc has enhanced 
susceptibility to prion infection in cells (Nishida et al., 2000;Giri et al., 2006) and reduced 
prion disease incubation time in mice (Prusiner et al., 1990;Carlson et al., 1994). Furthermore, 
methionine homozygosity at codon 129 o f PRNP (129 MM) is a major determinant of 
susceptibility to vCJD since it is the genotype o f all vCJD cases to date (Collinge, 2005). 
Therefore, the expression o f human PrPc and codon 129 status was determined in the 
candidate human cell lines by immunoblotting, immunofluorescence and DNA sequence 
analysis. To remove the species barrier o f prion transmission in non-human cell lines, human 
PrP ORF (129 MM) was ectopically expressed.
3.4.2.1 PRNP codon 129 genotype of candidate human cell lines
The PRNP codon 129 genotype of all but one of the human candidate cell lines was 
methionine homozygous, the genotype o f all vCJD cases to date. The BE(2)M17 cell line was 
heterozygous at codon 129 (129MV) but it was included in the screen because methionine 
homozygosity at codon 129 o f PrP may not be the only susceptible genotype; pre-clinical 
vCJD was reported at autopsy in a heterozygous individual (MV) (Peden et al., 2004).
human cell line PrP codon 129 polymorphism
BE(2)M17 MV
H4 MM
HEK293 MM
NP2 MM
SHSY5Y MM
SKN-SH MM
U87 MM
Table 3.2 PrP codon 129 polymorphism present in human candidate cell lines
The PRNP ORF of human candidate cell lines was sequenced to check for mutations in the 
coding region and to determine the codon 129 status. No mutations were found in the 
sequence and all cell lines were codon 129 methionine homozygous (129 MM), except the 
neuroblastoma BE(2)M17 cell line, which was heterozygous (129 MV).
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3.4.2.2 Endogenous PrPc expression in human candidate cell lines
The expression o f human PrPc was detected in all the human cell lines studied. There was high 
endogenous human PrPc expression in BE(2)M17, SKN-SH, U87 and HEK 293 cell lines and 
relatively low expression in NP2 cell line compared to mouse PK1 cells and normal human 
brain (figure 3.2). The lowest endogenous expression o f human PrPc was observed in the 
SHSY5Y and H4 cell lines (figure 3.3). Since overexpression o f PrPc has been hypothesised 
to result in increased cellular susceptibility to prion infection (Nishida et al., 2000;Giri et al., 
2006), these two lowest PrPc-expressing cell lines were transfected with human PrPc to 
increase expression levels. Two human PrPc-overexpressing H4 clones were isolated from 
plasmid transfection (A and B; figure 3.3). We acquired a human PrPc-overexpressing 
SHSY5Y clone (clone A) derived by retroviral transfection from K.Chumakov (FDA, USA) 
because the wild-type cells failed to transfect with the plasmid construct (figure 3.3). Because 
conversion o f PrPc to PrP^ is proposed to occur at the cell surface (Caughey and Raymond, 
1991), expression of PrPc was determined for cell lines by immunofluorescence and all cell 
lines showed PrPc expression at the cell surface (figure 3.4).
3.4.2.3 Heterologous human PrPc expression in non-human candidate cell lines
For the development of heterologous prion cell models, non-human cell lines were transfected 
with human PrP ORF (129 MM) construct. N2aG and RG6 were transfected with a plasmid 
human PrP ORF construct, which generated two human PrPc-expressing RG6 clones (A and 
B) and one human PrPc-expressing N2aG clone (A) with high expression levels (figure 3.5A). 
Two human PrPc-overexpressing L929 clones (A and B) and four human PrPc-overexpressing 
RK13 clones (A-D) were generated by retroviral infection (figure 3.5B). High human PrPc 
expression levels were observed in three RK13 clones, A, C, D, and one L929 clone, B, and 
intermediate expression levels were observed in RK13 clone B and L929 clone A.
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Figure 3.2 Endogenous PrP° expression in human candidate cell lines
Cell lysates of human cell lines BE(2)M17, U87, NP2, SKN-SH, HEK 293, mouse control cell 
line, PK1, and normal human brain homogenate (brain) were immunoblotted using anti-PrP 
antibody, biotinylated ICSM35. 25 pg protein from cell lysates and 50 pg human brain 
homogenate was loaded per lane. PrPc runs between 50-30 kDa in its 3 glycosylation states 
(dh mono- and un-glycosylated). The endogenous human PrPc expression in BE(2)M17, 
HEK293, U87 and SKN-SH cell lines was significant compared to normal human brain and 
comparable to PK1 PrPc expression. However, that of NP2 was relatively low.
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Figure 3.3 Human PrPc overexpression in low-expressing human candidate cell lines
To improve expression level of human PrPc expression in H4 and SHSY5Y (SH) cell lines, 
they were transfected with human PrP ORF and stable clones established. Cell lysates of wild- 
type cells and their human PrP°-transfected clones were immunoblotted using anti-PrP 
antibody, biotinylated ICSM35. 25 pg protein from cell lysate and 50 pg protein from normal 
human brain homogenate (brain) was loaded per lane. Human PrPc, which runs between SO­
SO kDa, was significantly overexpressed compared to wild-type cells (wt) in 2 H4 clones (A and 
B) and slightly overexpressed in the SHSY5Y clone (A). The transfected human PrPc in the H4 
clones was of a slightly higher molecular weight than wild-type, possibly due to increased 
glycosylation.
DAPI PrPc merged
Figure 3.4 Representative image of PrP° expression to confirm cell surface expression 
in candidate cell lines
SKN-SH human neuroblastoma cells were grown on poly-L-lysine coated glass coverslips and 
immunostained for PrP°. (A) DAPI staining of nuclei (blue). (B) PrPc staining with ICSM18 
primary antibody and FITC-conjugated anti-mouse IgG secondary antibody (green). This was 
PrPc-specific staining since secondary antibody only controls were blank (data not shown) 
Cells show PrPc expression throughout the cell, particularly at the cell surface. (C) Merged 
image of A and B.
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Figure 3.5 Heterologous human PrP expression in non-human candidate cell lines
Stable human PrPc-expressing clones were established from non-human candidate cell lines: 
RG6, N2aG, RK13 and L929. Cell lysates of wild-type (wt) and human PrPc-transfected clones 
were immunoblotted using anti-PrP antibody, biotinylated ICSM35. 25 pg protein from cell 
lysates was loaded per lane. Since ICSM35B detects rodent and human PrP, successful 
human PrPc expression was indicated by an increased PrPc band intensity (between 50-30 
kDa) in human PrPc-transfected clones compared to wild-type. (A) Stable human PrPc- 
expressing clones established by plasmid transfection. Human PrPc was highly expressed in 2 
RG6 clones (A and B) and one N2aG clone (B). (B) Stable human PrPc-expressing clones 
established by retroviral infection. Human PrPc was highly expressed 3 RK13 clones (A, C and 
D) and in one L929 clone (B). One RK13 clone (B) and one L929 clone (A) showed 
intermediate expression levels of human PrPc. Endogenous PrP° expression was negligible in 
RK13 cells and very low in L929 cells. Appreciable levels of endogenous PrPc were detected 
in RG6 and N2aG cells.
97
prpc
Chapter 3 vCJD prion susceptibility of cell lines
3.4.3 Optimisation of vCJD prion infection and screening methodology to isolate highly 
prion-susceptible cells
3.4.3.1 Sib-selection subcloning
There is a marked heterogeneity in susceptibility o f cells to prion infection and propagation 
within a prion permissive cell population (Bosque and Prusiner, 2000;Vilette et al., 
2001b;Vorberg et al., 2004b). Therefore, subcloning has been successfully employed in the 
development o f some cell models o f prion disease to isolate the most prion-susceptible cells 
(Nishida et al., 2000;Klohn et al., 2003;Vorberg et al., 2004a;Raymond et al., 2006). 
Following exposure o f N2a cells to RML prions, bulk passaging of cells results in the 
detection o f negligible levels o f infectivity because only 1-20% of the parent population are 
proposed to be susceptible to prion infection. However, single cell cloning o f this infected 
parent population isolates clones, which accumulate high levels of PrP^ and are 80-90% 
infected (Race et al., 1987;Butler et al., 1988;Bosque and Prusiner, 2000). In light o f these 
findings, a subcloning technique, called sib-selection, was devised for this study to isolate 
vCJD prion-susceptible cells within candidate cell lines (figure 3.6). The proportion of 
susceptible cells in a population is strictly dependent on prion strain and may be lower for 
human prions (especially since human prion-propagating cell lines have not ever been 
identified). Therefore, we hypothesised (at least) 1 in 10,000 cells o f a candidate population 
was susceptible to vCJD prions. According to the Poisson distribution (which models discrete 
random variables), in order to have a 95% chance of finding a vCJD prion-susceptible cell o f 
this rarity, at least 30,000 cells needed to be screened, as explained by the equation below:
P(0) = e m. For P»0.05, m (variance) = 3. Therefore 10,000 x 3 = 30,000.
To screen this number o f clones in a time and cost-effective manner, rather than single cell 
cloning, the candidate lines were initially subcloned at 100 cells per 96-well following vCJD 
prion infection (2.7.2.1) and assayed for PrP80 by the high-throughput SCA (see figure 3.6). 
Because the SCA uses a 96-well format, only three plates needed to be assayed per cell line to 
determine vCJD prion susceptibility. I f  a candidate cell line consistently showed susceptibility 
to vCJD infection (indicated by highly PrP^ positive SCA wells), two strategies were planned 
for the isolation o f vCJD prion-propagating line. First, clones from highly positive SCA wells 
could be re-infected with vCJD prions and single-cell cloned; any positive clone would be 
cured of vCJD prion infection with anti-PrP antibody treatment (Enari et al., 2001). 
Alternatively, the parent cell line could be single-cell cloned and each clone split to two wells 
(generating replica plates). One plate would be infected with vCJD prions and assayed for 
PrPSc by the SCA and the second plate would remain uninfected; highly susceptible uninfected 
clones could be traced back from highly positive SCA wells (Klohn et al., 2003).
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seed cells 24h pre-infection
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propagate 1:1000 
to clear original 
homogenate
5 SCA of
-30,000 clones
isolation of a highly susceptible clone by 
-re-infection of positive wells & further sub-cloning 
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Figure 3.6 Sib-selection subcloning of candidate cell line for isolation of rare highly 
vCJD prion-susceptible clone
A candidate cell line was exposed to vCJD prion-infected brain homogenate for 72 hours. 
Viable cells were then counted (indicated by the haemocytometer) and seeded to yield 100 
cells per well in three 96-well plates (yellow), thus allowing the screening of ~30,000 clones. 
Cells were grown to confluency and passaged normally. At each passage, 25,000 cells per 
well were seeded in Elispot plates (grey) to assay for the presence of PrP80 by SCA. Once the 
original vCJD inoculum had cleared from the cultures (indicated by negative SCA of the 
resistant particle monitor control cells; explained in 3.4.3.4), positive SCA wells (solid pink 
wells) indicated prion-infected cells. In order to isolate a vCJD prion-propagating clone, these 
infected cells were either (1) re-infected with vCJD prions, single-cell cloned and cured of prion 
infection, or (2) the parent population was single-cell cloned, replica clones produced and one 
set re-infected with prions.
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3.4.3.2 Validation of sib-selection subcloning strategy for the isolation of rare prion- 
susceptible clones
RML mouse prion-susceptible N2a cells were used to validate the sib-selection subcloning 
technique for the detection o f rare prion-susceptible clones. N2a cells were infected with RML 
mouse prions and RML prion susceptibility was determined for both sib-selection subcloning 
technique and regular passaging of the bulk population (bulk passaging). The sib-selection 
subcloning of RML prion-infected cells detected more prion-infected wells than bulk 
passaging over four passages, once the original RML-prion inoculum was cleared (figure 3.7). 
Bulk passaging resulted in the complete loss o f infected cells by the third passage, possibly 
because the infected cells, o f which there was a low number, were discarded at passage and/or 
the uninfected cells overgrew the infected cells due to a selection advantage (figure 3.7). Sib- 
selection appeared to isolate highly prion-susceptible cells since the N2a subclones isolated in 
this way accumulated three-fold higher levels o f PrPSc than the bulk passaged N2a cells (figure 
3.8). A second round of subcloning was undertaken, in which the most highly RML prion- 
infected well, with the highest SCA value from the first passage (974) was single-cell cloned 
into four 96-well plates. 2% o f these clones were highly infected with RML prions; with a 
mean (±SEM) o f 1067 (±66). These data imply that sib-selection subcloning increased the 
likelihood o f isolating prion-susceptible clones and they produced higher levels of prions than 
they would normally do in a mixed population. This is most likely because the subcloning 
method allows random enrichment o f susceptible cells, which do not become overgrown by 
the non-susceptible cells as they would in the bulk population. Their isolation permits them to 
accumulate higher PrPSt levels than would otherwise be possible. Therefore, these findings 
validate the use o f sib-selection subcloning for the detection o f rare vCJD prion-susceptible 
cells in the candidate cell lines.
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Figure 3.7 Detection of PrP^-positive cells in an RML prion-infected N2a population by 
sib-selection subcloning and bulk passaging
N2a cells were exposed to 0.01% RML prion-infected brain homogenate for 72 hours. Cells 
were either passaged at 1:10 ratio 3 times (bulk passaging) in three 96-well plates, or cells 
were subcloned to yield 100 colonies per well in three 96-well plates (sib-selected). When RML 
inoculum was clear (3x 1:10 passages for bulk passage and at the first passage for SCA), the 
presence of de novo PrP30 was assayed by SCA. Data are expressed as the percentage of 
PrPSc-positive wells per total number of wells screened (+ SEM). Sib-selection subcloning 
picks up significantly more RML prion-infected wells at the 1s*, 2nd and 3rd passage than bulk 
passaging. RML prion-infected wells were detectable by sib-selection even up to the 3rd and 4th 
passage, whereas bulk passaging of N2a cells resulted in loss of infected cells by the 3rd 
passage. This may be due to the fact that infected cells were discarded at passage or that in 
the bulk cultures the uninfected clones grew faster and overgrew the infected cells.
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sib-selection bulk passage
Figure 3.8 Levels of PrP^ in RML prion-infected N2a wells detected by sib-selection and 
bulk passage
N2a cells were exposed to 0.01% RML prion-infected brain homogenate for 72 hours. Cells 
were either passaged at 1:10 ratio 3 times (bulk passage), or cells were subcloned to yield 100 
colonies per well (sib-selected). Both set of cells were grown to confluency and assayed for 
PrP80 by SCA. Data are presented as mean SCA value (PrPSc-positive cells) per well (+ SEM) 
of RML prion-infected wells at the 1s1 passage (at which the RML inoculum has been cleared 
from the cultures). The number of PrP^-positive cells in RML prion-infected wells detected 
using sib-selection is significantly higher than when bulk passaging the cultures (f-test: 
*P<0.05).
3.4.3.3 Optimisation steps for each candidate cell line prior to screening
First, the plating efficiency for each candidate cell line was determined (2.2.6) in order to
calculate the number o f cells required for seeding to yield 100 colonies per well for sib-
selection (table 3.3). Second, the concentration o f vCJD prion-infected brain homogenate for
infection of each cell line was optimised. Existing prion-propagating cell lines were developed
by infecting cells with between 0.01% and 2.5% prion-infected brain homogenate (Archer et
al., 2004;Cronier et al., 2004;Vorberg et al., 2004a;Vorberg et al., 2004b). Similar dilutions
were used for this study; cells were infected with between 2% and 0.1% vCJD prion-infected
brain homogenate. The highest concentration of vCJD prion-infected brain homogenate that
each cell line could tolerate, without overtly affecting its normal proliferation rate and
morphology, was selected. Third, the Proteinase K (PIC) concentration used for SCA was
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optimised for each cell line to ensure that all PrPc was digested and thus only PrP50 detected. 
Each new batch o f PK (Roche # 03115828001) required titration for each cell line. Dilutions 
used were between 1:15,000 and 1:20,000, which was equivalent to approximately 1 jig/ml.
cell line plating efficiency (%)
BE(2)M17 40
H4 50
L929 50
N2aG 67
NP2 40
RG6 50
RK13 40
SHSY5Y 25
SKN-SH 25
U87 40
Table 3.3 Plating efficiency of candidate cell lines
Plating efficiency for each candidate cell line was determined (as described in 2.2.6) in order to 
ascertain the number of cells to be seeded to yield 100 colonies per well for sib-selection. i.e., 
for BE(2)M17, 100/0.4 cells (250 cells) were seeded to give 100 colonies.
3.4.3.4 Summary of standard vCJD prion infection, “particle monitors” and PrP^ 
screening procedure of candidate cell lines
The standard infection and screening procedure involved 72 hour vCJD infection of candidate 
cell lines with between 0.1% and 2% vCJD prion-infected brain homogenate (12811) diluted in 
culture medium. This was followed by subcloning o f cells at 100 final clones per well in three 
96-well plates. Cells were grown to confluency and simultaneously passaged normally and 
seeded (25,000 cells per well) into Elispot plates to be assayed for the presence of PrPSc by the 
SCA. In order to distinguish novel PrPSc production in the candidate cell lines from PrP& in the 
vCJD inoculum, a vCJD prion-resistant cell line with a similar doubling time to each candidate 
line was infected with vCJD prions in parallel. In this way, the prion-resistant cell line was 
termed a “particle monitor” since it detected the presence of PrPSc particles from the vCJD 
inoculum. The rabbit RK13, mouse N2a and GT1 cells were all used for this purpose. Once the 
mean SCA value for these particle monitor cells was nearly the same as the mean of the
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uninfected cells, the PrPSc signal could be attributed to de novo production of PrP^ in the 
candidate cells. Wells containing vCJD prion-infected cells were identified i f  they exceeded a 
threshold SCA spot number, which was calculated thus: 
threshold SCA value to identify for vCJD prion-infected wells
= mean particle monitor SCA value + 5 x standard deviation
In this way, each cell line was given a measure o f “vCJD prion susceptibility” , based on the 
proportion of wells screened that was above this threshold SCA spot number. It was essential 
to calculate the threshold SCA value as described, rather than selecting an arbitrary SCA spot 
number, because SCA values can very considerably between assays. vCJD prion-infected 
wells were monitored over several passages. Consistently PrPSc-positive cell lines were single­
cell cloned in one of two ways (summarised in figure 3.6) to isolate a highly vCJD prion- 
susceptible clone.
3.4.4 Screening of cell lines for susceptibility to vCJD prion infection
Taking into account the human PrPc -expressing clones generated from candidate cell lines, 19 
lines were screened in total. The standard infection and screening procedure (described in 
3.4.3.4) was used to assess the susceptibility o f the majority of cell lines to vCJD prion 
infection. Some cell lines were screened by bulk passage and CBA because it was the most 
sensitive technique available at the start o f the project. Promising cell lines indicated by CBA 
screens were subsequently assessed by the standard procedure.
3.4.4.1 Cell lines resistant to vCJD prion infection
Of the 19 cell lines screened, 13 showed no susceptibility to vCJD prion infection as 
demonstrated by negative CBA or SCA data (table 3.4). These included the neuroblastoma 
BE(2)M17, neuroglial H4, NP2 and U87 and epithelial HEK293 human cell lines. The L929 
mouse fibroblast cell line, N2aG mouse neuroblastoma cell line and RG6 rat neuroglial cell 
line, all expressing human PrPc, were also resistant.
3.4.4.2 Candidate cell lines susceptible to vCJD prion infection
6 cell lines, namely 4 human PrPc-expressing RK13 clones, SKN-SH and SHSY5Y showed 
some susceptibility to vCJD prion infection
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cell line concentration vCJD prion-infected 
inoculum (%)
screening method number of 
screens
BE(2)M17 2&  0.2 CBA 2
BE(2)M17 1 & 0.1 SCA 3
H4 2& 0.2 CBA 2
H4_A 0.1 SCA 1
H4_B 0.1 SCA 1
HEK 293 2 CBA 2
NP2 1 & 0.1 SCA 2
SHSY5Y 0.2 CBA 2
U87 0.1 SCA 2
L929_A 0.1 SCA 2
L929_B 0.1 SCA 2
N2aG_A 2& 0.2 CBA 3
RG6_A 2 & 0 .2 CBA 9
RG6_A 0.2 SCA 2
RG6_B 2 & 0.2 CBA 5
Table 3.4 Cell lines unable to propagate vCJD prions
Following vCJD prion infection (at the concentration indicated in column 2), cell lines were 
screened for the presence of PrPSc with cell blot assay (CBA; after bulk passaging) or by 
scrapie cell assay (SCA; after sib-selection). At least 300,000 cells were screened per CBA (3 
coverslips) and -28,800 clones per SCA (three 96-well plates). 13 of the 19 cell lines screened 
were not susceptible to vCJD prion infection are shown in the table. These included human 
neuroblastoma, neuroglial and epithelial, and non-human neuroglial and fibroblast cell lines.
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3.4.4.2.1 Human PrPc-expressing rabbit epithelial RK13 clones
Four RK.13 human PrPc-overexpressing clones, A-D, were screened by the standard protocol 
and showed susceptibility to vCJD prion infection (figure 3.9 and 3.10). RK13 clones B and D 
were initially highly susceptible with de novo PrP^ detected in about 40% and 50% o f wells at 
the first passage, respectively. However, these clones lost prion infection rapidly and did not 
propagate prions for more than two passages. RK13 clones A and C were infected with de 
novo PrP& at first passage since it was detected in approximately 20% and 30%, respectively. 
Although the proportion o f prion-infected wells declined over time in these two clones, novel 
PrPSc was consistently produced over three passages. This suggested that there was short-term 
vCJD prion propagation in these clones (A and C) for approximately two weeks.
The most susceptible RK13 human PrPc-overexpressing clone was RK13 clone C. First, it was 
susceptible to vCJD prion infection at a lower concentration of vCJD inoculum (0.1%) 
compared to the other RK13 clones (1%). Second, in one o f the nine replicate infections, 
RK13 clone C showed the longest period o f vCJD prion propagation of all the candidate cell 
lines. PrPSc was detected in RK13 clone C for six passages following infection with 0.1% 
vCJD, and for five passages following infection with 1% vCJD, which corresponded to a 
period o f about three weeks (figure 3.11). For both inoculum concentrations de novo PrP^ was 
present in about 80% wells at first passage. The percentage of vCJD prion-infected wells 
decreased over time, particularly after the third passage. However, the increasing SCA value in 
the PrP^-positive wells, suggested that there was accumulation of PrPSc in the infected clones 
over time, which further supported de novo PrPSc production in this clone (figure 3.12). The 
vCJD prion propagation observed over six passages in RK13 clone C could not be replicated 
more than once.
Attempts to subclone these highly vCJD prion-susceptible RK13 clone C wells failed. First, 
eight highly PrP^-positive wells from the 0.1% vCJD prion infection (mean SCA value: 789 ± 
136) were pooled after the second passage, single cell clones were generated and re-infected 
with 0.1% vCJD prion-infected brain homogenate. However, these clones were not prion- 
infected at the first SCA (after three 1:10 passages). Second, 864 single cell clones were 
derived from the uninfected RK.13 clone C parent population, replica plates generated, and one 
set infected with vCJD prions. However, no PrP5* was present in these single cell clones by 
SCA.
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Figure 3.9 vCJD prion infection of human PrPc-overexpressing RK13 clones A, B and D
RK13 clones A, B and D and RK13 wild-type particle monitor cells were infected with 1% vCJD 
prion-infected brain homogenate according to the standard procedure. Cells were assayed for 
the presence of PrP^ by SCA at passage 1-3. Data are expressed as the percentage of PrPSc- 
positive wells above threshold per total number of wells screened (+ SEM). Threshold for 
vCJD prion infection was calculated as mean SCA value for vCJD prion-infected particle 
monitor plus 5 standard deviations. Data presented are from three 96 well plates (28,800 
clones). Although RK13 clones B and D were the most susceptible to vCJD prion infection at 
the 1s‘ passage, with 40% and 50% wells prion-infected, this tailed off after the 2nd passage. 
20% of wells from RK13 clone A were prion-infected at 1st passage and remained infected for 
three passages. The presence of PrP80 in RK13 clone A over 3 passages suggested there was 
short-term propagation of vCJD prions in this clone.
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Figure 3.10 vCJD prion infection of human PrPc-overexpressing RK13 clone C
RK13 clone C and RK13 wild-type particle monitor cells were infected with 0.1% vCJD prion- 
infected brain homogenate according to the standard procedure. Cells were sib-selected at 
250 cells per well in three 96-well plates. Cells were assayed for the presence of PrP80 at each 
1:10 passage. Data are expressed as the percentage of PrP^-positive wells above threshold 
per total number of wells screened (+ SEM). Threshold for vCJD prion infection was calculated 
as mean SCA value for vCJD prion-infected particle monitor plus 5 standard deviations. Data 
presented are from 9 independent experiments. Approximately 20% of wells of RK13 clone C 
were prion-infected at 1s’ passage and the proportion of wells tailed off over 3 passages. The 
presence of PrPSc in RK13 clone C over three passages suggested there was short-term 
propagation of vCJD prions in this clone.
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Figure 3.11 Short-term vCJD prion propagation in human PrPc-overexpressing RK13 
clone C
RK13 clone C cells and RK13 wild-type particle monitor cells were infected with 0.1% and 1% 
vCJD prion-infected brain homogenate according to the standard procedure. Cells were 
assayed for PrPSc by SCA at each 1:10 passage. Data are expressed as the percentage of 
PrPSc-positive wells above threshold per total number of wells screened (+ SEM). Threshold 
for vCJD prion infection was calculated as mean SCA value for vCJD prion-infected particle 
monitor plus 5 standard deviations. Data presented are from three 96- well plates (28,800 
clones). The percentage of vCJD prion-infected clones was high (>30%) until the 3rd passage 
for both dilutions of inoculum, at which point it fell dramatically. A small percentage of wells 
remained infected up to the 5th passage for 1% infected cells (13%) and the 6th passage for the 
0.1% infected cells (6%). This was the longest period of vCJD prion propagation observed in 
any of the candidate cell lines (~3 weeks).
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Figure 3.12 Time-course of PrP^-positive levels in vCJD prion-infected human PrPc- 
overexpressing RK13 clone C
RK13 clone C and RK13 wild-type particle monitor cells were infected with 0.1% and 1% vCJD 
prion-infected brain homogenate for 72 hours according to the standard procedure. Data 
presented are from three 96-well plates (28,800 clones). Data are presented as mean SCA 
value per well (+ SEM) for vCJD prion-infected wells. Mean SCA values increased over time 
from -50  at passage 1 to -350 at passage 5. This strongly suggested there was de novo 
production of PrP^ in the vCJD prion-infected cells of the RK13 clone C.
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3.4.4.2.2 Human neuroblastoma cell lines: SKN-SH and SHSY5Y clone A
SKN-SH showed some susceptibility to vCJD prion infection with de novo PrPSc present in 
18% of wells assayed the first passage, following infection with 0.1% vCJD prion-infected 
brain homogenate (figure 3.13). Prion infection was consistently present over two passages 
(three replicate infections), suggesting there was short-term propagation in this cell line (2-3 
weeks). The overexpression o f human PrPc in SHSY5Y clone A appeared to marginally 
increase their susceptibility to vCJD prion infection. Compared to wild-type cells, which were 
resistant to vCJD prion infection at first passage (table 3.4), de novo PrP^ was detected in 
SHSY5Y clone A in 6% o f wells assayed following infection with 0.1% vCJD prion-infected 
brain homogenate. However, de novo PrP^ propagation was very short-lived in these cells, 
occurring for just one passage.
3.4.5 Retroviral infection of SKN-SH cell line to prolong vCJD prion propagation
The intercellular spread o f prions in two ovine scrapie-propagating cell lines (Vilette et al., 
2001b;Archer et al., 2004) has been linked with exosomes (Fevrier et al., 2004), which are 
membranous vesicles secreted upon fusion o f multivesicular endosomes with the plasma 
membrane. Recently it has been shown that retroviruses, in a similar process to exosome 
generation, exploit cellular multivesicular late endosomes for viral budding (Morita and 
Sundquist, 2004). Therefore, we hypothesised that co-infection of the SKN-SH human 
neuroblastoma cell line with vCJD prions and the retrovirus, murine leukaemia virus (MuLV), 
may initiate chronic prion infection in this weakly vCJD prion-susceptible cell line. It was 
proposed that infectious prions would be transmitted within the SKN-SH population by 
recruitment into viral particles, which would infect neighbouring cells.
Co-infection o f SKN-SH cells with vCJD prions and replication-competent MuLV was done 
sequentially. Either MuLV infection was established in SKN-SH cells for ten days (figure 
3.14), followed by infection with 0.1% and 0.01% vCJD prion-infected brain homogenate, or 
SKN-SH cells were first infected with vCJD prions followed by MuLV infection at the sib- 
selection stage. However, whichever co-infection regime was used, MuLV-infected SKN-SH 
cells were less susceptible to vCJD prion infection than uninfected cells. In three independent 
infections, MuLV-infected SKN-SH cells were completely clear o f prion infection at the first 
SCA, whereas a small proportion o f SKN-SH wild-type cells (mean 16% of wells) were prion- 
infected. Therefore, retroviral infection of SKN-SH cells did not enhance intercellular 
transmission o f vCJD prions within the culture.
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Figure 3.13 vCJD prion infection of human neuroblastoma cell lines SHSY5Y clone A 
and SKN-SH
SHSY5Y clone A, SKN-SH cells and BE(2)M17 particle monitor cells were infected with 0.1% 
vCJD prion-infected brain homogenate according to standard procedure. Data are expressed 
as the percentage of PrPSc-positive wells above threshold per total number of wells screened 
(+ SEM). Threshold for vCJD prion infection was calculated as mean SCA value for vCJD 
prion-infected particle monitor plus 5 standard deviations. Data are presented are from 3 
independent experiments. Human PrPc-overexpressing SHSY5Y clone A showed very low 
susceptibility to vCJD prion infection at the first passage, with 6.4% prion-infected wells. SKN- 
SH cells were more susceptible with PrPSc present in 18.2% wells.
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Figure 3.14 Retroviral MuLV infection of SKN-SH cells
SKN-SH cells were infected overnight with 33% supernatant from mink amphotropic MuLV 
producer cells (supplemented with 4 pg/ml polybrene). Cells were cultured for a further 10 
days in the presence of 2 pg/ml polybrene to facilitate the spread of MuLV infection. Cell 
lysates were prepared from uninfected SKN-SH cells (SKN; 700,000 cells), amphotropic 
MuLV-infected SKN-SH cells (SKN-ampho; 700,000 cells), mink amphotropic MuLV producer 
cells (mink-ampho; 360,000 cells) and MuLV-infected 3T3 fibroblast cells (i3T3; gift from 
P.KIohn). These cells were analysed for MuLV infection by immunoblotting with anti-Rauscher 
MuLV p30 primary (1°) goat polyclonal antibody and anti-goat-HRP secondary antibody (2°), 
which detects the viral capsid protein, CAp30. The CAp30 protein runs at -36 kDa (left-hand 
blot) and was present in the positive controls, i3T3 and mink-ampho (although not as strongly, 
probably because less protein was loaded), in SKN-ampho but not in SKN-SH wild-type 
negative controls. The presence of the CAp30 band in SKN-ampho cells indicated they had 
been successfully infected with MuLV. A concurrent secondary antibody control blot (right- 
hand blot; 2° only) was run to distinguish the CAp30-specific bands from non-specific 
secondary antibody binding. Importantly there was no non-specific binding at 36 kDa.
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3.4.6 Summary of results
Eleven candidate mammalian cell lines of neuronal and non-neuronal origin were selected to 
test for vCJD prion susceptibility. Four non-human cell lines and two very low PrP1- 
expressing human cell lines were transfected with human PrP ORF (129 MM). In this way, all 
cell lines expressed human PrP (129 MM), except BE(2)M17. In total, nineteen cell lines were 
generated and screened for susceptibility to vCJD prion infection using methodology validated 
on N2a cells with RML prions. 13 of the cell lines were resistant to vCJD prion infection 
(table 3.4). Two human neuroblastoma cell lines, SKN-SH and human PrPc -overexpressing 
SHSY5Y clone A, and four human PrP1-overexpressing rabbit RK13 clones showed 
susceptibility to vCJD prion infection. Following infection with 0.1% vCJD inoculum, the 
RK13 clone C was the most susceptible to prion infection (27% wells), followed by SKN-SH 
(18% wells) and SHSY5Y clone A (2% wells). Following infection with 1% vCJD inoculum, 
20%, 40% and 50% o f RK13 clones A, B and D, respectively, were prion-infected at first 
passage. The prion infection observed in the cell lines was not persistent. De novo PrP& was 
detected in SHSY5Y clone A for just one passage, in RK13 clones B and D and SKN-SH for 
two passages, and in RK13 clone A and C for three passages. In one infection o f RK13 clone 
C, de novo PrP^ was detected over six passages (~3 weeks). Single cell subcloning of this 
highly susceptible RK13 clone C, in an infected and uninfected state, did not yield a stably 
vCJD-prion propagating cell line. SKN-SH cells were co-infected with MuLV retrovirus and 
vCJD prions in an attempt to prolong prion propagation in this line. However, the cells were 
made less susceptible to prion infection following MuLV retroviral infection.
3.5 Discussion
As described above, nineteen mammalian cell lines expressing human PrPc, of neural and non- 
neural origin, were comprehensively screened for susceptibility to vCJD prion infection. This 
was not an exhaustive screen o f cell lines due to pressure on time and resources. There are 
certainly a number o f other human neuroblastoma, epithelial and fibroblast cell lines that could 
have been screened. Given the involvement of the lymphoreticular system in vCJD 
pathogenesis (Wadsworth et al., 2001), it would certainly have also been worth screening the 
follicular dendritic cell line, HK (Kim et al., 1994). Follicular dendritic cells reside in follicles 
and germinal centres of lymphoid tissue and are reported to highly express PrPc (Brown et al.,
1999), accumulate PrPSc in vivo (Kitamoto et al., 1991 ;van Keulen et al., 1996;Jefifrey et al.,
2000) and play a key role in prion neuroinvasion and disease susceptibility (Montrasio et al., 
2000;Mabbott et al., 2003;Mabbott and Bruce, 2003).
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3.5.1 Dynamic susceptibility model of prion propagation
Despite efforts to ensure that genetic requirements for prion susceptibility were met in the cell 
lines by expression o f human PrPc with a similar sequence to PrP in the inoculum (codon 129 
MM), this approach did not yield a stably vCJD prion-propagating cell line. Therefore, it is 
apparent that although PrPc is indispensable for prion infection, other factors play a role in 
prion propagation in cells. The dynamic susceptibility model o f prion propagation proposes 
that, whilst certain genetic factors must be present, prion propagation in a cell is determined by 
the relative rates o f synthesis and degradation o f PrP80 (see figure 3.15; Weissmann, 2004). 
For chronic prion infection to be established in a cell, a delicate balance between synthesis and 
degradation o f infectivity must be struck; formation o f infectivity should exceed degradation to 
avoid elimination o f prion infection but not to the extent where infectivity reaches cytotoxic 
levels.
3.5.2 Possible reasons for lack of prion propagation in candidate cell lines
Taking into account the dynamic susceptibility model o f prion propagation (figure 3.15), the 
cell lines screened in this study may have been resistant to vCJD prion infection for a number 
o f epigenetic reasons. First, infectivity is not as stable as once thought, with less than a 24 hour 
half-life in N2a cells. It may be that PrPSc, from the vCJD inoculum and/or formed de novo 
within the cell, was degraded rapidly due to a high protease content in the candidate cell lines. 
For example, lysosomal cysteine proteases (but not aspartic and metal lop roteases) have been 
proposed to degrade PrPSc in ScGTl and C D llc+  dendritic cells in vitro (Luhr et al., 2004). 
Second, since infectivity is halved at each cell division, cell lines with a short doubling time, 
such as the RG6 cell line (which needed passaging three times a week), would lose infectivity 
i f  the rate o f PrPSc synthesis could not compensate. However, selecting cell lines on the basis 
o f long doubling times was not practical, since this would not have made a rapid diagnostic 
test. Attempts were made to culture the HCN-2 human cortical neuronal cell line but, even in 
the uninfected state, it did not withstand passaging at a one in three ratio every two weeks. 
Third, it may be that prion replication was very efficient in the cell lines and that PrPSc 
accumulated to lethal levels. This may certainly have been the case for the neuroblastoma cell 
lines since neurones are particularly susceptible to prion toxicity and there was evidence of 
some minimal cell death following vCJD prion infection (Muller et al., 1993;Cronier et al.,
2004). Fourth, mechanical injury (scratch-wounding) to prion permissive cell lines reduces 
their susceptibility to prion infection, an effect proposed to be mediated by nucleotide release 
into the culture medium (Etessami et al., 2005). Therefore, poor tissue culture technique prior 
to prion infection, such as over-trypsinisation, over-trituration or brisk delivery o f prion- 
infected brain homogenate to the wells may have rendered cells resistant to prion infection. 
This is unlikely to be the cause of the resistance of cells to vCJD prion infection
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Figure 3.15 Dynamic susceptibility model of prion propagation in cells
The dynamic susceptibility model proposes that stable prion propagation in cells (with all the 
genetic and biochemical requisites for susceptibility present) is determined by the relative rate 
of prion synthesis and degradation, defined as K, and stable propagation can only occur within 
narrow limits of K. The amount of infectivity in a cell can be calculated as P= P(0)eWD, where P(o> 
is the infectivity content of the cell at the start of the cell cycle and tD is the doubling time of the 
host cell. After each cell division, infectivity in each cell halves. In order to initiate infection in a 
cell, K must be equal to or larger than ln2/tD. If k>tD, there will be a steady accumulation of 
infectivity in the cell. If at the start and for the continuation of the experiment K=ln3/tD (blue 
line), infectivity will increase logarithmically until eventually the lethal limit is met and the cell 
will die. If K falls to ln2/tD (red line), there will be a stabilisation of infectivity levels over time 
and the cell will be chronically infected with prions. However, if K falls further to ln1.4/tD (green 
line), infectivity will fall to undetectable levels. An infected population contains a mixture of 
cells with different K values in dynamic equilibrium; chronic infection is maintained by cells with 
correct K values. In summary, accumulation of infectivity and stable propagation will only be 
observed if a cell population contains appropriate factors to favour formation at a certain rate 
over degradation.
Figure is modified from “The State of the Prion” (Weissmann, 2004).
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in these experiments because we were aware of these data and, therefore, we took the utmost 
care to maintain cells in optimal condition. Fifth, since, vCJD prion-infected brain homogenate 
is prepared by lysing brain tissue it may it contain inhibitory factors for prion replication in 
cells. Sixth, the low vCJD prion susceptibility observed in the candidate cell lines may be due 
to the subcloning technique used. Growing up colonies from such low density may have been 
challenging for cells, therefore, compromising their ability to simultaneously support prion 
propagation. Finally, glycosylation can affect affinity o f PrPc for specific PrP^ conformations 
(DeArmond et al., 1997). Since vCJD is diglycosylated (top band dominant), it may be 
important to choose a cell line in which the diglycosylated form of PrPc is highly expressed.
There is considerable evidence that co-expression o f heterologous (non-identical) PrPc 
molecules can inhibit conversion o f the PrPc molecules homologous to PrP80 via competition 
o f the heterologous PrPc molecules for PrP^ (this topic is further investigated in chapter 4 
(Telling et al., 1995). Thus, the non-human cell lines expressing human PrPc may have been 
resistant to prion infection because, the endogenous mouse PrPc (in L929 and N2aG) and 
endogenous rat PrPc (in RG6) may have prevented the conversion of ectopically expressed 
human PrPc to vCJD prions. For similar reasons, the human neuroblastoma cell line,
BE(2)M17, which is heterozygous at codon 129 o f PRNP may have been resistant to vCJD
prion infection. This genotype is protective for prion disease because the valine variant o f PrPc 
is proposed to interfere with the homologous protein-protein interactions of the methionine 
variant of PrPc and vCJD PrP^ (Palmer et al., 1991). The rabbit RK.13 cell line may have been 
exempt from this inhibitory effect because rabbit PrPc has a unique amino acid composition 
(Vorberg et al., 2003), which lacks sufficient sequence homology to human PrPc to interfere 
with human vCJD prion replication.
3.5.3 Transient and chronic prion propagation are distinct
In this study, transient vCJD prion propagation was observed in three candidate lines.
Typically, stable prion propagating cell lines remain infected for long periods, for example, 
RML prion infection was present in a PrP-overexpressing N2a cell line and mouse 
neurospheres for over 30 passages and for 70 days, respectively (Nishida et al., 2000;Giri et 
al., 2006). The most susceptible cell lines to vCJD prion infection found in this screening 
study, the human PrPc-overexpressing RK13 clones A and C, propagated prions for three 
passages (two weeks). On one occasion, the RK13 clone C propagated prions for six passages 
(three weeks). The human neuroblastoma cell lines, SKNSH and human PrPc-overexpressing 
SHSY5Y clone A, remained prion-infected for two passages (about two weeks) and for one 
passage (10 days), respectively. A study on mouse fibroblast and neuroblastoma cells found 
that following exposure to different prions, all cell lines could transiently generate PrPSc for up 
to 96 hours, possibly due to the interaction o f the target cell PrPc with the PrPSc in the
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inoculum. However, only certain cell lines could establish chronic prion infection when the 
inoculum was cleared (Vorberg et al., 2004a). Due to a change observed in glycosylation of 
PrPSc in chronically prion-infected clones, it was inferred that chronic prion infection required 
the localisation o f PrP& formation to a specific cellular compartment under the direction of 
cell-specific and/or prion strain-specific factors. Endolysosomal organelles and the 
endoplasmic reticulum have been proposed as subcellular sites o f prion replication. (Laszlo et 
al., 1992;Mayer et al., 1992;Taraboulos et al., 1992;Amold et al., 1995;Harris, 2003). 
Lysosomes have been dubbed bioreactors for PrP& because the acidic environment induces 
protein unfolding and may facilitate the conversion of PrPc to PrPSc (Laszlo et al., 1992). It is 
unlikely that the transient vCJD prion propagation we observed in the experiments presented 
here was the result o f contact with residual PrP^ in the vCJD inoculum because, not only did 
the particle monitor control cell lines indicate the inoculum had been cleared, but the time­
frame of prion propagation here was much longer than in the Vorberg study. It is more likely 
that the transient nature o f PrP80 formation we observed over a number o f weeks is associated 
with the genetic instability o f a tumour cell lines which leads to loss or change in factors 
required for prion propagation. Indeed, prolonged passaging of the highly RML prion- 
susceptible N2a clones has been reported to diminish their susceptibility to prions for this 
reason (Bosque and Prusiner, 2000;Klohn et al., 2003;Vorberg et al., 2004a).
3.5.4 Mechanisms of intercellular prion transfer
Rabbits are amongst the few species resistant to prion infection (CJD, kuru, and scrapie 
strains; Gibbs and Gajdusek, 1973), possibly because the unique amino acid composition of 
rabbit PrPc prevents it folding into the disease-associated isoform (Vorberg et al., 2003). 
However, the rabbit epithelial kidney cell line, RK13, appears to be highly susceptible to prion 
infection when ectopically expressing the appropriate species o f PrPc; in this chapter it was 
shown to transiently propagate vCJD prions and it is also permissive to ovine scrapie (Rov) 
(Vilette et al., 2001a) and mouse-passaged CJD prions (A.Hill, Melbourne University, 
personal communication). The susceptibility o f the RK.13 cell line may be explained by its 
epithelial nature. The nervous system, which is highly susceptible to prion infection, is 
developmentally-derived from epithelium, thus it has been proposed these cell types may share 
prion susceptibility factors (Vilette et al., 2001b). However, the most likely reason for the 
exceptional prion permissive nature o f the RK13 cell line is its ability to spread prions 
intercellularly via the secretion of exosomes containing PrPc and PrPSc (Fevrier et al., 2004). 
Exosomes are membranous vesicles o f 50-90 nm, which are secreted upon fusion of 
multivesicular endosomes with the plasma membrane. They are secreted by many cell types, 
particularly o f the haematopoietic system, and are proposed to be involved in intercellular 
communication and eradication o f undegraded proteins (reviewed in
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Stoorvogel et al., 2002;Thery et al., 2002;van Niel et al., 2006). They have recently also been 
implicated in the transmission o f retroviruses, including HIV (Nguyen et al., 2003). For the 
ovine scrapie-propagating RK.13 cell line (Rov), both PrPc and approximately 1% o f cellular 
PrPSc are secreted in membrane vesicles, with the specific size, lipid and protein (TsglOl; 
flotillin) composition, and subcellular localisation characteristic of exosomes. Moreover, these 
exosomes were demonstrated to be infectious in vitro and in vivo. PrPSt-containing exosomes 
have also been detected in an ovine scrapie-propagating Schwann cell line (Fevrier et al., 
2004) and there is evidence for their presence in other prion-propagating cell lines, whose 
culture supernatants contain infectivity (Schatzl et al., 1997;Cronier et al., 2004). Therefore, 
exosomes appear to represent an important mechanism of intercellular prion transfer and 
because they are secreted by many cell types, it is conceivable they are involved in transfer of 
prions in vivo from the periphery to the nervous system (Mabbott and MacPherson, 2006). 
Exosomes secreted from prion-infected cells may either fuse with the plasma membrane of 
uninfected cells or be internalised and then fuse with endosomal membranes; prion conversion 
o f adjacent PrP molecules in a membrane occurs much more readily than when molecules are 
in facing membranes (Baron et al., 2002).
Intercellular prion transfer has been proposed to occur by other mechanisms. Direct cell-cell 
contact seems to be required for spread o f infectious prions in some cell lines, such as the 
scrapie-infected mouse neuroblastoma SMB cell line (Kanu et al., 2002). Co-culture of 
scrapie-infected SMB cells and uninfected antibiotic-resistant SMB cells results in the 
transmission of prion infection to the uninfected cells (as shown by selective killing o f the 
originally prion-infected cells with antibiotic). Moreover the culture supernatant from SMB 
cells is not infectious and neither is co-culture o f both infected and uninfected cells separated 
by a porous membrane.
Given the involvement o f exosomes in intercellular prion transfer in epithelial and Schwann 
cell lines (Fevrier et al., 2004) and that retroviral budding and prion release in exosomes are 
thought to share the same pathway (Pelchen-Matthews et al., 2004), we attempted to enhance 
the spread of vCJD prions within the SKN-SH cell line by infection with MuLV retrovirus. 
This approach has been taken in a mouse prion-infected 3T3 fibroblast cell line. MuLV 
infection o f 3T3 cells stimulated release o f prion infectivity in viral particles and cellular 
exosomes and increased infection o f target cells (Leblanc et al., 2006). However, in our study, 
MuLV infection of the SKN-SH cell line reduced its susceptibility to prion infection, rather 
than prolonging the period o f propagation. This may have been because the SKN-SH cells 
were rendered sick from viral infection and, therefore, had reduced capacity to replicate prions. 
However, it was most likely because the level o f de novo PrPSc observed in the vCJD prion-
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infected SKN-SH cells was too low to initiate prion infection in neighbouring cells in the first 
place.
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Chapter 4
Humanisation of mouse prion-susceptible N2a- 
derived cell lines and their screening for 
susceptibility to human prion propagation
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4.1 Introduction
This study set out to exploit the inherent cellular prion susceptibility o f the N2a mouse 
neuroblastoma line (Race et al., 1987) and its highly RML prion-susceptible subclone, PK1 
(Klohn et al., 2003b), for the propagation of human vCJD prions. Human PrPc (129 MM) was 
expressed in these cells to eliminate the prion species barrier. However, it is known this is 
insufficient to render the cells susceptible to human vCJD prions (see human PrP-expressing 
N2aGary data, chapter 3) and considerable data suggests this is due to “dominant negative” 
inhibition of human prion propagation by endogenous murine PrPc (Prusiner et al., 
1990;Bueler et al., 1993;Priola et al., 1994;Telling et al., 1994;Telling et al., 1995;Collinge et 
al., 1995;Horiuchi et al., 2000;Perrier et al., 2002). The inhibition o f PrPSc formation by non- 
homologous PrPc molecules has been observed in transgenic mouse models, cell culture and 
cell-ffee conversion assays. Human PrP transgenic mice with endogenous murine Prnp 
expression are as resistant as wildtype mice to sCJD prions and require the ablation o f Prnp to 
acquire susceptibility (Telling et al., 1994;Telling et al., 1995). Similarly, mice expressing both 
the hamster PrP transgene and endogenous murine Prnp exhibit longer disease incubation 
periods for hamster scrapie compared to those in which murine Prnp has been ablated (Bueler 
et al., 1993;Race et al., 2000) Furthermore, hamster PrP expression impairs mouse PrP^ 
formation in scrapie-infected mouse neuroblastoma cells (Priola et al., 1994). The basis for this 
inhibitory phenomenon o f PrP^ formation is thought to be that non-homologous PrPc 
molecules readily interact with PrP^ but cannot be converted (Horiuchi et al., 2000).
Therefore, in this study, to eliminate the inhibition o f human prion propagation by endogenous 
murine PrPc in human PrPc-expressing N2a-derived cells, the murine Prnp gene was 
specifically silenced using RNA interference (RNAi). RNAi is a naturally-occurring, post- 
translational gene silencing mechanism that is highly conserved in eukaryotes. It refers to a 
pathway in which double-stranded RNAs trigger the degradation o f homologous mRNA 
molecules. RNAi has been hailed as one of the most exciting biotechnology advances in recent 
decades by Science magazine (2002) and its discovery by Fire and Mello has since earned 
them the Nobel prize for medicine in 2006 (Fire et al., 1991 ;Fire et al., 1998). It is thought to 
have evolved to silence alleles in development and to protect the genome from invasion by 
mobile genetic elements, such as transposons and viruses (Jensen et al., 1999;Tabara et al., 
1999).
The RNAi pathway (see figure 4.1) first involves the cleavage of precursor double-stranded 
RNA molecules (either endogenously expressed pre-microRNAs or exogenous double­
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stranded RNAs) by a cytoplasmic ribonuclease Ill-like enzyme, called Dicer (Bernstein et al.,
2001). Dicer cleavage results in short RNA duplexes of 21-22 nucleotides in length, with 
symmetric two nucleotide 3'-overhangs (Zamore et al., 2000;Elbashir et al., 2001b). These 
effector molecules o f exogenous double-stranded RNA, called short interfering RNAs 
(siRNAs), become incorporated into a ribonucleoprotein complex called the RNA-inducing 
silencing protein complex (RISC) (Hammond et al., 2000;Hammond et al., 2001). The siRNA 
duplex is unwound by a helicase subunit o f RISC and the anti-sense strand guides RISC to its 
homologous target mRNA (Martinez et al., 2002). Gene expression is inhibited by degradation 
o f target mRNA molecules by an endonuclease component of RISC, Argonaute 2 (Liu et al., 
2004;Meister et al., 2004). The microRNAs enter a distinct pathway to siRNAs and inhibit 
gene expression by repressing translation of target mRNA for which they are not perfectly 
complementary (Olsen and Ambros, 1999;Seggerson et al., 2002).
The use of RNAi technology as a tool to inhibit gene expression was originally limited to 
plants or C.Elegans since it proved cytotoxic in the mammals. This is because in mammalian 
cells double stranded RNA molecules o f greater than 30 nucleotides in length activate an 
innate anti-viral response involving interferon production to non-specifically suppress gene 
expression (Williams, 1997;Clemens, 1997). Therefore, chemically synthesised siRNAs 
mimicking Dicer cleavage products were developed for use in the mammalian system 
(Elbashir et al., 2001a). Delivery o f these exogenous siRNA molecules to cells with lipophilic 
agents allowed them to tap into the native RNAi pathway, incorporating into the cellular RISC 
and mediating the degradation o f homologous mRNA. Stable long-term down-regulation 
(“knockdown” ) in gene expression by RNAi is now possible using DNA expression vectors 
containing RNA polymerase III promoters (Brummelkamp et al., 2002;Yu et al., 
2002;Paddison et al., 2004). These vectors drive the expression o f short hairpin RNAs 
(comprising an RNA duplex of 19-29 nucleotide stems, precisely complementary to the target 
sequence, linked by a 3-9 nucleotide loop), which are cleaved intracellularly by Dicer to 
produce functional siRNAs (see figure 4.1).
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Figure 4.1 RNAi gene silencing pathway
Long double stranded RNA molecules and short hairpin (shRNA) precursor molecules are 
processed to siRNA duplexes of 21-23 nucleotides by the cytoplasmic ribonudease Ill-like 
enzyme, Dicer. These siRNA molecules are assembled into effector complexes, RISC (RNA- 
induced silencing complex), and subsequently unwound by its helicase subunit. The sense 
strand is released and degraded, while the anti-sense strand guides RISC to its target mRNA. 
Sequence complementarity between siRNA and mRNA is required for spedfic degradation of 
target mRNA to take place. The endonuclease subunit (Argonaute 2) of activated RISC 
preferentially cleaves target mRNA between positions 10 and 11 relative to the 5’ antisense 
strand to inhibit gene expression (Elbashir et al., 2001c). 7mG: 7-methylguanine, AAAA: 
polyadenosine tail, 5’p: 5’phosphate. Figure modified from (Wall and Shi, 2003).
Target cleavage (endonuclease)
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For this project, eight siRNA sequences were designed to specifically target mouse Prnp gene 
but not the human PRNP gene (see table 2.3). Specificity against mouse Prnp was achieved by 
selecting siRNA sequences targeting the 3' untranslated region (3'UTR) of mouse Prnp gene. 
Since the human PRNP construct expressed in N2a and PK1 cells comprised the coding 
region, and not the 3’UTR, these sequences should not have affected the human PRNP 
expression. One siRNA did target the open reading frame of mouse Prnp but contained four 
mismatches to the human PRNP sequence; this lack of sequence specificity made it unlikely to 
interfere with human PRNP expression.
4.2 Aims of this study
• To specifically knock out endogenous mouse Prnp in N2a and PK1 mouse prion-
susceptible cell lines using shRNAs.
• To reconstitute mouse Prnp open reading frame (ORF) in knockout cells and
determine i f  susceptibility to mouse prions (RML) is retained, as a proof-of-principle 
experiment.
• To ectopically express human PRNP ORF in Prnp knockout cells and determine
susceptibility to human vCJD prion infection using the standard procedure developed 
in chapter 3.
4.3 Methods
The data presented in this chapter were produced using methods described in chapter 2. Prnp 
sequences targeted by the eight siRNAs are shown in table 2.3. Their design, cloning as short 
hairpin RNAs into retroviral expression vectors and their expression in cells are described in 
section 2.5. The effectiveness o f /V/7/?-specific shRNAs was assessed by immunoblotting 
(2.6.2), immunofluorescence (2.6.3) and quantitative PCR (2.5.6). Human PrPc expression in 
cells is described in 2.4 and was analysed by immunoblotting (2.6.2), High human PrPc- 
expressing cells were isolated by subcloning (2.4.2.1) and FACS-sorting (2.6.4), vCJD prion 
infection of cells was done as described in section 2.7.2 and the presence of PrPSt assessed by 
the scrapie cell assay (SCA; 2.7.5.2).
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4.4 Results
4.4.1 Selection of siRNA target sequences in Prnp mRNA
4.4.1.1 Empirical rules of siRNA design
Not all siRNAs that are complementary to their target mRNA can efficiently silence their 
cognate target gene. At the start o f this project (2003), the field o f RNAi was in its infancy and 
little was known about what determined siRNA functionality. Empirical guidelines on siRNA 
design existed, which were based on the first successful siRNA sequences found by trial-and- 
error. These guidelines are briefly outlined below:
• Select siRNA from the mature mRNA target sequence (cDNA), preferably starting 50- 
100 nucleotides (nt) downstream of the start codon and avoiding the 3' and 5’ UTRs to 
prevent interference from regulatory binding proteins of RISC binding to the mRNA 
(Elbashir etal., 2002).
•  In the mRNA sequence, search for sequences 5'-AA(N19)UU, where N is any nt. 
SiRNA duplexes of 21 nt paired so as to have 2 nt 3’-overhangs were found to be the 
most efficient (Elbashir et al., 2001c). Selecting sequences to provide uridine in the 
two nucleotide overhangs of the siRNA duplexes is suggested because they offer 
protection from endonuclease degradation and 2’deoxythymidine can be used for RNA 
synthesis, which is cheaper and does not result in loss of activity (Elbashir et al.,
2002).
• The siRNA duplexes should have < 50% GC content. Too low a GC content is thought 
to destabilise the siRNA duplex and result in low affinity of the antisense strand for 
target mRNA, whilst a higher content may impede RISC loading and/or siRNA duplex 
unwinding (Elbashir et al., 2002;Holen etal., 2002).
• Avoid a run of 4 uridine or adenine residues because this is the termination signal for 
RNA polymerase (Geiduschek and Tocchini-Valentini, 1988).
• Avoid palindromic sequences that may form fold-back structures (Kirchner et al., 
1998).
• Blast-search (www.ncbi.nlm.nih.aov/BLAST) the selected siRNA sequences against 
mRNA sequences of the respective organism to ensure only the desired gene is 
targeted (Elbashir et al., 2002).
These basic empirical guidelines were used to design the first set o f four siRNA sequences 
targeting mouse Prnp, named siRNA# l-#4. SiRNA# 1 targeted the coding region o f Prnp. 
Despite the guidelines above, siRNAs#2-#4 were designed to target the 3'UTR o f Prnp to 
allow the sequences to be mouse-specific. Moreover, there was growing evidence suggesting 
siRNAs targeting 3’UTRs could be effective (McManus et al., 2002).
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4.4.1.2 In silico rational design of siRNA sequences
Improved understanding of the RNAi mechanism and the statistical analyses o f siRNA 
libraries (with experimentally determined efficiencies) has lead to the development of 
computational tools to increase the probability o f selecting effective siRNAs (Reynolds et al., 
2004;Saetrom and Snove, Jr., 2004;Huesken et al., 2005). For this project, the second set of 
candidate siRNAs targeting Prnp was designed using SMART Selection™ technology 
(Dharmacon Inc., USA). Use o f the Dharmacon algorithm has been estimated to increase the 
average probability o f selecting an effective siRNA (which suppresses target gene expression 
by greater than 80%) 3.5-fold compared to random selection (Reynolds et al., 2004). This 
Dharmacon technology employs an algorithm integrating eight thermodynamic and sequence- 
related criteria outlined below. The thermodynamic criteria are proposed to affect the initial 
siRNA-RISC recognition and the sequence-related criteria are proposed to affect critical 
siRNA-protein interactions (Reynolds et al., 2004).
Thermodynamic criteria
• Absence of internal repeats to prevent inappropriate folding of siRNA.
• Low to moderate GC content (36-52%) promotes efficient unwinding of duplex.
• High internal stability of 5’-sense strand and low internal stability at 5’-antisense strand 
both promote antisense strand selection and incorporation into RISC.
Sequence-related criteria
• Sense strand base preferences at specific positions; 3, 10, 13 and 19. For example, 
the presence of U at position 10 and the absence of G at position 13.
A BLAST-search is conducted by default to ensure the siRNA sequences do not target other 
sequences in the genome. For our purposes, Dharmacon rationally designed a further four 
siRNA candidate sequences to target mouse Prnp, all o f which targeted the 3'UTR o f mouse 
Prnp.
4.4.2 Verification of Pr/ip-specific siRNA sequences
Following cloning into the pSuper.retro and pMSCV expression vectors, the sequence of 
siRNAs #l-#8 were checked and found to be correct by DNA sequencing using vector-specific 
primers.
4.4.3 Screening of candidate siRNA sequences for Prnp knockdown efficiency in N2a 
cells
The first set o f mouse Prnp specific siRNAs #l-#4, designed by Professor Parmjit Jat using 
basic empirical rules, were cloned into the retroviral expression vector, pSuper.retro, and 
packaged into PhiNX-eco retroviral producer cell line. Ecotropic virus was harvested and used 
for the retroviral transduction of N2a cells with siRNAs #l-#4. Successfully transduced cells
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were isolated by puromycin selection, and mixed clones stably expressing siRNA were 
established. Initial analysis by immunoblotting indicated that siRNA#2 and #4 were more 
effective than #1 and #3 at suppressing PrPc protein expression in N2a cells and they produced 
about 75% PrPc knockdown (figure 4.3). However, PrPc knockdown was not complete and 
therefore insufficient for our purposes. As a result, a further four siRNA sequences (siRNA#5- 
#8) were designed using SMART Selection™ technology (Dharmacon Inc., USA; (Reynolds 
et al., 2004)) and cloned into pSuper.retro.
The efficiency o f Dharmacon siRNAs to knockdown Prnp expression was first analysed by 
their transient expression in N2a cells followed by immunofluorescence for PrPc expression 
(figure 4.2). SiRNA#8 produced the most significant and widespread PrPc knockdown (figure 
4.2H) compared to wildtype expression. There were variable levels of PrPc knockdown in N2a 
siRNA#5 and N2a siRNA#7 mixed clones. They exhibited significant PrPc knockdown in a 
small proportion o f cells (figure 4.2D and G) but this was not widespread (figure 4.2C and F). 
Variability in knockdown observed following immunoflourescence may be explained by the 
fact puromycin selection was not complete (only 72 hours o f gentle selection) and 
untransduced cells lacking the siRNA construct remained in the cultures. PrPc knockdown was 
specifically due to siRNA expression since the negative control vector-only expressing cells 
had similar PrPc expression levels to wildtype N2a cells (figure 4.2B).
Stable mixed clones of N2a cells expressing Dharmacon siRNA sequences were established so 
that a comparison o f PrPc knockdown efficiency could be made with the best empirically- 
designed siRNAs, #2 and #4 by immunoblotting (figure 4.3). SiRNA#8 exhibited the best 
PrPc knockdown efficiency followed by #4, #2 (which was slightly underloaded as indicated 
by the endogenous biotin bands) and then #5. PrPc knockout was not complete but expression 
was suppressed by between 50 and 80% in these clones. Interestingly, although siRNA#5 and 
#6 differed in sequence by just 2 nucleotides, siRNA#5 was more effective at suppressing PrPc 
expression.
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Figure 4.2 Transient expression of Dharmacon Prnp-specific siRNAs on PrPc 
expression in N2a cells
N2a cells were grown on poly-L-lysine coated glass coverslips and retrovirally transduced at 
50% confluency with Dharmacon siRNA sequences and pSuper vector-only negative control. 
12 hours after transduction, gentle puromycin selection at 1.5 pg/ml was started. 72 hours after 
transduction, PrPc expression was analysed by immunofluorescence. PrPc is stained green 
with ICSM18 and FITC-conjugated anti-mouse IgG secondary antibody. Nuclei are stained 
blue with DAPI. Photographs A -  H were acquired with fixed exposure times for DAPI and 
FITC (500 and 1500 ms, respectively) to accurately assess PrPc levels. SiRNA#8 (H) 
produced the most significant and widespread suppression of PrPc expression compared to 
wildtype N2a controls (A). PrPc knockdown was not homogeneous within the mixed clones. 
For example, siRNA#5 and siRNA#7 clones had regions of almost complete PrP° knockdown 
(D and G), whilst others retained wildtype expression levels (C and F). SiRNA#6 was least 
effective at knocking down PrPc expression (E).
128
Chapter 4 vCJD susceptibility of humanised mouse prion-susceptible cells
biotin
Figure 4.3 Comparison of the PrPc knockdown efficiency of empirically and Dharmacon 
designed Prnp-specific siRNAs in N2a cells
Cell lysates from stable puromycin-resistant mixed clones of N2a cells expressing siRNA#2, 
#4 and #5 - #8 were immunoblotted using anti-PrP antibody, biotinylated ICSM35. 25 pg 
protein from cell lysates was loaded per lane. Endogenous biotin bands (two bands between 
-100 and 60 kDa detected by avidin-biotin-AP secondary complex) are included to indicate 
differences in protein loading. The most effective suppression of PrPc expression compared to 
wildtype N2a cells was produced by siRNA sequences #8, #4, #2 (underloaded) and #5, in that 
order. PrPc knockdown was between 50 and 80% in these clones.
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4.4.4 Achieving maximal mouse Prnp knockdown in N2a and PK1 cells
As mentioned above, in order to prevent interference of endogenous Prnp expression with 
human prion propagation in N2a and PK1 cells, it was essential to achieve as close to complete 
Prnp knockout as possible. Two strategies were adopted to achieve maximal Prnp knockdown 
with the siRNAs designed.
1) Single cell subcloning of N2a and PK1 cells expressing siRNA#8
It was apparent from immunofluorescence data (figure 4.2) that there were cells within the 
mixed siRNA-expressing populations that expressed negligible PrPc. First, it was 
hypothesised that single cell cloning of the stable mixed population of both N2a and PK1 
cells expressing the most effective siRNA, #8, would isolate cells with the best 
knockdown and yield Prnp KO clones.
2) Expression of 2 anti -Prnp siRNA sequences
Second, it was hypothesised that the introduction of a second potent siRNA sequence 
(siRNA#2, #4 or #5) into N2a and PK1 cells expressing siRNA#8 would have an additive 
effect on PrPc knockdown and produce Prnp KO clones. The second siRNA expression 
cassette was moved from pSuper into a different retroviral vector, pMSCV, with a 
hygromycin B selectable marker and subsequently introduced into siRNA#8 mixed clones 
by retroviral transduction.
4.4.4.1 Improving Prnp knockdown in N2a and PK1 siRNA#8 expressing cells by single 
cell subcloning
4.4.4.1.1 N2a siRNAM clones
Forty-two single cell clones were isolated by limiting dilution subcloning (see 2.4.2.1) from 
N2a mixed clones stably expressing siRNA#8 (N8). PrPc knockdown was first screened by 
immunofluorescence, promising clones were expanded and PrPc knockdown was assessed by 
immunoblotting. Approximately 50% PrPc knockdown was observed in most clones but four 
clones exhibited approximately 80 and 90% PrPc knockdown compared to N2a wildtype cells 
(figure 4.4). The best PrPc knockdown was observed in a clone named N8a, in which protein 
expression was reduced by approximately 90%. PrP was deglycosylated so that it ran as a 
single unglycosylated band, which allowed more accurate estimation of PrPc knockdown 
(figure 4.7). Following deglycosylation, unglycosylated PrPc was undetectable in N8a by 
immunoblotting. Quantitative PCR demonstrated that the reduction of PrPc expression in clone 
N8a was associated with a concomitant 90% reduction in Prnp mRNA transcript levels 
compared to N2a wildtype (figure 4.8A), confirming that the observed reduction in PrPc 
protein expression was due to siRNA-mediated mRNA degradation and not inhibition of 
protein synthesis.
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Figure 4.4 PrPc knockdown in N2a clones expressing siRNA#8
Cell lysates from single cell clones isolated from N2a mixed clones stably expressing siRNA#8 
(N8), N2a siRNA#8 mixed clone (N8mix) and N2a wildtype were immunoblotted using anti-PrP 
antibody, biotinylated ICSM35. 25 pg protein from cell lysates was loaded per lane. PrPc 
expression in four single cell clones of N8 was reduced by an estimated 80-90% (lanes 1-4). 
Compared to N2a wildtype expression (lane 6), only N8a (lane 3) showed greater PrPc 
knockdown than N8 mixed clones (lane 5). The band running just above 30 kDa in N2a lane is 
a degradation product of PrPc.
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4.4.4.1.2 PK1 siRNA#8 clones
PK1 cells were retrovirally transduced with siRNA#8 and when puromycin selection was 
complete, single cell clones were picked (by P.Arora; 2.4.2.1). PrPc knockdown in clones was 
initially assessed by immunofluorescence (figure 4.5) and then confirmed by immunoblotting 
(figure 4.6). PrPc protein expression was significantly reduced from PK1 wildtype levels in 
three clones, P8a, P8b and P8c and was estimated to be between 80-85% using quantitative 
densitometric immunoblot analysis (table 4.1). However, PrPc knockdown in these clones may 
have been greater than this because following deglycosylation, unglycosylated PrPc was 
undetectable by immunoblotting (figure 4.7) and immunofluorescence analysis failed to detect 
PrPc expression (figure 4.5) compared to wildtype and vector-only controls. Suppression of 
PrPc protein expression was accompanied by greater than 90% reduction in Prnp mRNA levels 
in these PK1 single knockdown clones by quantitative real-time PCR (figure 4.8B and table 
4.1). Prnp mRNA levels were most significantly reduced in P8b by 99%, followed by P8c 
(97%) and then P8a (93%).
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Figure 4.5 Immunofluorescence analysis of PrPc knockdown in PK1 clones expressing 
siRNA#8
Stable PK1 siRNA#8-expressing single cell clones were isolated by retroviral transduction of 
PK1 cells with siRNA#8, followed by 4 pg/ml puromycin selection and clone picking of 
surviving clones. Clones were grown on poly-L-lysine coated glass coverslips. Middle column 
shows immunostaining for PrPc (green) with ICSM18 primary (1°) antibody and FITC- 
conjugated anti-mouse IgG secondary (2°) antibody. Left-hand column shows cells by nuclear 
DAPI staining (blue). Right-hand column shows merged images. Images A-l were acquired 
with fixed exposure times for DAPI and FITC (500 and 1500 ms, respectively). PrPc expression 
was knocked out in three PK1 siRNA#8 single cell clones, P8a, P8b, and P8c (L,O.R) 
compared to wildtype (C) and vector-only controls (I). These data were produced by P.Arora.
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Figure 4.6 PrPc knockdown in PK1 clones expressing siRNA#8
Stable PK1 single cell clones expressing siRNA#8 were isolated by clone picking following 
retroviral transduction of PK1 with siRNA#8 and subsequent 4 pg/ml puromycin selection. Cell 
lysates of PK1 single cell clones expressing siRNA#8 clones, P8a, P8b and P8c and PK1 were 
immunoblotted using anti-PrP antibody, biotinylated ICSM35. 25 pg protein from cell lysates 
was loaded per lane. PrP° expression in three clones, P8a (lane 2), P8b (lane 3) and P8c 
(lane 4) was significantly reduced compared to wildtype PK1 cells (lane 1).
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Figure 4.7 PrP° deglycosylation in PK1 and N2a clones expressing siRNA#8
Cell lysates were deglycosylated with 30U/ml N-glycosidase-F and immunoblotted using anti- 
PrP antibody, biotinylated ICSM35. 30 pg protein was loaded per lane. Unglycosylated PrPc 
was visualised as a single band at -30 kDa. No PrPc expression was observed in P8a (lane 
5), P8b (lane 6), P8c (lane 7) compared to PK1 wildtype (lane 1) or N8a (lane 3) clones 
compared to N2a wildtype (lane 4). Very low PrPc expression was detected in N8 mixed 
clones (lane 2) compared with N2a wildtype expression.
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Figure 4.8 Quantitation of Prnp mRNA knockdown in PK1 and N2a clones expressing 
siRNA#8 by quantitative real-time PCR (qRT-PCR)
Relative Prnp gene expression compared to wildtype (N2a or PK1) cells was determined for 
single siRNA knockdown clones using qRT-PCR and the comparative threshold method 
(described in 2.5.6.4), for which GAPDH house-keeping gene was used to normalise the data. 
Validation experiments were performed and it was determined that GAPDH and Prnp probe 
amplification efficiencies were equal because the difference of Prnp and GAPDH slopes was 
0.12. Data are presented as mean relative Prnp mRNA and represent means of triplicate 
samples (+ SEM). Prnp mRNA levels were significantly reduced in N8a to 10% N2a wildtype 
level. Prnp mRNA levels were further reduced in PK1 single KO clones, P8a, P8b, P8c, to 
7.4%, 0.8% and 3.1% of PK1 wildtype, respectively. 2-tailed f-tests were performed * = P<0.05 
and ** = P<0.005. J.Podesta performed the experiments and I performed the data analysis.
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P8 clone PrPc knockdown 
(%±SEM)
mean Prnp mRNA 
suppression
(%±SEM)
PK1 pSuper 18 not done
P8a 81.5 +0.5 93 ±0.5
P8b 83.5 ±0.5 99 ±0.2
P8c 82.5 ±0.5 97 ±0.5
Table 4.1 Suppression of PrP° protein and mRNA levels in PK1 knockdown clones
Taking into account qRT-PCR and quantitative immunoblot data, P8b exhibited the most 
significant suppression in PrPc expression, followed by P8c and P8a. A small reduction in 
PrPc expression resulted from pSuper vector expression but this was probably a clonal 
property. Data for PrPc knockdown compared to wildtype PK1 were obtained from 
densitometry analysis of immunoblots (as described in 2.6.3.5) and represent mean with SEM 
of 2 blots. Suppression of Pmp mRNA was calculated by qRT-PCR and is presented as mean 
suppression (+ SEM) relative to wildtype PK1.
4.4.4.2 Prnp knockdown in N2a and PK1 cells by double siRNA expression
4.4.4.2.1 N2a double siRNA PrP* knockdown clones
A second siRNA construct #2, 4 or 5 (cloned into pMSCV.hyg) was sequentially introduced 
into the N8 stable mixed clone by retroviral transduction. Following hygromycin selection, 
which typically took 10-14 days, mixed double siRNA clones were established. Fifty-four 
single cell clones were subsequently isolated by limiting dilution subcloning (2.4.2.1), Twenty- 
four clones of both N8 siRNA#2 and N8 siRNA#4 were isolated however the N2a siRNA#5 
clones were less viable and only six survived. The clones were screened for PrPc knockdown 
compared to wildtype N2a cells by immunofluorescence, for which eighteen clones appeared 
promising with areas o f significant knockdown. PrPc knockdown was assessed in these clones 
by immunoblotting. The best PrP1 knockdown achieved was about 80% in two N8 siRNA#4 
single cell clones (e and f) (figure 4.9). 75% and 60% PrP1 knockdown was observed in three 
other N8 siRNA#4 single cell clones, 40 and 50% in most N8 siRNA#2 clones but no 
significant PrPc knockdown was observed in the N8 siRNA#5 clones. The PrPc knockdown 
observed by immunofluorescence in the double siRNA clones was very heterogeneous. In one
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N8 siRNA#2 clone, in which the total PrPc knockdown was 50%, there were regions of 
complete PrPc knockout (figure 4.10). Although these lines were supposed to be clonal, during 
proliferation from a single cell it is inevitable there are some changes, particularly i f  PrPc 
knockdown were conferring a growth disadvantage. In summary, PrPc knockdown in N2a 
double siRNA clones was not as good as seen in single siRNA clone, N8a (approximately 90% 
PrPc knockdown).
4.4.4.2.2 PK1 double siRNA PrP^ knockdown clones
The best PK1 single siRNA PrPc knockdown clone, P8b, was chosen and a second siRNA 
construct #2, 4 or 5 was sequentially introduced by retroviral transduction. Following 
hygromycin selection, single cell clones were picked (2.2.4.1) and fifty clones were assessed 
for PrPc knockdown by immunofluorescence and verified by immunoblotting (P.Arora). Three 
PK1 clones expressing double siRNA exhibited improved PrPc knockdown compared to P8b 
(figure 4.11). One o f the clones expressed siRNA#8 and siRNA#2 and was named P8b2a, the 
other two clones expressed siRNA#8 and #4 and were named P8b4a and P8b4b. Since PrPc 
was almost undetectable by immunoblotting and immunofluorescence, PrPc knockdown was 
estimated to be between 95 and 99% in these three clones.
4.4.4.3 Summary of maximal PrPc knockdown in PK1 and N2a cells
In the PrPc RNAi study, the maximal PrPc knockout achieved in PK1 and N2a cells with a 
single siRNA was 90% in P8b and N8a clones. Expression of two siRNA constructs did not 
improve PrPc knockdown in N2a cells. However, PrPc knockdown was improved in PK1 
double siRNA clones, P8b2a, P8b4a and P8b4b, and was estimated to be between 95 and 99%. 
These maximally PrPc suppressed clones were used to ectopically express human PrPc in 
order to develop a human vCJD prion-propagating cell line.
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biotin
Figure 4.9 PrPc knockdown in N2a clones expressing double siRNA sequences
N2a double siRNA single cell clones were generated by introduction of siRNA#2 or #4 into N8 
mixed clone followed by limiting dilution subcloning. Cell lysates of four N8 siRNA#2 clones 
(N8/2) and six N8 siRNA#4 clones (N8/2) and N2a were immunoblotted using anti-PrP 
antibody, biotinylated ICSM35. 25 pg protein from cell lysates was loaded per lane. PrPc 
expression was most significantly reduced in the N8 siRNA#4 clones; two clones exhibited an 
estimated 80% PrPc suppression (lanes 10 and 11), one clone exhibited 75% PrPc 
suppression (lane 1) and three clones exhibited 60% PrPc suppression (lanes 2-4) compared 
to wildtype N2a (lanes 9 and 12). PrP° expression was suppressed by an estimated 40-50% in 
N8 siRNA#2 clones (lanes 5-8).
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Figure 4.10 Confocal analysis of PrPc knockout in N8 siRNA#2 double siRNA knockout 
clone, N8/2b
N8/2b clone and N2a wildtype cells were grown on poly-L-lysine coated glass coverslips and 
immunostained for PrP° (green) with ICSM18 and FITC-conjugated anti-mouse IgG secondary 
antibody and nuclei were stained blue with DAPI. (A-C) represents N2a controls and (D-F) 
represent N8/2b. (B) PrPc expression was predominantly seen at the plasma membrane in 
wildtype N2a cells. (E) N8/2b (double siRNA knockdown clone expressing both siRNA#8 and 
#2) exhibited almost total PrPc knockout in some regions (E), though expression was 
maintained to a low level at points of cell-cell contact.
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Figure 4.11 PrPc knockdown in PK1 single cell clone expressing double siRNA 
sequences
PK1 double siRNA PrPc knockdown clones were generated by the introduction of siRNA#2 or 
siRNA#4 into the P8b clone. Cell lysates of one P8b siRNA#2 clone, two P8b siRNA#4 clones 
and PK1 were immunoblotted using anti-PrP antibody, biotinylated ICSM35. 25 pg protein from 
cell lysates was loaded per lane. Compared to wildtype PK1 cells (lanes 1 and 5), PrPc 
expression was suppressed to >90% in three clones (lanes 2-4) The clone in lane 2 expressed 
siRNA#8 and #2 and was named P8b2a. The clones in lanes 3 and 4 expressed siRNA#8 and 
#4 and were named P8b4a and P8b4b, respectively.
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4.4.5 Reconstitution of PrPc KO cells with ectopically expressed murine PrPc restores 
susceptibility to RML prions
4.4.5.1 Ectopic expression of murine PrPc in PrPc KO N2a and PK1 cells
To determine if  siRNA expression and extensive subcloning had affected the innate 
susceptibility o f N2a and PK1 cells to RML mouse prions, mouse PrPc was ectopically 
expressed in the seven PrP KO clones. The mouse Prnp ORF was transduced into the KO 
clones P8a, P8b, P8c, P8b2a, P8b4a, P8b4b and N8a and stable mixed clones generated by 
G418 selection. PrPc expression in these clones was assessed by immunoblotting. Murine PrPc 
expression was reconstituted to greater than wildtype level in P8b, P8c, P8b2a, P8b4a and 
P8b4b clones (figure 4.12 and 4.13), and equal to wildtype level in P8a (figure 4.13). 
However, reconstitution o f murine PrPc was not achieved in N8a cells despite three attempts 
(figure 4.14).
4.4.5.2 RML susceptibility of murine PrPc reconstituted PrPc KO clones
The RML prion susceptibility o f murine PrPc (moPrP) reconstituted clones was assessed by 
the scrapie cell assay (SCA). P8b moPrP and P8c moPrP, which overexpressed PrPc, showed 
very similar RML prion susceptibility to PK1 cells (figure 4.15). P8b4a and P8b4b, which also 
overexpressed murine PrPc, exhibited about 80% susceptibility o f PK1 to RML prion infection 
(at 3 x 105 dilution o f RML-infected brain homogenate; figure 4.17). However, P8b2a moPrP, 
which overexpressed PrPc, showed about 50% susceptibility o f PK1 to RML prion infection 
(figure 4.16) and P8a moPrP, which expressed wildtype levels o f PrPc, showed only 30% PK1 
susceptibility to RML prions (figure 4.15).
4.4.5.3 Summary of RML prion susceptibility of PK1 PrPc KO clones
In summary, reconstitution o f murine PrPc in PrPc KO PK1 clones restored susceptibility to 
RML prions. RML prion susceptibility did not correlate with murine PrPc expression levels. 
These were P8b moPrP and P8c moPrP, in which susceptibility was fully restored, followed by 
P8b4a and P8b4b, in which susceptibility was partially restored. All murine PrPc-reconstituted 
clones showed susceptibility at very low RML prion-infected brain homogenate concentrations 
(from 1 x 10'6 dilution). These data demonstrate that following siRNA expression and 
extensive subcloning, overexpression o f PrPc is required to restore cellular prion susceptibility. 
This was an important proof-of-principle experiment validating the strategy o f ectopically 
expressing human PrPc in PK1 and N2a KO clones for the generation o f vCJD prion- 
propagating cell line.
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Figure 4.12 Reconstitution of murine PrPc in PK1 single siRNA PrPc KO clones
Stable mixed dones expressing murine PrP ORF (moPrP) were established in PK1 single 
siRNA KO clones, P8a, P8b and P8c. Cell lysates of murine PrP° reconstituted clones and 
PK1 wildtype were immunoblotted using anti-PrP antibody, biotinylated ICSM35. 25 pg protein 
from cell lysates was loaded per lane. Murine PrPc expression was reconstituted to wildtype 
PK1 level (lane 1) in P8a clone (lane 2) and to above wildtype level in P8b and P8c clones 
(lanes 3 and 4, respectively). These data were produced by P.Arora.
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Figure 4.13 Reconstitution of murine PrP°in PK1 double siRNA PrPc KO clones
Stable mixed dones expressing murine PrP open reading frame (moPrP) were established in 
PK1 double siRNA KO clones, P8b2a, P8b4a and P8b4b. Cell lysates of KO dones and their 
corresponding murine PrPc-reconstituted clones and PK1 wildtype were immunoblotted using 
anti-PrP antibody, biotinylated ICSM35. 25 pg protein from cell lysates was loaded per lane. 
Murine PrP° expression was reconstituted to greater than PK1 wildtype level (lane 1) in P8b2a 
(lane 7), P8b4a and P8b4b (lanes 3 and 5, respectively). These data were produced by 
P.Arora.
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Figure 4.14 Failure to reconstitute murine PrPc in N8a single siRNA PrPc KO clone
Stable G418-resistant mixed clones of N8a transduced with murine PrP open reading frame 
(moPrP) were established. Cell lysates of N8a, N8a mo PrPc and N2a were immunoblotted 
using anti-PrP antibody, biotinylated ICSM35. 25 pg protein from cell lysates was loaded per 
lane. There was no significant difference in PrPc expression levels in N8a clone (lane 1) 
compared to that which had been transduced with mouse PrP open reading frame (lane 2).
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Figure 4.15 RML prion infection of PK1 single siRNA PrPc KO clones following 
reconstitution with murine PrPc
PK1 PrPc KO clones (P8a, P8b and P8c), corresponding murine PrPc-reconstituted clones and 
PK1 (positive control) cells were infected with 0.01% RML prion infected brain homogenate 
(13165) and negative controls were not infected. After the third passage at 1:8 ratio (when the 
original inoculum had been cleared), cells were assayed for presence of PrP80 by the scrapie 
cell assay (SCA; see 2.7.5.2). The graph shows RML infection data only. Each bar represents 
mean SCA value per well (+ SEM) of 12 replicates -  this value is the number of PrP80 positive 
spots in a well and is an indicator of RML prion susceptibility. The experiment controls are 
shown in grey and the samples in pink. PK1 cells are highly susceptible to RML prions and 
represent the positive control for the prion infection; a SCA value of -1300 spots indicates that 
the infection was successful. The iPK1 cells are chronically RML prion-infected PK1 cells and 
were used as a positive control for the SCA; a SCA value of nearly 1000 (938) indicates that 
the SCA assay was also successful. The pSuper vector only clone showed reduced 
susceptibility to RML compared to PK1 cells (-40% reduction) but this may have been due to 
the 18% reduction in PrPc expression level observed (table 4.1). The PrPc KO clones were all 
resistant to RML infection. P8a moPrP, which expressed PrPc to wildtype level, exhibited 
-70% reduction in susceptibility to RML prions compared to PK1 wildtype. P8b moPrP and 
P8c moPrP clones, which overexpressed PrPc, exhibited similar susceptibility to RML prions 
compared to PK1 cells.
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Figure 4.16 RML prion infection of PK1 double siRNA PrPc KO clone, P8b2a, following 
reconstitution with murine PrPc
P8b2a and P8b2a murine PrP° reconstituted cells and PK1 (positive control) cells were 
infected with seven dilutions of RML prion-infected brain homogenate (0 - 3x1 O'5). After the 3rt 
passage at 1:8 ratio (when the original inoculum had been cleared), cells were assayed for 
PrPSc by SCA. Mean SCA value per well (+ SEM) of 12 replicates are presented. Murine PrPc 
reconstitution of P8b2a to over wildtype expression level improves RML susceptibility 
(compared to the PrPc KO clone, which is resistant). However, on average only 50% 
susceptibility is restored compared to PK1 cells over all RML prion dilutions. These data were 
produced by P.Arora.
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Figure 4.17 RML prion infection of PK1 double siRNA PrPc KO clones, P8b4a and 
P8b4b, following reconstitution with murine PrPc
P8b4a and P8b4b PrPc KO, corresponding moPrPc reconstituted cells and PK1 (positive 
control) cells were infected with seven dilutions of RML homogenate (0- 1x10'7). After the 2nd 
1:10 passage, cells were assayed for PrP80 by SCA. Mean SCA value per well (+ SEM) of 12 
replicates are presented. Murine PrPc reconstitution of clones P8b4a and P8b4b to over 
wildtype level restores their susceptibility to RML prions. RML prion susceptibility is not fully 
restored to PK1 wildtype level but is not significantly different; approximately an 80% reduction 
in susceptibility at 3 x 10'5 dilution of brain homogenate was observed. These data were 
produced by P.Arora.
147
Chapter 4 vCJD susceptibility of humanised mouse prion-susceptible cells
4.4.6 Ectopic expression of human PrP( in PrP knockdown lines
In order to eliminate the species barrier for vCJD prion propagation in the N2a and PK1 mouse 
cells, human PrP1 (codon 129 MM) was expressed in PrPc KO clones. Initially, mixed human 
PrP( -expressing clones were established. In order to achieve higher PrPc expression levels, 
single cell clones were isolated and sorted by FACS.
4.4.6.1 Generation of stable human PrPc expressing mixed clones in PrP( KO clones
Human PrP (129 MM) ORF was expressed in the PK1 and N2a PrPc KO clones via the 
pLNCX2 retroviral vector. Stable mixed human PrPc-expressing clones were established for 
seven KO clones (P8a, P8b, P8c, N8a, P8b2a, P8b4a and P8b4b) and PrPc expression levels 
were assessed relative to wildtype PK1 and N2a by immunoblotting (Figures 4.18, 4.19 and 
4.20). Overexpression o f human PrPc was observed in P8a, P8b2a, P8b4a and P8b4b, w ildtype 
expression of human PrPc was observed in P8b and P8c, and less than wildtype expression was 
observed in a second P8b2a clone (figures 4.18 and 4.19). N8a cells were resistant to 
transduction with human PrPc (figure 4.20).
4.4.6.2 Achieving maximal human PrP( expression in P8b PrPc KO line
PrPc overexpression has been found to increase susceptibility of some cell lines to prion 
infection (Nishida et al., 2000;Giri et al., 2006). The murine PrPc reconstitution o f PrPc KO 
cells presented here corroborates this since overexpression of murine PrPc increased 
susceptibility to RML prion infection. It was hypothesised that human PrPc overexpression 
would enhance susceptibility o f KO clones to vCJD prions due to increased availability o f 
human PrPc template for conversion to human PrP^. The P8b line was used for this study 
because at the time o f experiments it was the clone with the best PrP( KO clone available and 
had also showed the most susceptibility to RML prions (figure 4.15). Two strategies were 
adopted for the isolation o f clones maximally overexpressing human PrP*\ (1) single cell 
cloning o f P8b human PrPc mixed clone and (2) isolation o f P8b human PrPc cells highly 
expressing PrP( by FACS sorting.
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Figure 4.18 Ectopic expression of human PrP°in PK1 single siRNA PrP1' KO clones
PK1 single siRNA clones (P8a, P8b and P8c) were retrovirally transduced with human PrP 
ORF (129 MM) and G418-resistant stable mixed clones established. Cell lysates of stable 
mixed human PrPc clones (HuPrP+) and corresponding PK1 PrPc KO clones (HuPrP-), PK1 
pSuper and PK1 positive control were immunoblotted using anti-PrP antibody, biotinylated 
ICSM35. 25 pg protein from cell lysates was loaded per lane. Human PrPc was expressed to 
at least PK1 wildtype level (lane 3 A-C) in all PK1 single siRNA PrPc KO clones, P8a, P8b and 
P8c (lane 1 A-C respectively) compared to KO clones (lane 2 A-C). P8aH (lane A1) 
overexpressed human PrPc.
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Figure 4.19 Ectopic expression of human PrP in PK1 double siRNA PrP KO clones
PK1 double siRNA clones, P8b2a, P8b4a and P8b4b, were retrovirally transduced with human 
PrP ORF (129 MM) and G418-resistant stable mixed clones established. Cell lysates of stable 
mixed human PrPc clones and PK1 positive control were immunoblotted using anti-PrP 
antibody, biotinylated ICSM35. 25 pg protein from cell lysates was loaded per lane. Compared 
to PK1 wildtype (lanes 1 and 4), human PrPc was overexpressed in P8b2a (lane 2), P8b4a 
(lane 5) and P8b4b (lane 6). In an independent transduction, human PrP° was expressed to 
below wildtype level in P8b2a (lane 3).
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Figure 4.20 Failure to generate human PrPc -expressing N8a cells
Cell lysates of G418-resistant mixed human PrP-transduced N8a cells (lane 1), N8a KO done 
(lane 2) and N2a (positive control; lane 3) were immunoblotted using anti-PrP antibody, 
biotinylated ICSM35. 25 pg protein from cell lysates was loaded per lane. No human PrPc 
expression was observed following transduction of N8 with human PrPc.
4.4.6.2.1 Single celI cloning P8b human PrP* mixed done
Twenty-three P8b human PrP( -expressing single cell clones were isolated by limiting dilution 
subcloning o f the mixed P8b human PrP population, which expressed human PrPc to PK1 
wildtype level (figure 4.18B). Analysis o f PrPc expression by immunoblotting indicated that 
eleven clones were expressing human PrPc significantly over PK1 wildtype level (asterisked in 
figure 4.21). The highest human PrPc expressor was named P8bH2 (lane 17, figure 4.21) 
because it appeared to express human PrPc to approximately two-fold PK1 wildtype level 
(figure 4.22).
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Figure 4.21 Screening for human PrP° overexpression in P8b clones
23 P8b human PrPc-expressing single cell clones (labelled 1 -23) were isolated by limiting 
dilution subcloning of P8b human PrP mixed population. Cell lysates of clones and PK1 
wildtype were immunoblotted using anti-PrP antibody, biotinylated ICSM35. 25 pg protein from 
cell lysates was loaded per lane. Eleven clones overexpressing human PrPc clones above 
PK1 wildtype level are indicated by an asterisk (*). Compared to PK1 wildtype, the highest 
human PrPc overexpressor was clone 17, named P8bH2 (red asterisk).
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Figure 4.22 Two-fold human PrPc overexpression in P8bH2
Cell lysates of P8bH2, P8b huPrPc mixed done, P8b KO done and PK1 wildtype were 
immunoblotted using anti-PrP antibody, biotinylated ICSM35. 25 pg protein from cell lysates 
was loaded per lane. P8bH2 (lane 1) is estimated to overexpress human PrPc by >2-fold. As 
determined previously, the P8b huPrP0 mixed done (lane 2) expresses human PrP° to PK1 
wildtype level (lane 4) and the P8b KO done expresses barely detectable levels of PrPc (lane 
3).
4.4.6.2.2 Isolation o f P8b cells highly expressing human PrP( by FACS sorting 
It appeared from screening P8b human PrPc single cell clones that it would not be possible to 
get more than 2-fold wildtype expression o f human PrPc with retroviral transduction. 
Expression o f human PrPc from an additional vector with a different selectable marker was 
considered, but the antibiotic selection and subcloning involved in this technique may have 
resulted in the loss of susceptibility due to the extended time in culture. A FACS sorting 
strategy was adopted to isolate cells very highly expressing PrPc (at the cell surface) from the 
two-fold overexpressing P8bH2 clone. The P8bH2 clone underwent a further three overnight 
retroviral transductions with human PrPc viral supernatant and forty-eight hours later the 
highest overexpressors were isolated by FACS sorting (figure 4.23). 7% of P8bH2 population 
had significantly higher PrPc expression compared to PK1 wildtype expression. The relative 
prion-FITC brightness o f this FACS-isolated clone, expressed as mean fluorescent intensity 
(MFI), was 5-fold greater than that o f PK1 wild-type. Densitometric analysis o f immunoblot 
demonstrated that this FACS-sorted clone overexpressed human PrP( to four times wildtype 
level and was thus named P8bH4 (figure 4.24).
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Figure 4.23 Isolation of highly expressing human PrPc cells from P8bH2 clone by FACS 
sorting
48 hours following human PrP transduction, P8bH2 cells were stained for PrPc with ICSM35 
and FITC-conjugated anti-mouse IgG Fab and then sorted on Beckman Coulter Epics Altra 
sorter for human PrPc overexpression. PK1 cells were assayed to determine wildtype level 
PrP° expression (gate C). Gate D was set at approximately top 10% brightness of wildtype 
PK1 population to allow isolation of cells expressing greater than wild-type PrPc levels. 34.9% 
P8bH2 cells were overexpressing human PrPc (gate D). Another gate was set to isolate the 
very highest human PrPc expressors (gate E). 7% of the P8bH2 population was isolated for 
significantly higher human PrPc expression by FACS. FACS data were generated with the help 
of J. Buddie, Institute of Child Health, London
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Figure 4.24 Four-fold human PrPc overexpression in FACS-isolated P8bH2 clone: P8bH4
Cell lysates of FACS-isolated human PrP-overexpressing P8bH2 done, P8bH2, PK1 wildtype 
and P8b PrPc KO done were immunoblotted using anti-PrP antibody, biotinylated ICSM35 to 
assess PrPc levels. 25 pg protein from cell lysates was loaded per lane. FACS sorting of 
P8bH2 (lane 3) isolated a population of cells overexpressing human PrPc to four-fold PK1 
wildtype level (determined by densitometric analysis of the immunoblot; Iane4), which was 
named P8bH4.
4.4.6.3 Summary of human PrPc-expressing murine PrPc KO cells
Human PrPc was expressed in the six PKl PrPc (single and double siRNA) KO clones. Four of 
the mixed clones expressed PrPc to just over PKl wildtype level (P8a, P8b2a, P8b4a P8b4b), 
and two expressed PrPc equal to wildtype level (P8b and P8c). No N2a KO cells expressing 
human PrPc were isolated. Single cell subcloning of P8b human PrP mixed clone generated 
eleven clones overexpressing human PrPc, P8bH2 being the highest expressor that exhibited 
about 2-fold wildtype PKl PrPc expression levels. Further retroviral transduction of P8bH2 
with human PrPc and sorting o f the highest human PrPc expressing population by FACS 
isolated a 4-fold human PrPc overexpressing clone: P8bH4.
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4.4.7 Assessment of vCJD prion susceptibility of human PrP( -expressing mouse PrPc 
KO PKl cells
For these experiments, human PrPc-expressing PKl PrPc KO cells (mixed, single cell and 
FACS-isolated clones) were vCJD prion-infected, subcloned and screened for PrP^ according 
to the standard procedure outlined in section 3.4.3.4, 0.1% vCJD prion-infected brain 
homogenate was used and one 96-well plate o f sib-selection subclones was assayed. 
Corresponding PrPc KO clones, which are resistant to prion infection due to lack o f PrPc 
expression, were used as a particle monitor for the vCJD infections to identify de novo PrP80 
production in cells. The cells were assayed for the presence of PrPSt by SCA after each 
passage. As outlined in chapter 3, to determine i f  cells contained de novo PrPSc following 
vCJD prion infection, a threshold SCA value was set and calculated as follows:
threshold SCA value of vCJD prion-infected wells
> mean particle monitor SCA value + 5x standard deviations
4.4.7.1 vCJD prion susceptibility of human PrPc-expressing mixed clones of PKl PrPc 
KO clones
Of the six mixed human PrPc-expressing PKl PrPc KO clones, only two showed any 
susceptibility to vCJD prion infection but this was very low. PrP& was detected in 8% o f P8a 
huPrP wells and 3% o f P8b huPrPc wells by SCA (figure 4.25). P8b huPrPc, P8b2ahuPrPc, 
P8b4a huPrPc and P8b4b huPrPc were all resistant to vCJD prion infection since no positive 
wells were detected. Levels o f PrPc did not correlate with susceptibility; P8c huPrPc expressed 
wildtype levels o f human PrPc but was more susceptible than the overexpressing P8b2a 
huPrP0, P8b4a huPrPc and P8b4b huPrPc.
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Figure 4.25 vCJD prion infection of mixed human PrPc expressing PK1 PrPc KO clones
Mixed human PrPc, clones were infected with 0.1% vCJD prion-infected brain homogenate 
(12811) and the standard infection, subcloning and PrP30 assay procedures were followed. 
vCJD prion infection of the mixed human PrPc clones cells was evident if SCA values per well 
(PrP^-positive spots) were above a certain threshold value, calculated as “mean SCA value 
for vCJD prion-infected particle monitor plus 5x standard deviations". SCA data from three 
experiments at 2nd 1:8 passage (when particle monitor indicated the inoculum was cleared) are 
presented as mean percentage wells (+ SEM) above this threshold SCA value. (24 wells of 
each PK1 KO clone and 96 wells huPrPc mixed clones were assayed per experiment). De 
novo PrP80 was detected in a low proportion of P8a huPrPc and P8c huPrPc wells, 8% and 
3%, respectively. No PrPSc was detected in the other mixed clones, P8b huPrPc, P8b2a 
huPrP0, P8b4a huPrPc, P8b4b huPrPc.
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4.4.7.2 vCJD prion susceptibility of human PrPc over-expressing P8b single cell clones
Eleven P8b clones over-expressing human PrP1 (asterisked in figure 4.21) were investigated 
for susceptibility to vCJD prions as described for the human PrPc-expressing mixed clones 
above. Low susceptibility to vCJD prion infection was observed in two clones, P8b clone 4 
and P8b clone 20, for which de novo PrP5* was detected in 3% and 14% of wells, respectively, 
by SCA (figure 4.26). P8bH2 (originally clone 17) was, which overexpresses human PrPc 
two-fold, was most susceptible to vCJD prion infection (with two different inocula). At second 
passage, de novo PrP5* was detected in 70% wells following infection with 12811 vCJD 
inoculum, and 60% wells following infection with 13139 vCJD inoculum (figure 4.26 and 
4.27). However, only very transient prion propagation was observed in P8bH2 following 
infection with these vCJD inocula, since PrP5*  was present for just one passage after the 
inoculum was cleared. P8bH2 was not susceptible to a third vCJD prion inoculum, 14618 
(figure 4.27).
4.4.13 vCJD prion susceptibility of FACS-isolated human PrPc-overexpressing clone - 
P8bH4
It was hypothesised that to achieve more persistent vCJD prion propagation in P8bH2, which 
overexpressed human PrPc two-fold, higher PrPc expression was required. A four-fold human 
PrPc overexpressing clone was isolated from P8bH2 by FACS sorting, P8bH4 (see figure 
4.24). The vCJD prion susceptibility o f P8bH4 was assessed, as described above. PrP5* was 
detected in 6% of P8bH4 wells compared to 42% o f P8bH2 wells, showing that FACS sorting 
to increase the PrPc expression actually reduced susceptibility to vCJD prion infection 7-fold 
(figure 4.28). A number o f reasons may explain this reduction in vCJD prion susceptibility. 
First the combined human PrPc retroviral transductions and FACS procedure was stressful for 
the cells because at the time o f the FACS sort, only 22% P8bH2 were viable compared to 55% 
o f PKl controls. It is known that i f  PKl cells are not kept in optimal conditions, they lose their 
susceptibility RML prions (Dr P. Klohn, personal communication). Second, by selecting for 
high human PrPc expression, currently unknown prion susceptibility factors may have been 
lost.
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Figure 4.26 vCJD prion infection of human PrPc-overexpressing P8b clones
Human PrPc-overexpressing P8b clones (4, 17, 20) were infected with with 0.1% vCJD prion- 
infected brain homogenate (12811) and the standard infection, subcloning and PrP80 assay 
procedures were followed. vCJD prion infection of the human PrPc-expressing P8b clones 
was evident if SCA values per well (PrP80 -positive spots) were above a certain threshold 
value, calculated as “mean SCA value for vCJD prion-infected particle monitor plus 5x 
standard deviations”. Data from three experiments at 2nd 1:8 passage (when particle monitor 
indicated inoculum was cleared) are presented as mean percentage wells (+ SEM) above this 
threshold SCA value. (24 wells of each PK1 KO clone and 96 wells huPrPc P8b clones were 
assayed per experiment). P8bH clone 4, and 20 showed only low susceptibility to vCJD prion 
infection, with the presence of de novo PrP8c detected in 3% and 14% wells, respectively. 
P8bH2 (originally done 17) appeared highly susceptible to vCJD prions at this passage 
number with de novo PrP80 being detected in 70% wells.
158
Chapter 4 vCJD susceptibility of humanised mouse prion-susceptible cells
80n
12811
o 6 0 -
13139
4 0 -
14618
20 -
1 2 3 4
passage number
Figure 4.27 Prion infection of P8bH2 with 3 different vCJD inocula
P8bH2 was exposed to three different vCJD prion inocula, 12811, 13139 and 14618 at 0.1% 
dilution and the standard infection, subcloning and PrP80 assay procedures were followed. 
vCJD prion infection in P8bH2 was determined if SCA values per well (PrP^-positive spots) 
were above a certain threshold value, calculated as “mean SCA value for vCJD prion-infected 
particle monitor plus 5x standard deviations”. Data from one experiment are presented as 
mean percentage of P8bH2 wells (+ SEM) above this threshold SCA value over 4 passages. 
12811 vCJD inoculum has the lowest PrP80 titre because the particle monitor cleared earlier (at 
the 2nd passage) than the other inocula (at 3rd passage). There is no de novo PrP80 production 
in P8bH2 at first passage following vCJD infection. De novo PrP80 accumulates in P8bH2 up to 
the second passage, following infection with 12811 and 14618, and up to the 3rd passage, 
following infection with 13139. The longer prion infection observed in 13139-infected cells 
compared to 12811-infected cells is probably be due to prion conversion induced by PrP8c from 
the residual inoculum in the 13139 cultures instead of genuine de novo prion propagation. 
Prion conversion as a result of contact with PrP80 in the residual inoculum is probably also 
responsible for the accumulation of vCJD prions in cells infected with 14618 between passage 
1 and 2. P8bH2 is most susceptible to 12811 at 2nd passage, when PrP8c is present in 70% 
wells, compared to about 40% for 13139 and 14618. In summary, in response to infection by 2 
of the 3 vCJD inocula (12811 and 13139) there is transient prion propagation for one passage 
after the inocula are cleared from the cultures.
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4.4.7.4 Summary of vCJD prion susceptibility of human PrPc expressing PrPc KO 
PKl clones
Of the mixed clones, P8a huPrPc, which slightly overexpressed human PrPc was most 
susceptible to human vCJD prions. However, only a small proportion of the population (8%) 
was infected with de novo PrPSc for one passage. P8c huPrP( mixed clone (with wildtype 
human PrPc expression) showed very low susceptibility to vCJD prion infection with 3% of 
the population prion-infected for one passage. P8bH2, which overexpressed human PrPc two­
fold, was the most susceptible o f all the human PrP1-expressing clones. It was susceptible to 
vCJD prions from two different inocula with PrPSc detected in 60-70% of the population. 
However, prion propagation in P8bH2 was transient, lasting for just one passage after the 
inoculum was cleared. Further PrPc overexpression in P8bH2, to approximately four-fold 
wildtype levels (P8bH4), reduced its susceptibility to vCJD prion infection. Low levels of 
vCJD susceptibility observed in human PrPc-expressing KO clones may have been due to the 
increasing murine PrPc levels as indicated by qRT-PCR data (figure 4.29).
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Figure 4.28 vCJD prion susceptibility of human PrP°-overexpressing P8bH4 clone 
isolated by FACS
P8bH4 clone overexpresses human PrPc four-fold and was isolated by FACS from P8bH2, 
which overexpresses human PrPc two-fold. Both P8bH2 and P8bH4, were infected with 0.1% 
vCJD prion-infected brain homogenate (12811) and the standard infection, subcloning and 
PrPSc assay procedures were followed. vCJD prion infection of cells was determined if SCA 
values per well (PrP^-positive spots) were above a certain threshold value, calculated as 
“mean SCA value for vCJD prion-infected particle monitor plus 5x standard deviations”. SCA 
data from 2nd 1:8 passage (when particle monitor indicated the inoculum was cleared) are 
presented as mean percentage wells (+ SEM) above this threshold SCA value. (24 wells of 
P8b KO clone and 96 wells of P8bH4 and P8bH2 were assayed). The P8bH4 clone was 7-fold 
less susceptible to vCJD prion infection than its parent population, P8bH2 since PrP80 was 
detected in 6% wells by SCA compared to 42% wells for P8bH2. Thus, further overexpression 
of human PrPc in P8bH2 clone did not improve susceptibility to vCJD prion infection.
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Figure 4.29 Quantitation of murine Pmp mRNA levels in human PrPc-overexpressing 
P8b clones compared to KO clone by qRT-PCR
Relative Pmp gene expression was determined for human PrP°-overexpressing P8b clones, 
P8bH2 and P8bH4, compared to wildtype PK1 cells and P8b KO clone by the comparative 
threshold method (described in 2.5.7.4), using GAPDH to normalise the data. Validation 
experiments were performed to determine that GAPDH and Pmp probe amplification 
efficiencies were equal because the slope of log input amount vs A C t plot was 0.12. Data are 
presented as relative Pmp mRNA levels and represent means of triplicate samples (+ SEM). 
2-tailed f-tests were performed to determine if there was a difference in Pmp expression in 
human PrPc-expressing clones compared to the control P8b KO clone. Pmp mRNA levels in 
the human PrPc-expressing clones, P8bH2 and P8bH4, had significantly (*P<0.05) increased 
by 7-fold compared to the P8b KO. J.Podesta performed the experiments and I performed the 
data analysis.
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4.4.7.S Screening human PrP( expressing clones for susceptibility to vCJD prion 
infection without selecting for high human PrP( expression levels
The data presented above suggested there was some degree of vCJD prion susceptibility in the 
human PrPc-expressing KO clones. However, it was found that excessive selection for high 
PrPc expression in clones, such as by FACS, lead to loss o f susceptibility. This supports the 
idea that PrPc expression is not the sole basis o f susceptibility to prion infection. In order to 
screen for clones on the basis prion susceptibility factors and not human PrP( expression 
levels, a large-scale screen of single cell clones o f freshly transduced human PrPc expressing 
KO cells was undertaken. The cells underwent antibiotic selection for human PrPc expression 
but expression levels were not initially determined. For this strategy, the best PrPc KO clones 
were studied (P8b2a, P8b4a, P8b4b) because it was thought that any endogenous mouse PrPc 
would seriously inhibit prion replication. The P8b PrPc KO clone was also studied because it 
had shown the best vCJD prion susceptibility in prior experiments, in the form of P8bH2. As 
described in section 2.4.6, cells were transduced with human PrPc and then clones picked from 
single colonies. Some mixed clones were kept aside to check human PrPc expression. The 
single clones were grown to confluency in 96-well plates and split to two replica plates. One 
plate was infected with vCJD prions and the other was stored at -80°C, to be thawed when a 
positive clone was identified. Prion-infected plates underwent three 1:8 passages to clear the 
inoculum and were then assayed for the presence o f PrP80 by SCA. Results are summarised in 
table 4.2. The human PrPc-expressing P8b4a and P8b4b subclones (300 o f each) were not at 
all susceptible to vCJD prions demonstrating that improved PrPc knockdown did not increase 
susceptibility. Human PrPc-expressing P8b and P8b2a subclones (referred to as P8bH and 
P8b2aH) appeared more susceptible to vCJD prion infection with 12% and 10%, respectively, 
o f clones containing PrP80 (figure 4.30). However, the level of PrP80 accumulation in the 
clones indicated by the SCA values was very low; 39 being the highest SCA value for one 
P8b2aH subclone. This method detected lower susceptibility of human PrPc-expressing P8b to 
vCJD prions than studying clones isolated on the basis o f high PrPc expression levels. This 
could have been because the human PrPc expression levels o f the freshly transduced clones 
were too low; mixed clones were lower than wildtype. It was apparent in the murine PrPc 
reconstitution experiments expression needed to be wildtype or above to regain susceptibility 
to RML prions.
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Table 4.2 Summary of vCJD prion susceptibility of freshly picked human PrP - 
expressing PrPc KO PK1 clones
PrPc KO clones P8b (brown panel), P8b2a (purple panel), P8b4a (pink panel), P8b4b (red 
panel) were retrovirally transduced with human PRNP ORF. G418-resistant single colonies 
were picked and transferred to 96-well plates and split to two sister plates when confluent. One 
plate was stored at -80°C, the other infected with 0.1% vCJD inoculum. The appropriate PrPc 
KO clone was infected in parallel as a particle monitor. SCA was performed after the 3rd, 4th 
and 5th passage for the presence of de novo PrP80. vCJD prion susceptibility data are 
expressed as mean percentage human PrPc-expressing clones above threshold SCA value 
(calculated as “mean SCA value for vCJD prion-infected particle monitor plus 5x standard 
deviations”). (-) indicates SCA was not performed. The human PrPc expression level of mixed 
clones is shown in 2nd column and the number of clones screened in the 3rd column. There 
was essentially negligible susceptibility to vCJD prion infection. Any indication that there was 
vCJD prion susceptibility, for example in P8bH subclone plate I and in P8b2aH subclone plate 
l-IV, was due to the fact that the threshold level was very low because the particle monitor was 
virtually zero. The highest SCA value observed was 39.
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Figure 4.30 vCJD prion susceptibility of freshly picked human PrPc-expressing PrP° KO 
PK1 clones
Freshly picked human PrPc-expressing single cell clones from KO clones, P8b, P8b2a, P8b4a 
and P8b4b were infected with 0.1% dilution of vCJD prion-infected brain homogenate (12811) 
without analysis for PrPc expression levels. The appropriate PrP° KO clone was infected in 
parallel as a particle monitor. These clones were assayed for the presence of PrPSc by SCA 
after three 1:8 passages (to dear the inoculum). SCA data after the 3rd 1:8 passage are 
presented as mean percentage wells above SCA threshold value (those with PrP80 SCA value 
greater than mean vCJD prion-infected particle monitor plus 5 standard deviations) indicating 
which wells are prion-infected. The P8bH and P8b2aH subclones were most susceptible to 
vCJD prion infection but at a relatively low level, with with PrPSc detected in 12 and 10% wells, 
respectively. P8b4aH and P8b4bH were not at all susceptible to vCJD prion infection.
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4.5 Discussion
4.5.1 Knockdown of PrPc expression by RNAi
It has been proposed that even with novel in silica tools to aid selection of effective siRNAs 
(discussed in section 4.4.1.2), only one third o f siRNAs can suppress their target gene 
expression by greater than 80% (Cullen, 2006). Therefore, in this project the efficiency o f the 
Prnp-sipedfic siRNAs designed (with both empirical and rational rules) was better than 
expected because half the /Vw/?-specific siRNAs, which targeted the 3'UTR o f Prnp, 
effectively knocked down murine PrPc expression in N2a and PKl cells by greater than 80%. 
The maximum PrPc knockdown achieved was estimated to be between 95-99% in PKl clones 
expressing double siRNA constructs and 90% in PKl and N2a clones expressing a single 
siRNA construct. The reduction in PrPc protein levels observed in these clones was 
accompanied by a similar reduction in Prnp mRNA levels, confirming that the reduction in 
PrPc protein expression was due to siRNA-mediated mRNA degradation and not inhibition of 
protein synthesis.
The level o f murine PrPc knockdown achieved here is equivalent to levels recently reported in 
the literature for cell lines. In two studies involving chronically prion-infected N2a cells, in 
which the siRNAs targeted different sequences of the Prnp coding region, endogenous PrPc 
expression was suppressed by 97% using lentiviral-delivered shRNA (Pfeifer et al., 2006), and 
by approximately 95% using transiently transfected siRNA duplexes (Daude et al., 2003). In 
both cases depletion o f PrPc in these cells abrogated PrP& accumulation. The lentiviral- 
delivered anti-PrP shRNA was also expressed in chimeric mice from embryonic stages and 
was found to prolong the life-span o f RML-prion infected mice. In another study, 96% 
reduction in expression o f murine PrPc in rabbit epithelial kidney cells was achieved by stable 
plasmid-based expression o f shRNA targeting the coding region o f Prnp (Tilly et al., 2003).
The level o f Prnp knockdown achieved in the N2a-derived lines did not meet the original aim 
o f completely knocking-out murine PrPc expression. Complete Prnp knockout (KO) was 
required because murine PrPc is proposed to inhibit human prion formation in human 
transgenic mice by a dominant negative inhibition, whereby non-homologous host murine PrPc 
inhibits conversion of human PrPc to PrP^ (Telling et al., 1995;Col!inge et al., 1995;Perrier et 
al., 2002). As already outlined, complete Prnp KO in cell lines by RNAi has not been achieved 
by any groups, and there are several reasons which may explain why this is such a challenging 
task. First, N2a cells possess 5-7 copies o f the Prnp gene (Dr Solstadt, personal 
communication). RNAi may not be the ideal technique to completely knockout Prnp
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expression in N2a cells due to the potential abundance of target Prnp mRNA. Either the 
expression level o f /V/7/?-specific siRNA may be insufficient to target the degradation o f the 
large quantity of Prnp mRNA or the capacity o f the cellular RNAi machinery may be 
inadequate.
Second, complete Prnp knockout may be lethal to cells because PrP( has been proposed to 
play a role in cell survival (Chiarini et al., 2002;Zanata et al., 2002;Chen et al., 2003;Lopes et 
al., 2005;Zhang et al., 2006). For example, decreasing endogenous PrPc expression in human 
neurones with antisense PrP cDNA renders them more susceptible to Bax-mediated cell death, 
whilst co-expression of PrPc with Bax prevents cell death (Bounhar et al., 2001). In addition, 
PrP-deficient primary cerebellar and cortical neurones are more susceptible to oxidative stress 
in vitro (Brown et al., 1997). PrPc is proposed to exert its neuroprotective effect by interaction 
with apoptotic pathways to prevent permeability o f the mitochondrial membrane (Roucou and 
LeBlanc, 2005). Therefore, the lower viability observed in the N2a and PKl double siRNA 
Prnp KO clones with both siRNA#5 and siRNA#8 may be due to the fact that this combination 
o f siRNAs resulted in complete PrPc KO. However, in general the proliferation rate o f the 
Prnp KO clones compared to vector-only clones was similar. In accordance with this 
observation, Prnp KO in mice is not lethal and they show no overt phenotype (Bueler et al., 
1992). Moreover, neither does depletion of neuronal PrPc in Prnp conditional KO mice (with 
the Cre-lox system) produce an overtly deleterious phenotype in adulthood (Mallucci et al., 
2002).
Third, siRNA-induced knockdown o f gene expression may not be stable, therefore it may not 
be possible to sustain 100% PrPc knockdown even i f  it were achieved. The RNAi technique is 
relatively new so the duration o f gene suppression by shRNA has not been well documented. 
In order to attain stable Prnp knockdown in our experiments, a polymerase 111 HI promoter 
driven retroviral expression vector was used to deliver shRNA to the cells. With this system, 
the shRNA integrates into the host cell genome and produces persistent knockdown compared 
to chemically synthesised siRNAs, which are delivered directly to the cytoplasm and only 
provide transient knockdown (Jia et al., 2006). This retroviral-based shRNA delivery system 
also overcomes the problem o f knocking down expression of proteins with long half-lives 
because siRNA is persistently transcribed to degrade target mRNA; fortunately the half-life of 
PrPc is short at five hour (Daude et al., 2003). To further ensure stable Prnp shRNA 
expression, cells were constantly maintained in selection antibiotics. However, despite taking 
these steps the qRT-PCR data on the human PrP( -expressing Prnp KO clones (figure 4.29) 
suggested Prnp mRNA levels had slightly increased after the Prnp KO clones had been in 
culture for three months. Stability o f Prnp knockdown observed here is consistent with 
duration o f stable knockdown reported in the literature; shRNA-induced GFP knockdown by a
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U6-driven lentiviral vector is stable for three months in vitro (Makinen et al., 2006)
4.5.2 Reconstitution of murine PrP( restores susceptibility to RML prions
Reconstitution o f murine PrPc to wildtype expression levels restored susceptibility o f Prnp KO 
PKl clones to RML prion infection confirming that PrPc is crucial for prion infection (Bueler 
et al., 1993;Fischer et al., 1996). However, susceptibility to RML prions was fully restored to 
PKl wildtype levels only in two clones (P8a and P8b), despite all clones having similar PrPc 
expression levels (all were overexpressing except P8a, which expressed to wildtype level). 
This finding that the level o f PrPc expression is not related to susceptibility to prion infection 
corroborates previous work (Montrasio et al., 2001;Enari et al., 2001) and confirms that 
additional factors contribute to cellular prion susceptibility (discussed below). Since it was 
expression of the ORF o f the murine Prnp gene that restored susceptibility to RML prions, the 
non-coding sequences o f the Prnp gene do not seem critical determinants o f prion 
susceptibility. This may be a prion strain-specific observation since in a genetic study o f the 
PRNP locus, one polymorphism identified upstream of exon 1 was associated with 
susceptibility to sCJD (Mead et al., 2001;Vollmert et al., 2006). The identification of genetic 
susceptibility factors to human prion disease, outside of the PRNP locus, has been seriously 
hampered by small sample sizes, due to the rarity o f prion disease and the lack o f technology 
for a true genome-wide study (although this technology has recently become available). A 
putative association of vCJD and the HLA-DQB7 serogroup (Jackson et al., 2001) has not 
been replicated in a larger study (Pepys et al., 2003).
The murine PrPc reconstitution study presented here was a crucial proof-of-principle 
experiment, which suggested that the ectopic expression o f the PrP ORF in Prnp KO PKl cells 
may confer susceptibility to prions. Thus, in much the same way as for PrP KO mice 
(Weissmann and Flechsig, 2003), expression o f different species o f PrP ORF in Prnp KO PKl 
cells may provide a permissive cell system for the propagation different prion strains, such as 
sCJD, inherited CJD, BSE and hamster prions. These PrP ORF reconstitution experiments in 
Prnp KO PKl cells are currently being pursued in the department and would provide a much 
more rapid way of studying prion propagation. Overexpression o f a truncated murine PrP 
construct (residues 89-231) in Prnp KO PKl cells has been shown to restore their 
susceptibility to RML mouse prions (Jat, unpublished data), supporting similar work in PrP 
KO mice implying that the N-terminus o f PrP( is not critical for prion propagation (Shmerling 
et al., 1998;Flechsig et al., 2000).
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4.5.3 Human PrPc expression does not render Prnp KO cells susceptible to vCJD 
prions
To eliminate the transmission barrier for vCJD prion propagation in PKl Pmp KO cells, 
human PRNP (129 MM) ORF was ectopically expressed in Pmp KO clones so that donor and 
recipient PrP sequence were identical. A high degree of sequence homology between the 
infecting PrPSc and resident host PrPc is often, but not always, crucial for efficient prion 
replication (Prusiner et al., 1990;Priola and Chesebro, 1995). A single siRNA Prnp KO clone 
overexpressing human PrPc to twice wildtype level (P8bH2) was isolated. FACS sorting of 
this clone resulted in the isolation o f a four-fold overexpressing human PrPc clone (P8bH4). 
Indeed, this approach in transgenic mice, in which the human PRNP 129 MM transgene is 
overexpressed to 2 and 4-fold wildtype level on a murine Pmp KO background, has 
successfully generated mice that are susceptible to vCJD prions (Tg35 and Tg45 strains; 
(Asante et al., 2002). 100% o f these mice become infected with vCJD prions, indicated by the 
detection o f type 4 PrP^ distributed as florid plaques in the brain. However, they do not 
exhibit clinical signs o f prion disease in their normal lifespan (Asante et al., 2002); a recently 
recognised phenomenon referred to as subclinical infection which may result from the lack of 
PrPL (the lethal intermediate o f PrP; (Hill et al., 2000). In this chapter, the two-fold human 
PrPc overexpressing line (P8bH2) proved the most susceptible to vCJD prion infection with 
two different inocula. There appeared to be short-term de novo production of vCJD prions for 
one passage. Four-fold overexpression of human PrPc in this clone did not enhance 
susceptibility to vCJD prions; instead it reduced susceptibility. The double siRNA Pmp KO 
clones overexpressing human PrPc were not susceptible to vCJD prion infection. In summary, 
the strategy of generating a human transgenic N2a-derived cell line, by knocking out 
endogenous murine PrPc and ectopically expressing human PrPc, failed to produce a 
susceptible cell line that stably propagated vCJD prions. There are a number o f reasons why 
this might have occurred.
First, the fact that PKl Pmp KO cells do not propagate human prions once the transmission 
barrier has been eliminated raises important issues with regard to cellular susceptibility factors 
and prion strains. The data presented here support several lines o f evidence (including the fact 
that full length PrP1 alone has been refractory to infectious prion conversion in cell-free 
reactions), which strongly suggest PrPc is insufficient to allow prion replication and that other 
factors may be involved. It was Stanley Prusiner who first conjectured the existence o f a 
molecular chaperone for prion conversion and named it protein X (Telling et al., 1995). Its 
identity is still unknown but a number o f candidate molecules have since been proposed. 
Recently polyanionic polymers, such as nucleic acids and sulphated glycosaminoglycans, have 
gained favour. Host-derived small RNA molecules have been shown to stimulate PrPSc
169
Chapter 4 vCJD susceptibility of humanised mouse prion-susceptible cells
formation in vitro and RNAase enzymes abolish this effect (Deleault et al., 2003). This finding 
supports Weissmann’s “ unified prion theory” (Weissmann, 1991), which represents an 
alternative to the “protein-only hypothesis” and postulates a small host-encoded nucleic acid, 
named a co-prion, is associated with PrP^. Sulphated glycosaminoglycans (GAGs), 
particularly those involving heparan sulphate (HSPG), can also stimulate in vitro prion 
conversion (Wong et al., 2001) and have been implicated in PrP^ biosynthesis and PrP,Sc 
uptake in cell lines (Ben Zaken et al., 2003;Hijazi et al., 2005;Horonchik et al., 2005). The 
demonstration that the LDL-related receptor protein (LRP1) internalises scrapie-associated 
fibrils and is also a key interactive partner for PrPc endocytic trafficking (Taylor and Hooper, 
2006) has led to the suggestion that this transmembrane receptor may be the scaffold that 
brings both PrP1 and PrPSc together for conversion on neurons (C.Parkyn, Kings College 
London, personal communication). Due to the different sites identified for interacting 
molecules on PrPc, it has been hypothesised that multi-component protein complexes may be 
involved in PrPc conversion (Caughey and Baron, 2006). One such complex may include the 
37 kDa/67 kDa laminin receptor and its precursor (LRP/LR), which can both bind PrPc and 
take part in PrP& formation in scrapie-infected lines (Morel et al., 2005;Vana and Weiss, 
2006). This complex may also include the above-mentioned HSPG, which can bind LRP/LR 
(Hundt et al., 2001) and copper, which participates in HSPG binding to PrPc (Gonzalez- 
Iglesias et al., 2002) and hence may bring PrPc and PrPSc together to mediate prion conversion. 
However, definitive evidence for this is still lacking. Therefore, it may be that these Prnp KO 
cells may, for some reason, lack critical factors for human prion conversion. However, because 
the PKl cell line is a highly murine prion-susceptible line, permissive to RML (Klohn et al., 
2003a) and 22L mouse prions (Professor C.Weissmann, unpublished data), one may assume 
that they do, in fact, possess the critical conversion factors for mouse prion propagation, but 
not human prion conversion.
Therefore, the second reason that the human PrPc-expressing Prnp KO cells may be resistant 
to human prion propagation is that these conversion factors were “ knocked out” in the Prnp 
KO clones due to off-target effects o f /V/7/?-specific siRNA. Off-target effects are a commonly 
reported problem with the RNAi technique. These occur when the siRNA targets unrelated 
genes with only partial sequence complementarity. The technologies available for the selection 
o f effective siRNA attempt to minimise off-target effects, for example by performing a Blast- 
search on the sequence, but these steps still do not completely eliminate off-target effects (Pei 
and Tuschl, 2006). Since off-target effects are more likely with two siRNA molecules, this 
may explain why the double siRNA Prnp KO clones were more resistant than single siRNA 
Prnp KO clones to both RML and vCJD prions; the conversion factors are more likely to have 
been silenced. However, this is doubtful because susceptibility is mostly restored by murine 
PrP ORF reconstitution whilst the siRNA knockout system is operating.
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Third, these prion conversion factors may be prion strain-specific. At the start o f this project it 
was initially hypothesised that N2a and PKl cells possess “prion-propagating cellular 
machinery” and that human PrP( would be able to hijack this machinery for the formation of 
vCJD prions. However, human PrPc may not bind murine prion conversion factors with 
sufficient affinity to achieve efficient human PrPv  formation; particularly because human PrPc 
differs from murine PrPc at the putative protein X binding site at the C-terminus by five amino 
acids (Telling et al., 1995). Therefore, the affinity of PrP( for protein X, or cofactors for prion 
conversion, may also underlie the prion transmission barrier. However, because human prions 
can be efficiently propagated in human transgenic mice {Prnp-/-, PRNP 129 MM +/+), this is 
unlikely to account for the absence o f stable vCJD prion propagation observed in these cells.
Fourth, the fact this strategy {Prnp KO and human PrP 129 MM expression) allows vCJD 
prion propagation in human transgenic mice but not cells, strongly suggests that one o f the 
principal reasons for the inability o f PKl cells to propagate vCJD prions is the nature o f the 
cell system. The dynamic susceptibility model (outlined in chapter 3) would predict that these 
PKl Prnp KO cells are resistant to prion infection simply because the degradation rate of PrPSc 
exceeds the formation rate (Weissmann, 2004). It may be that vCJD prions are more sensitive 
than RML prions to murine proteases, which would speed up vCJD prion degradation. Indeed, 
different prion strains have distinct susceptibility to proteinase K digestion (Kuczius et al., 
1998). Alternatively. vCJD prion synthesis may be slower because conversion is less efficient 
with murine cell factors, as mentioned above. These two possibilities are not mutually 
exclusive.
Fifth, the importance of eliminating murine PrPc expression to prevent dominant negative 
inhibition o f human prion propagation has already been highlighted. However, the maximal 
murine PrPc KO achieved in the cells screened for susceptibility to vCJD prions was between 
90-99%, meaning there was between 1-10% murine PrPc remaining. There is also suggestion 
from the qRT-PCR data presented here that murine PrPc expression may have increased to 
more than this level in the human PrP*"-expressing KO clones. Thus, this residual murine PrPc 
may well have been sufficient to inhibit vCJD prion propagation and seems like another very 
likely reason for the lack o f vCJD prion susceptibility observed; particularly because in 
transgenic mice even 5-10% expression o f endogenous murine PrPc compared to human PrPc 
(V I29) expression can inhibit human PrPkSc formation (sCJD) (Telling et al., 1995).
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Chapter 5
Development of a vCJD prion-propagating cell 
line from a human foetal neural stem cell line
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5.1 Introduction
Stem cells, by definition, possess twin properties; the capacity for extended self-renewal in an 
undifferentiated state and the capacity to differentiate into specialised cell types, a property 
known as potency. Embryonic stem (ES) cells, which are derived from the inner cell mass of a 
blastocyst stage embryo (4-5 days old in humans), are pluripotent. They can develop into any 
cell type generated from the three primary embryonic germ layers (ectoderm, mesoderm and 
endoderm); that is, any cell in the body except the placenta. As ES cells develop they become 
more restricted in their potential, generating only a defined set o f cell types. Neural stem cells 
(NSC) are multipotent primary progenitors, found in the embryonic, foetal and adult 
mammalian brain, which give rise solely to cells o f neural lineage: neurones, astrocytes and 
oligodendrocytes (Davis and Temple, 1994;Gritti et al., 1996;Weiss et al., 1996;Vescovi et al„ 
1999;Johansson et al., 1999;Nunes et al., 2003). It is possible to propagate NSC ex vivo and 
this has proved critical in improving the understanding of mechanisms controlling 
developmental decisions in NSC (reviewed in McKay, 1997;Gage, 2000;Nunes et al., 
2003;Galli et al., 2003), the development o f cell replacement therapies for neurological 
diseases (Lindvall et al., 2004) and the development o f disease models (De Filippis et al., 
2006). NSC lines are a versatile in vitro model system. Using chemically defined media 
containing mitogens, they can be cultured as undifferentiated self-renewing stem cells, either 
as an adherent monolayer or as neurospheres (non-adherent spherical aggregates o f neural 
precursor cells; (Uchida et al., 2000). Alternatively, reflecting their stem cell nature, they can 
be differentiated into a mixture o f neurones and glia by mitogen withdrawal or exposure to 
extrinsic factors. Factors for directed differentiation towards a specific neural cell lineage have 
also been established, for example, ciliary neurotrophic factor (CNTF) induces astrocyte 
differentiation of NSC (Weiss et al., 1996;Johe et al., 1996;van der and Weiss, 2000).
This chapter details the investigation o f the 197 human foetal neural stem cell line (ReNcell 
197VM; ReNeuron Ltd., UK) for susceptibility to human vCJD prion infection. These human 
NSC terminally differentiate into cells resembling primary neurones and glia. Therefore it was 
hypothesised they may be permissive to vCJD prions because they recapitulate the human 
brain much better than any CNS tumour cell line, potentially providing the necessary factors 
for prion propagation. Furthermore, chronic propagation o f several mouse prion strains has 
recently been reported in CNS stem cell-derived cultures, including differentiated mouse foetal 
and adult NSC (Milhavet et al., 2006) and mouse embryonic neurospheres (Giri et al., 2006).
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5.2 Aims of this study
• To determine the suitability o f the ReNcell 197VM human foetal neural stem cell 
line (referred to throughout as 197 cells) for infection with vCJD prions by 
characterising PRNP codon 129 genotype and PrP1 expression levels.
• To optimise conditions for the vCJD prion infection o f 197 cells in both their 
undifferentiated and differentiated states.
• To investigate the susceptibility o f the 197 cell line to vCJD prion infection in both 
undifferentiated and differentiated states.
5.3 Methods
197 NSC and PrPt -null mouse embryonic neurospheres were cultured and differentiated as 
described in 2.2.4 and 2.2.5, respectively. The PRNP genotype of the 197 cell line was 
determined using DNA sequence analysis (23.7) and PrPc expression levels were assessed by 
immunoblotting (2.6.2), Undifferentiated 197 cells were infected with vCJD prions using the 
standard infection procedure (2.7.2), whilst differentiating 197 cells were infected with semi­
purified vCJD brain homogenate, as described in section 2.73. The presence o f PrP& in cells 
was detected using either the SCA (2.7.S.2) or immunoblotting o f PK-digested material 
(2.6.2),
5.4 Results
5.4.1 197 characterisation
197 cells are immortalised human foetal neural stem cell line derived from the ventral 
mesencephalon of an electively aborted 10-week human foetus (ReNeuron Ltd., UK; detailed 
in Hoffrogge et al., 2006). They were immortalised by overexpression of the v-myc oncogene 
and are karyotypically stable for more than forty-five passages (Dr. E.Miljan, ReNeuron Ltd., 
unpublished data). As proliferating 197 multipotent undifferentiated cells they appear 
morphologically as small polygonal cells with few processes (figure 5.1A). They were 
identified phenotypically as neural stem cells by positive staining for nestin (figure 5.1 C), a 
member of the intermediate filament family present in undifferentiated cells o f neuroepithelial 
origin (Lendahl et al., 1990). 197 NSC were reliably differentiated by removal o f two growth 
factors; epidermal growth factor (EOF) and basic fibroblast growth factor (bFGF). Upon 
differentiation, cells adopted a predominantly neuronal phenotype; with shrunken cell bodies 
and extended neuritic processes, that lead to the formation o f a complex dendritic lattice by 
day 14 (figure 5.1 B and D). By immunofluorescence, the cultures were determined to 
comprise 80-90% (3111-tubulin-positive neurones (of which 10% were dopaminergic), with the 
remainder being predominantly astroglial (Dr. E.Miljan, ReNeuron Ltd.). Following 7-14 days
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o f differentiation, cells displayed a neuronal physiology with 25% of cells exhibiting voltage- 
gated sodium currents (figure 5.2) and firing action potentials (Dr R.Donato, in press BMC 
Neuroscience). Transmission electron microscopy indicated that differentiated 197 cells form 
synapses in vitro, with evidence o f axonal transport o f synaptic vesicles (Dr A.Wood- 
Kaczmar, unpublished data; figure 53).
5.4.2 Determining suitability of 197 cell line for vCJD prion infection
Since PrPc is absolutely required for prion infection (Bueler et al., 1993), the 197 cell line was 
also analysed for PrPc expression by immunoblotting, which showed substantial PrPc 
expression in the 197 cell line that appeared to marginally increase following differentiation 
(figure 5.4). DNA sequence analysis of the PRNP locus demonstrated that the 197 NSC line 
was methionine homozygous at PRNP codon 129; this is the most susceptible genotype for 
vCJD in vivo (Collinge, 2005).
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Figure 5.1 Morphology and phenotype of undifferentiated and differentiated 197 cells
(A) By light microscopy, undifferentiated 197 cells displayed paving stone morphology and (C) 
by immunofluorescence stained positive for the CNS stem cell marker nestin (blue). Rare 
spontaneous differentiation of NSC into GFAP-positive astrocytes (red) appeared in the 
undifferentiated population. (B) 197 NSC were differentiated by removal of growth factors 
(EGF and bFGF) from the culture medium. After 14 days, cells had adopted a neuronal 
phenotype, in which neuritic processes extended from the rounded, shrunken cell bodies to 
form a complex dendritic lattice. (D) Immunofluorescence staining at day 14 differentiation 
showed a predominance of pill-tubulin-positive neurones (green); a small number of GFAP- 
positive astrocytes (red) were also present. Nuclei were visualised with Hoechst (blue). 
Images C and D were produced by Dr. E. Miljan, ReNeuron Ltd., UK.
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Figure 5.2 Neuronal physiology of differentiated 197 cells
(A) Incremental voltage steps of 10mV (between -20mV and +20mV) activated a fast inward 
current in 7 to 14-day differentiated 197 cells. (B) This inward current was abolished in the 
presence of a voltage-gated sodium (Na+) channel blocker (0.6 pM tetrodotoxin, TTX), 
indicating it was mediated by the type of Na+ channels that underlie the generation of action 
potentials. (C) Inward current-voltage relationship in control differentiated 197 cells with and 
without exposure to TTX. Data produced by Dr R. Donato, UCL.
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Figure 5.3 Ultrastructure of 197 neurones
Transmission electron microscopy shows (A) that 197 neurones can form synapses in vitro, as 
demonstrated by the accumulation of vesicles in the pre-synaptic terminal, parallel membranes 
and post-synaptic densities; (B) axonal transport of vesicles; (C) higher magnification cross- 
section through an axon transporting vesicles. Data produced by Dr A. Wood-Kaczmar, 
Institute of Neurology, UCL
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Figure 5.4 Endogenous PrPc expression in human foetal 197 NSC in both 
undifferentiated and differentiated states
Lysates from undifferentiated 197 cells (197 SC), differentiated (day 14) 197 cells (197 diff) 
and P8b4b were immunoblotted using anti-PrP antibody, biotinylated ICSM35. 25 pg protein 
from cell lysates was loaded. PrPc ran between -50-30 kDa in its 3 glycosylation states (di-, 
mono- and un-glycosylated). Compared to the positive control cell line, P8b4b, a mouse 
neuroblastoma cell line that highly overexpresses human PrPc (see chapter 4), 197 cells 
displayed lower, but still substantial expression of human PrPc The expression level of 
human PrPc in 197 cells was slightly higher in the differentiated state compared to the 
undifferentiated state even taking into account the fact that the differentiated lane was 
overloaded, as indicated by the non-specific biotin band.
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5.4.3 vCJD prion infection of human undifferentiated 197 cells
Undifferentiated 197 cells were initially infected according to the standard protocol (see 2.7.2) 
with 2% and 0.2% vCJD prion-infected brain homogenate for 72 hours (infection conditions 
(1) and (2), table 5.1). These cells were not able to propagate vCJD prions as determined by 
the absence of PrPSc in the SCA following bulk passaging (see low SCA values in table 5.1). 
The cells infected in this way exhibited a marked reduction in proliferation rate compared to 
uninfected cells; requiring passage every 7-10 days instead o f the usual every other day. 
Moreover, on six previous attampts, cells died shortly after vCJD prion infection. The 
cytotoxicity at infection appeared to be due to factors in the brain homogenate itself, rather 
than toxicity o f prions, because cells infected with normal human brain homogenate also 
exhibited a reduced proliferation rate. To reduce soluble toxicity by factors, such as cytokines 
and glutamate, the brain homogenate was washed in PBS (as described in section 2.7.3.2.1), 
and reduced concentrations were used (infection conditions (3)-(5), table 5.1). 
Undifferentiated 197 cells grew well under these conditions, but still did not demonstrate 
vCJD prion propagation as determined by the absence of PrPSc in the SCA. To further purify 
the vCJD inoculum, it was treated with lysis buffer in a process termed “ semi-purification” 
(described in 2.7.3.2.2) and cells were infected at 0.01% brain homogenate (infection condition 
(6), table 5.1). However, although cells remained mostly healthy under these conditions, they 
were not susceptible to vCJD prion infection. In summary, undifferentiated 197 cells were 
unequivocally unable to propagate vCJD prions.
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Infection
condition
vCJD
inoculum
preparation
vCJD inoculum 
concentration
(%)
Passage # 
(and ratio) 
post-vCJD 
infection
Mean SCA 
value 
(+ SEM)
Comments on cell 
viability
(1) crude 2 5th (1:3) 3.4 (+1.4) Significantly slowed 
cell proliferation; 
duration of experiment 
was 50 days post­
infection
(2) crude 0.2 5th (1:3) 1.9 (+5.1) Slowed proliferation; 
as above
(3) washed-
crude
0.1 4,h (1:3) 0.1 (+0.7) Normal proliferation
(4) washed-
crude
0.01 4th (1:3) 1.6 (+1.6) Normal proliferation
(5) washed-
crude
0.001 4,h (1:3) 0.0 (+0.8) Normal proliferation
(6) semi­
purified
0.1 3rd (1:4) 0.3 (+1.2) Normal proliferation; 
duration of experiment 
was 5 days post­
infection
Table 5.1 vCJD prion infection of undifferentiated 197 cells
Summary of scrapie cell assay (SCA) data for vCJD prion infection of undifferentiated 197 
cells. “Crude” indicates the brain homogenate* was prepared in PBS (see 2.7.1), “washed- 
crude” represents a rinse in PBS (see 2.7.3.2.1) and “semi-purified" involved a detergent 
incubation step (see 2.7.3.2.2). Passage number (#) post-vCJD prion infection at the time of 
the SCA is given as well as the passage ratio, indicating the inoculum is likely to have been 
diluted out. SCA values (minus mean uninfected 197 NSC background value) are given plus 
standard error of mean (SEM). SCA values were extremely low, indicating an absence of 
PrPScin the 197 cells and that they were unable to propagate vCJD prions.
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5.4.4 vCJD prion infection of human differentiated 197 cells
Previous published data shows that whilst mouse undifferentiated NSC are resistant to mouse 
prion infection, differentiation o f the cultures renders them more susceptible such that they are 
able to chronically propagate three strains o f mouse prions (Milhavet et al., 2006). Based on 
this work and the close resemblance of differentiated 197 cells to cells in the human brain in 
vivo, the susceptibility of differentiated human NSC to vCJD prion infection was investigated.
5.4.4.1 Optimisation of vCJD prion infection and PrP* screening for differentiated 197 
cells
Optimisation of vCJD prion-infected brain homogenate preparation
Since differentiated NSC cultures are post-mitotic, the vCJD prion-infected inoculum could 
not be cleared from the differentiated cultures merely by passaging. Therefore, a partial 
purification step termed “ semi-purificatioff’ (modified from Milhavet et al., 2006) involving 
incubation with a lysis buffer was employed to clarify the vCJD prion-infected brain 
homogenate (see 2.13.2.2), This step lysed the cells and disaggregated the brain homogenate, 
to minimise it sticking to the cultures and to increase the number o f infectious seeds, but 
critically not to reduce infectivity (since PrPSc is partially detergent resistant). Cells were 
exposed to semi-purified vCJD brain homogenate for 96 hours at differentiation day 0-4 and 
assayed for PrPSc approximately every 5-10 days by SCA or immunoblotting.
Optimisation of vCJD prion particle monitor control
In order to distinguish PrPSc in the inoculum from active cellular prion replication, a particle 
monitor control stem cell line was used. Initially, PrPc-null FVB mouse embryonic 
neurospheres were differentiated on laminin (these are described in 2.2.5) and used as the 
particle monitor cell line. Due to their lack o f PrPc expression they are resistant to any form of 
prion infection (Milhavet et al., 2006). However, this cell line has disadvantages. It was 
derived from a different species (mouse) to the human 197 cell line and most likely has a 
different cellular composition as neurospheres are reported to differentiate more readily into 
astrocytes than neurones in vitro (Morshead et al., 2002), whereas the differentiated 197 cells 
were predominantly neuronal. Therefore, following the preliminary experiments, a more 
relevant particle monitor was devised. This involved the use o f an anti-PrP antibody to treat 
the vCJD prion infected differentiated 197 cells. Anti-PrP antibody treatment inhibits prion 
replication in cells by sequestering cell surface PrPc and preventing its conversion to PrPSc 
(Enari et al., 2001). This particle monitor strategy was validated by the demonstration that
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ICSM18 anti-PrP antibody treatment for five days cured chronically RML prion-infected PK1 
cells (iPKl), but did not clear residual brain homogenate from prion-resistant PrPc-null 
differentiated mouse NSCs exposed to vCJD prions (figure 5.5).
Optimisation of Proteinase K (PK) concentration for digestion of PrP1 in differentiated 197 
celI lysates for immunoblotting
Lysates prepared from uninfected, differentiated (day 14) 197 cells were incubated with PK 
(for 37°C, 30 minutes) at 2.5 and 5 pg/mg protein. 2.5 pg/mg PK almost completely digested 
PrPc bands in uninfected 197 differentiated cultures, but 5 pg/mg PK fully digested the host 
PrPc (figure 5.6). To be confident that PrPc was completely digested in the differentiated 197 
cells, 5 pg/mg PK concentration was selected for subsequent experiments.
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Figure 5.5 Validation of anti-PrP antibody curing of prion-propagating cells as a particle 
monitor for vCJD prion infections of differentiated 197 cells
Chronically RML prion-infected PK1 (iPK1) cells and 0.1% vCJD prion-exposed PrPc-null 
differentiated NSC (PrP null; 29 days post-infection) were treated with 5 pg/ml ICSM18 anti- 
PrP antibody (18) for 5 days. Cell lysates were prepared, PK digested (5 pg/mg protein) and 
immunoblotted (25 pg protein) for PrP80 using anti-PrP antibody, biotinylated ICSM35. PK 
digested (10 pg/mg) vCJD prion-infected brain homogenate (25 pg protein) was run alongside 
as an immunoblotting positive control for PrP80 (lane 5). Three bands representing the three 
glycosylation states of PrP8c (di-, mono-, and unglycosylated) were observed between 33-16 
kDa. iPK1 cells propagate mouse RML prions, comprising mainly monoglycosylated PrP80 
(middle band -27 kDa), whereas vCJD prions are mainly diglycosylated (top band -32 kDa). 
iPK1 cells were cured of prion infection after ICSM18 treatment (lane 2) compared to untreated 
cells (lane 1). PrP80 levels in prion-resistant PrPc-null cells exposed to vCJD prion-infected 
brain homogenate (lane 4) were unaffected by ICSM18 treatment (lane 3), demonstrating that 
the antibody treatment specifically cures prion-propagating cells, but does not induce a 
clearing of brain homogenate from the cultures.
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Figure 5.6 Determination of optimal PK concentration to digest PrPc in differentiated 
197 cells
Cell lysates of differentiated (day 14) 197 cells were digested with PK at 0, 2.5 and 5 pg/mg 
protein. 50 pg protein was loaded per lane and samples were immunoblotted for PrPc using 
anti-PrP antibody, biotinylated ICSM35. PrPc remained in the PK-untreated sample (197) and 
ran characteristically between -50-30 kDa. Very faint bands remained in the differentiated 197 
sample digested with 2.5 pg/mg PK (197 + PK 2.5) but 5 pg/mg PK protein appeared to 
completely digest PrPc (197 + PK 5).
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§.4.4.2 Chronic vCJD prion infection in differentiated 197 cultures
Exposure o f differentiating 197 cells to 0.1% semi-purified vCJD inoculum resulted in chronic 
and stable vCJD prion infection o f the cells as determined by SCA and immunoblot. PrPSc 
levels in the differentiated 197 cells were consistently higher than the PrPc-null particle 
monitor cells by SCA from 15 to 49 days post-infection (figure 5.7). This was replicated by 
immunoblotting, in which PrPSt levels were consistently higher in differentiated 197 cells than 
in the anti-PrP antibody-cured particle monitor controls from 12 to 39 days post-infection 
(figure 5.8). These data strongly suggest the de novo production and replication o f PrP550 in 
differentiated 197 cells. From the SCA data, the levels of de novo PrPSc produced in the cells 
appeared to be relatively low (250-550 SCA spots) compared to mouse prion-propagating PK1 
cells, but they remained relatively constant over the course of the experiment. The PrP^ 
produced retained the properties o f the type 4 prions characterised by vCJD (figure 5.9). In 
both experiments, the vCJD prion-infected 197 cells died earlier (40-50 days post-infection) 
than the mock-infected cells (80+ days post-infection).
The particle monitors (days 12, 29 and 39) were PrPSc-positive throughout the immunoblot 
experiment, indicating that some PrP80 from the original inoculum remained in the cultures. 
The SCA experiment indicates about one third o f the inoculum (about 400 spots) appeared to 
be cleared by media changes over the course o f the 49-day experiment.
Across the data, it appears that there was variation in the amount o f PrP5* delivered to the wells 
at the time o f infection. This is exemplified by the particle monitor in the immunoblot 
experiment; at day 20 it was clear, but PrPSc was then detected at day 29 (figure 5.8). This may 
be explained by the total amount o f protein loaded in each experiment. However, equal 
amounts o f protein from antibody-treated and untreated samples were loaded at each time- 
point, verified by Coomassie staining o f the polyacrylamide gels (see section 2.6.3.4), It was 
not possible to show equal protein loading by stripping the blots and reprobing for P-actin 
because the samples had been PK-digested. The “ reappearance” o f the particle monitor was 
unlikely to result from lack o f antibody-curing efficacy, since each antibody batch was tested 
on iPKl cells and freeze-thawing was avoided. Optimising the homogeneity of the inoculum 
preparation required further work.
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Figure 5.7 De novo production of PrP^ in vCJD prion-infected differentiated 197 
cultures
197 NSC, at 60% confluency, on differentiation day 0, were prion infected with 0.1% semi­
purified vCJD inoculum (12811) for 96 hours. Mouse PrPc-null differentiated NSC were infected 
in parallel as the particle monitor. Data are presented as mean SCA value (PrP^-positive 
spots) for vCJD prion-infected 197 cultures minus mean particle monitor (+ SEM, n=8). Values 
above zero represent de novo PrP80 production in 197 cells. 197 cells appeared to clear more 
vCJD inoculum than the particle monitor cells at approximately day 10 post-infection, at which 
point the 197 cells started to actively replicate and accumulate de novo PrP50. PrPSc remained 
at a steady level between day 15 and day 49 post-infection when the cells died, about 30 days 
earlier than mock-infected 197 cells. One-way analysis of variance (ANOVA) showed a 
significant difference in PrP80 levels in 197 cells and the particle monitor cells over the 7 time 
time points (P<0.001).
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Figure 5.8 Chronic de novo vCJD prion replication in differentiated 197 cultures
Differentiated (day 4) 197 cells were infected with 0.1% semi-purified vCJD prion-infected 
brain homogenate (197 vCJD) for 96 hours. Cells were harvested at regular time-points post­
infection alongside particle monitor wells that had been exposed to 5 days of 5 pg/ml ICSM18 
antibody treatment (197 vCJD+18). Cell lysates were prepared, PK digested (5 pg/mg protein; 
PK+), and 37.5 pg protein from each sample immunoblotted for PrP80 with either ICSM35 B 
(days 12, 20, 29) or 3F4 (day 39) anti-PrP antibodies. 25 pg vCJD prion-infected brain 
homogenate was run as a positive control (vCJD brain) for each time-point. Diglycosylated 
type 4 PrP80 strain (which is characteristic of vCJD) was present in differentiated 197 cells 
between day 12 and day 39 post-infection. Equal amounts of protein were loaded in the 
particle monitor and 197 lanes at each time-point, determined by Coomassie staining of the 
gels. Therefore, the significant reduction in PrP80 levels in the vCJD-infected 197 cells 
following ICSM18 antibody treatment at each time-point indicates curing of active prion 
propagation. These data strongly suggested de novo prion synthesis in vCJD prion-infected 
differentiated 197 cells (lanes marked in red) from day 12 to 39 post-infection. Part of the PrP80 
signal in vCJD prion-infected 197 cultures was attributed to the original vCJD prion-infected 
brain inoculum, as shown in the antibody-treated lanes (197 vCJD+18) day 12, 29 and 39. The 
vCJD prion-infected cells died in vitro at day 45 whereas mock-infected differentiated 197 cells 
died at day 80.
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Figure 5.9 Following vCJD prion infection differentiated 197 cells propagate type 4 
human prions
(A) Following infection with vCJD prions, differentiated 197 cells produce PrPSc characteristic 
of the type 4 strain type associated with vCJD prions. (B) Type 4 prions are predominantly 
diglycosylated (top band dominant) according to Hill’s human prion strain classification system 
(Hill et al., 2003). This observation indicates that there is no cellular modification of the vCJD 
prion strain by 197 cells.
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5.4.4.3 Determining susceptibility of differentiated 197 cells to vCJD prions
Differentiated 197 cells were exposed to a range of concentrations of semi-purified vCJD 
inoculum (0.01, 0.001 and 0.0001%) to assess their susceptibility to infection. Cultures were 
infected with vCJD prions according to the standard protocol (section 2.7.3) and the presence 
o f PrPSc in the cells assessed by SCA (figure 5.10). Differentiated 197 cells were unable to 
propagate vCJD prions when infected with lower concentrations o f vCJD inoculum. There was 
some transient susceptibility o f the cells to infection with 0.01% vCJD brain homogenate; cells 
initially produced significant levels o f PrPs\  but this steadily fell over the course of the 23-day 
experiment to very low levels. These were detectable by SCA, but needed to be precipitated 
with sodium phosphotungstic acid (NaPTA; see 2.6.2.5) to be visualised by immunoblotting 
(figure 5.11). This demonstrates that the 197 cells required a minimum level o f 0.1% semi­
purified vCJD prion infected brain homogenate to establish chronic vCJD prion infection.
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Figure 5.10 Susceptibility of human differentiated 197 cells to vCJD prion infection at 
lower inoculum concentrations
197 NSC, at 60% confluency, on differentiation day 0, were prion infected with 0.1, 0.001 and 
0.0001% semi-purified vCJD inoculum (12811) for 96 hours. Mouse PrPc-null differentiated 
NSC were infected in parallel as the particle monitor. Data are presented as mean SCA value 
(PrP^-positive spots) for vCJD prion-infected differentiated 197 cells minus mean particle 
monitor (+ SEM, n=8). Following infection with 0.001 and 0.0001% vCJD, PrP80 was barely 
detectable by SCA over 18 days post-infection. Following infection with 0.01% vCJD, there was 
more PrP^in 197 cells at 6 days post-infection, but the level fell rapidly to insignificant levels 
over the course of the 23-day infection.
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Figure 5.11 Detection of vCJD prions in differentiated 197 cells following infection with 
0.01% vCJD prion-infected brain homogenate
Cell lysates were prepared from differentiated 197 cells infected with 0.01% vCJD prion- 
infected brain homogenate at 23 days post-infection. A single sample (60 pg) was run without 
PK digestion (right-hand lane). PrP80 was precipitated from the other sample (200 pg) using 
NaPTA precipitation followed by PK digestion (5 pg/mg protein; left-hand lane). Samples were 
immunoblotted for PrP using anti-PrP antibody, biotinylated ICSM35. PrP80 was only just 
detectable in the 197 cultures 23 days post-infection, following NaPTA precipitation (left-hand 
lane). The PrP band shift following PK digestion is indicative of PrP80; cleavage of -70 amino 
adds from the N-terminus of PrP80 caused it to migrate faster on the gel (-35 and 16 kDa) 
than the PK-undigested sample (which is composed of both PrPcand full-length PrP8c).
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5.4.4.4 Attempts to accelerate clearance of inoculum from differentiated 197 cells
It is evident from the experiments presented above that despite semi-purification o f vCJD brain 
homogenate, washing the cells post-infection and 50% media changes every week, a low level 
o f vCJD inoculum remained in the cultures when the cells died (day 39 and day 49). Simple 
strategies were devised to produce a clarified suspension of brain homogenate that was less 
likely to stick to the cultures, but also retain infectivity. It is important not to excessively 
purify PrP80 (for example by NaPTA precipitation), because membrane-associated PrPSc has 
been shown to infect cells much more efficiently than membrane-free detergent extracted 
PrPSc, possibly because membrane-associated PrPSc may more readily gain access to cells via 
binding with cell-surface receptors (Baron et al., 2006).
Most strategies tested reduced PrP50 levels, but none improved clearance of the vCJD 
inoculum from the cultures (see table 5.2 for details). Therefore, the original semi-purification 
method o f brain homogenate probably remains the best method for infecting the differentiated 
197 cells because it was less toxic compared to crude brain homogenate and retained most 
infectivity. The low level residual inoculum in the vCJD prion-propagating cultures does not 
pose a problem for further experiments on the cell line since it should not affect most methods 
used to study cell biology.
5.4.5 Summary of results
The 197 human NSC line proved a suitable candidate for testing susceptibility to vCJD prion 
infection; it was methionine homozygous at codon 129 of PRNP, and expression levels o f PrPc 
in both undifferentiated and differentiated states were good. Crude human brain homogenate 
per se was toxic to undifferentiated 197 cells, but it was determined that they could tolerate 
lower concentrations o f a “semi-purified” preparation o f vCJD prion-infected brain 
homogenate. However, undifferentiated 197 cells did not propagate vCJD prions. Conversely, 
differentiated 197 cells that were predominantly neuronal were susceptible to infection with 
0.1% dilution o f vCJD semi-purified brain homogenate. They produced de novo PrPSc over 
approximately 50 days post-infection as demonstrated by both SCA and immunoblotting. 
Differentiated 197 cells appeared to undergo prion-induced cell death because vCJD prion- 
infected cells died about 30 days earlier than mock-infected cells. The fact that these 
differentiated neurones chronically and stably propagate vCJD prions will enable the study of 
the cellular pathophysiology o f human prion disease.
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vCJD inoculum preparation Effect on PrP clearance from cultures
sonication (section 2.7.3.2.3) 37% reduction in PrP50 at time of infection 
(SCA) and not cleared from culture at 29 days 
post-infection
filtration (through 5pm PVDF membrane) 40% reduction in PrP80 at time of infection 
(SCA) but not cleared from culture by 20 days 
post-infection
0.01 % triton wash (at every media change) no effect
Table 5.2 Strategies to clear vCJD inoculum from differentiated 197 cultures
A number of different strategies were attempted to clear residual vCJD inoculum from the 
cultures: semi-purified vCJD brain homogenate was sonicated to disaggregate clumps; crude 
homogenate was filtered through a 5 pm PVDF membrane; cells were washed with a very low 
concentration of triton detergent at each media change. Most strategies reduced PrP80 in the 
inoculum, but none improved clearance from the cultures compared to the regular semi­
purified vCJD inoculum.
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5.5 Discussion
5.5.1 A novel human differentiated NSC model of vCJD
In this chapter, I demonstrated that a differentiated human neuronal culture derived from a 
human immortalised foetal neural stem cell line (ReNcell 197VM) was able to chronically 
propagate vCJD prions. Following infection with a semi-purified preparation of vCJD prion- 
infected brain homogenate, the cultures consistently produced low steady-state levels of type 4 
PrPSc for up to 50 days post-infection and subsequently died about 30 days earlier than mock- 
infected cultures (figures 5.7 and 5.8). This is the first description of an in vitro cellular system 
for replicating human prions. This is a highly relevant model system for several reasons. First, 
it closely mimics the human brain since it is a predominantly neuronal culture derived from the 
differentiation of human foetal midbrain NSC. Furthermore, these neurones can form synapses 
and appear to be electrically active. Second, the vCJD prion-propagating cell line only 
produces low levels of PrPSc, a feature consistent with vCJD patient brains, in which low prion 
titres are found (Dr J.Wadsworth, personal communication). Third, the cell line undergoes a 
delayed vCJD prion-induced cell death as occurs in disease. Fourth, the v-myc gene used for 
immortalisation (by enhancing tert and telomerase expression), confers genetic stability on the 
undifferentiated NSC over many passages making it a highly reproducible model (Dang et al., 
1999;Villa et al., 2004;Kim, 2004). This is in contrast to genetically unstable tumour cell line- 
derived prion models, including many o f the non-human prion disease cell models (Klohn et 
al., 2003). Finally, the stem cell nature o f the model means there is an unlimited resource to 
study, unlike other primary neuronal culture models of prion disease (Cronier et al., 2004).
5.5.2 Differentiated phenotype influences cellular susceptibility to vCJD prion 
infection
Undifferentiated 197 cells were unable to propagate vCJD prions. This is consistent with a 
previous report in which mouse NSC were resistant to mouse prion infection (Milhavet et al., 
2006). The fact that differentiation renders both mouse and human NSC susceptible to prion 
infection suggests that a terminally differentiated cell phenotype is a key determinant o f prion 
susceptibility. This hypothesis is supported by the fact that mouse embryonic neurospheres are 
susceptible to mouse prions. Though mouse NSC do not propagate mouse prions, the prion 
permissive nature o f the neurospheres was attributed to the fact they are comprised o f neural 
progenitor cells at different stages of maturation, with few stem cells; that is, the more 
differentiated cells were proposed to propagate prions (Garcion et al., 2004;Giri et al., 2006). 
There may be several reasons why a differentiated cellular phenotype confers susceptibility to 
prion infection. First, as the dynamic susceptibility model o f cellular prion infection predicts,
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it may simply be that because the cultures are non-dividing, therefore, they have the 
opportunity to synthesise and accumulate de novo PrP^, rather than the prion load o f the cell 
being reduced at each cell division (Weissmann, 2004). Second, differentiation of NSC has 
been shown to result in a dramatic increase in PrPc expression (Steele et al., 2006;Milhavet et 
al., 2006), a factor that has been proposed to underlie enhanced susceptibility to prion 
infection. However, this does not explain the lack o f susceptibility of undifferentiated 197 
cells, because a marked difference in PrP1 expression levels between the undifferentiated and 
differentiation states was not observed; a relatively high PrP( expression was observed in both. 
Third, a recent study of the proteome o f undifferentiated and differentiated 197 cells may 
explain the increased susceptibility o f differentiated 197 cultures to vCJD prion infection 
(Hoffrogge et al., 2006). Changes in expression of proteins involved in protein metabolism 
were most common. Therefore, one could speculate this influenced PrP& production and/or 
accumulation. For example, there was down-regulation of a lid subunit o f the proteasome, 
S3/Rpn3, in the differentiated 197 cells. Since the proteasome, is a structure responsible for 
the non-lysosomal degradation o f misfolded proteins in eukaryotic cells (Hershko and 
Ciechanover, 1998), this may have contributed to the accumulation of PrPSc in the cells. A 
down-regulation in heat shock proteins (Hsp) 70, 90, and 7C, was also observed. The 
constitutive form of Hsp70, a molecular chaperone, is expressed in neurones and has been 
implicated in the transport o f misfolded proteins to the lysosome for degradation (Chang et al., 
1989). Therefore, Hsp70 down-regulation in differentiated 197 cells may have reduced the 
degradation o f PrPSc and led to its further cellular accumulation.
5.S.3 Neuronal phenotype influences cellular susceptibility to vCJD prion infection
Differentiation of the human 197 NSC line by withdrawal o f mitogens from the culture 
medium resulted in a culture made up of between 80-90% neurones and about 10-20% 
astroglia. This is a very high proportion o f neurones compared to glia, particularly given that a 
recently developed human (8-9 week) foetal cortical NSC line generated a culture o f only 11% 
pill-tubulin-positive neurones following differentiation (Cacci et al., 2007). The high 
proportion of neurones in the differentiated 197 cultures could be explained by the high PrPc 
expression observed in the undifferentiated state (figure 5.4). PrPc has been proposed to play a 
role in guiding multipotent neural precursor cells to differentiate into mature neurones, because 
PrPc expression in mouse neural precursor cells positively correlated with the number of 
neurones generated in vitro (Steele et al., 2006). Alternatively, the v-myc gene may have 
integrated into the 197 genome and disrupted a gene involved in the regulation of neuronal 
differentiation or the culture conditions used may have favoured neuronal differentiation. 
Basic FGF is known to induce neurone formation from NSC cultures (Carpenter et al., 1999).
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Moreover, the 197 cell line was not allowed to become overconfluent or maintained in culture 
for prolonged periods, since both these practices reduce its neuronal differentiation potential 
(Dr. E.Miljan, personal communication). However, it cannot be discounted that the high 
neuronal component o f the 197 cultures was due to chance, perhaps related to the original 
donor tissue from which it was derived being of particularly high quality.
The high proportion o f neurones in the differentiated 197 cultures may explain their 
susceptibility to vCJD prion infection. This would add to a growing body of evidence 
suggesting that a neuronal phenotype confers susceptibility to prion infection. First, directing 
mouse prion-susceptible NSC cultures towards a neuronal fate (with factors such as retinoic 
acid and nerve growth factor) results in the increased production o f PrPSc compared to a mixed 
differentiated NSC population or those NSC directed to a glial fate (with CNTF), an effect 
which is independent of PrPc expression level (Milhavet et al., 2006). Second, prion-resistant 
N2a-derived clones were switched to a RML prion-susceptible phenotype with retinoic acid- 
induced neuronal differentiation (Dr P.Klohn, unpublished data). Third, a microarray study of 
highly RML prion-susceptible PK1 clones and RML prion-resistant sister clones indicated that 
the prion-susceptible cells differentially expressed genes that promoted neuronal 
differentiation (Dr. P.Klohn, unpublished data). These included the upregulation o f Sharp2, a 
transcription factor involved in the regulation of neuronal differentiation, marking the 
neurones that have reached their desired position (Rossner et al., 1997) and the down 
regulation of Id4, a negative regulator o f differentiation in development (Bedford et al., 2005).
5.5.4 Clearance of brain homogenate from non-dividing neuronal cultures
The particle monitors used (differentiated PrPc-null mouse NSC and anti-PrP antibody-treated 
differentiated 197 cells) indicate that residual vCJD prion-infected brain homogenate remained 
in the cultures at a low level throughout the course o f the experiments. Other groups have 
managed to achieve early clearance o f prion-infected brain homogenate from differentiated 
PrPc-null post-mitotic cultures at 7 and 2 days post-infection (Cronier et al., 2004;Milhavet et 
al., 2006). However, the data produced by Milhavet et al. has been unreproducible in our 
hands; when their PrP80 purification process of brain homogenate was applied to our vCJD 
brain homogenate it removed all the infectivity. However, Cronier et al. used a low dose of 
sonicated crude mouse-adapted scrapie brain homogenate to facilitate clearance from primary 
cerebellar granular neuronal cultures in seven days post-infection. The same dose of semi­
purified vCJD prion-infected brain homogenate was used in these experiments, but did not 
clear from the 197 cultures in seven days. One possible reason for faster clearance of inoculum 
from the cerebellar cultures was the presence o f 1% microglial cells, which were proposed to 
degrade the inoculum by virtue o f their phagocytic properties. There is also suggestion that
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microglia are important for neuronal and glial survival in prion disease in vivo as they have 
been found near PrP^ aggregates in the brain (Marella and Chabry, 2004). Since NSC do not 
have the capacity to develop into microglia, this mechanism of inoculum clearance was not 
available in the 197 cultures. Another possibility is that vCJD prion-infected human brain 
homogenate is physically different to brain homogenate (mainly mouse) used in the 
development o f other prion-propagating cell lines; it was much stickier and more aggregated. 
This may be due to the fact the vCJD-affected human brain is much older than scrapie-infected 
mouse brains, or because there is a longer post-mortem delay before freezing o f human brain. 
However, the presence o f low levels o f vCJD inoculum in the cultures should not affect the use 
o f the vCJD prion-propagating differentiated 197 cells in the study of pathophysiology of 
human prion disease.
5.5.5 Summary
The evidence presented in this chapter strongly suggests that differentiated 197 human foetal 
NSC stably propagate vCJD prions. The predominantly neuronal cultures appear to mimic in 
vivo disease by undergoing a delayed prion-induced cell death. Therefore, the 197 cell model 
represents a physiologically relevant system on which to study the biology of human prions at 
the cellular level (see chapter 6 for future experiments).
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6.1 Conclusions
This thesis aimed to develop a cell line that stably propagated human vCJD prions. This 
cellular model is of critical importance to the future o f human prion disease research but is 
currently lacking, despite over forty years o f investigation. To-date, research into human prion 
disease has been undertaken in transgenic mouse models but these possess inherent limitations, 
such as long disease incubation times. A cellular model is needed to provide a cheaper, faster 
assay system for human prions without the ethical constraints associated with animal 
experiments, and to provide a more easily manipulated model for the study of disease 
pathophysiology at the cellular and molecular levels.
In this thesis, mammalian cell lines were investigated for their ability to chronically propagate 
human vCJD prions. Because numerous cell models o f prion disease are derived from tumour 
cell lines, in chapter 3 a panel o f rodent and human tumour cell lines, derived from tissues 
capable o f propagating prions in vivo and in vitro, were screened for susceptibility to human 
vCJD prion infection. It became apparent that expression of human PrPc, which was 
methionine homozygous at codon 129 (to match the PrP& sequence in the vCJD brain 
homogenate), was insufficient to establish vCJD prion infection in these cell lines. Therefore, 
it can be concluded that cellular susceptibility to human prions is determined by multiple, as 
yet unidentified, factors (discussed in chapter 4). The transient propagation o f human vCJD 
prions observed in one cell line, the rabbit RK13 line expressing human PrPc, was most likely 
due to its ability to transmit prions intercellularly via exosomes (Fevrier et al., 2004). The 
RK13 cell line highlighted that tumour cell lines are not ideal cellular models due to their 
genetic instability, which may indeed have caused the loss o f their vCJD prion susceptible 
phenotype.
In chapter 4, the mouse PK1 cell line was hypothesised to possess factors required for cellular 
prion propagation because it is permissive to RML and 22L mouse prions (Professor 
C.Weissmann, unpublished data and Klohn et al., 2003). Cellular equivalents of the vCJD 
prion-susceptible transgenic mouse lines were generated. The inhibitory endogenous murine 
PrPc was knocked out and human PrPc overexpressed in PK1 cells. Nonetheless these cells 
were unable to propagate vCJD prions. This and the fact that the PK1 cell line is not 
permissive to mouse ME7 or hamster prions (Dr P.Klohn, unpublished data), suggested that 
cellular prion propagation factors may be prion strain-specific. Alternatively, human prion 
conversion in cell lines may be less efficient than mouse prion conversion to RML and 22L, 
requiring additional cellular factors.
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Given that vCJD is readily transmitted to both wild-type and human PrPc transgenic mice 
(Asante et al., 2002) but vCJD prion propagation was not achieved in either the human PrPc- 
overexpressing PK1 mouse PrP1 knockout lines or the mammalian tumour cell lines, it can be 
concluded that transmission o f vCJD prion infection to cell lines is much more difficult than to 
mice. Indeed, prion strains behave differently in cells than in animals. This is evidenced by the 
fact prion disease incubation times in mice do not influence cellular prion susceptibility; that 
is, short incubation time prion strains do not infect cells more easily than long incubation time 
strains (Vorberg et al., 2004). Therefore the whole organism appears to provide mechanisms to 
facilitate cellular prion uptake and/or propagation that may not be available in the reductionist 
approach o f cell lines. Such mechanisms may include, first, cleavage of PrPSc by digestive 
enzymes. The protease-resistant PrPSc fragments resulting from enzymatic digestion o f PrP^ 
are thought to form complexes with ferritin which results in their endocytosis into epithelial 
cells thus mediating their transport from gut to lymphoid tissue (Mishra et al., 2004). Second, 
complement component, Clq, has been reported to bind PrP50 and therefore may facilitate its 
uptake into complement receptor-expressing cells, such as follicular dendritic cells (Blanquet- 
Grossard et al., 2005). Third, the long incubation times associated with prion disease (a 
clinically silent phase prior to symptom onset) are critical for prion accumulation in non­
dividing cells, such as follicular dendritic cells and neurones. This time period is not available 
in rapidly dividing cell cultures and therefore could be the reason why they cannot achieve 
high enough prion levels to establish infection.
The experiments described in chapter 5 led to the establishment o f chronic, stable vCJD prion 
propagation in a primary human neuronal culture, derived from a foetal neural stem cell line 
(ReNcell 197VM). This is the first known description o f cellular human prion propagation in 
vitro. The fact that the NSC line, 197, was only susceptible to vCJD prion infection in its 
differentiated neuronal state, strongly suggests a neuronal phenotype is a key determinant of 
cellular prion susceptibility. This work demonstrates that it is essential to recapitulate PrP^ 
processing in vivo most faithfully in order to achieve human prion propagation in vitro. The 
development o f a vCJD prion propagating cell line opens up many avenues of investigation to 
further our knowledge o f human prion neurobiology.
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6.2 Future Work
6.2.1 Further development of the vCJD prion-propagating differentiated 197 
cell line
6.2.1.1 Confirmation of infectivity in vCJD prion-infected 197 differentiated cultures
The chronic presence o f protease-resistant PrP (the surrogate marker for prion infection) in the 
differentiated 197 cultures was shown in chapter 5. However, as is standard for prion- 
propagating cell lines, it would be important to demonstrate that the vCJD prion-infected 197 
cells are producing infectious prions by transmission o f infectivity in vitro and in vivo. This 
could be done by inoculating cell homogenate prepared from vCJD prion-infected 
differentiated 197 cultures into (1) uninfected differentiated 197 cultures and (2) vCJD prion- 
susceptible mice; Tg45 (which overexpress human PrP 129M four-fold) and SJL (wild-type) 
strains (Asante et al., 2002). PrP& would be detected in the cell cultures by the SCA or 
immunoblotting (Milhavet et al., 2006;Cronier et al., 2004). Since vCJD prion-inoculated mice 
do not always develop clinical signs of disease (Asante et al., 2002), prion transmission from 
197 cultures to mice would be assessed by histopathological examination o f brain tissue for 
PrPSc and immunoblotting o f brain tissue for type 4 PrP^. It would be important to include 
particle monitor cell homogenate in these experiments to control for infectivity from the 
residual inoculum. In some cases, infectivity from prion-propagating cell lines has been 
demonstrated using cell culture supernatant (Schatzl et al., 1997;Fevrier et al., 2004;Cronier et 
al., 2004). This method may also demonstrate the presence of infectious prions in the vCJD 
prion-infected 197 cultures and additionally show if  PrP80 is being released into the culture 
medium (perhaps in exosomes). In order to quantify infectivity in the differentiated 197 model, 
vCJD prion-infected cell homogenate from the cultures would need to be titrated against 
dilutions of vCJD brain homogenate in either the cellular system or the mouse bioassay.
6.2.1.2 Confirmation of de novo production of PrP^ in the vCJD prion-infected 197 
differentiated cultures
Further evidence oft/e novo PrPSc production in differentiated 197 cultures could be achieved 
by metabolic radiolabelling o f cellular proteins (using methods similar to those described in 
Schatzl et al., 1997;Follet et al., 2002). After vCJD prion infection of the differentiated 197 
cultures, cells would be incubated for several hours with methionine-free medium 
supplemented with L-[35S] methionine to allow incorporation of radiolabelled methionine into 
newly synthesised proteins. This would be followed by protein extraction from the cells and 
PK digestion o f the material (as described in section 2.6.2) and analysis by SDS-PAGE. Newly 
converted PrPSc in the differentiated 197 cultures would be radiolabelled and visualised by 
autoradiography, clearly distinguishing it from the unlabelled PrP80 in the residual vCJD
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inoculum. Assaying 197 cultures at different time-points post-infection would indicate the rate 
o f cellular PrP,Sc production during the lifespan o f the cultures.
6.2.1.3 Investigation of susceptibility of differentiated 197 cultures to other human
prion strains
Since vCJD differs in its clinicopathological phenotype to sporadic CJD, it would also be 
useful for basic and therapeutic research to have a cellular model o f sCJD. Therefore, it would 
be important to test i f  the differentiated 197 cells could propagate type 1 and type 2 sCJD 
prions (derived from PRNP codon 129 methionine homozygotes), using the methods described 
in chapter 5.
6.2.2 Human PrPSc cell biology
Since the differentiated 197 cells appear to undergo delayed prion-induced cell death, they 
may closely model the effect o f human prions on neurones during in vivo disease, in which 
progressive neuronal dysfunction precedes cell death.
6.2.2.1 Subcellular localisation of human PrP^
It would be important to determine where PrPSc accumulates in the vCJD prion-infected 197 
cells over time so this could be correlated with changes in biological parameters studied. 
Subcellular localisation o f PrP80 is difficult to assess (Taraboulos et al., 1990;Archer et al.,
2004) because the lack o f a PrP^-specific antibody means pre-treatment o f cells with 
denaturants (formic acid, guanidinium thiocyanate or thermolysin) is required to remove PrPc 
and reveal PrP8^ epitopes, but this pre-treatment results in poor immunoreactivity. Previous 
work has suggested that PrPSc is localised at the plasma membrane (Caughey and Raymond, 
1991), in the endolysosomal compartment (Arnold et al., 1995) and in the cytosol (in 
perinuclear structures responsible for clearance of cytoplasmic misfolded protein aggregates 
called aggresomes; Kristiansen et al., 2005). Immunofluorescence staining of the vCJD prion- 
infected differentiated 197 cells may allow the subcellular localisation o f human PrP8c 
accumulation to be determined and may provide clues to some fundamental unanswered 
questions in the prion field, such as the site o f PrPSc conversion and intra-cellular trafficking of 
human PrP^. Confocal analysis o f PrP^-stained cells would determine localisation at the cell 
membrane. It would also demonstrate the proportion o f the cells in the culture that become 
infected with vCJD prions. Determining the presence of PrP80 in the endolysosomal 
compartment and in the cytosol could be achieved by dual label immunostaining 
demonstrating co-localisation of PrPSc with the endolysosomal marker (LAMP-1) and 
cytosolic marker (Hsc70), respectively. The presence o f PrP80 aggresomes could be established 
by demonstrating colocalisation of PrPSc with vimentin, Hsc70, ubiquitin and 20S proteasome 
subunits.
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6.2.2.2 Study of apoptosis in differentiated 197 cultures
Apoptosis is regarded as the principal mechanism of cell death in prion disease as determined 
by in vivo and in vitro studies (Schatzl et al., 1997;Jamieson et al., 2001;Siso et al., 2002;Hetz 
and Soto, 2003;Hetz et al., 2003;Cronier et al., 2004;Kristiansen et al., 2005). The work 
presented in chapter 5 shows that vCJD prion infection of differentiated 197 cultures resulted 
in a delayed cell death, suggestive o f apoptosis. To confirm this mechanism of cell death, the 
simultaneous presence o f several apoptotic markers would need to be assessed in vCJD prion- 
infected differentiated 197 cultures at late stage infection (possibly day 45). Apoptotic cells 
exhibit fragmented nuclei (Oberhammer et al., 1993), the presence of which could be 
determined in the vCJD prion infected 197 cultures by nuclear DNA staining with DAP1 (4’,6- 
diamidino-2-phenylindole) and subsequent analysis by fluorescence microscopy. Poly (ADP- 
ribose) polymerase (PARP), a nuclear enzyme involved in DNA repair, is cleaved late in the 
apoptotic cascade by caspase 3. The presence of PARP cleavage products could be assessed in 
the vCJD prion infected 197 cultures by immunoblotting with a specific antibody. Apoptosis 
can be initiated through a number o f different pathways (Thomberry and Lazebnik, 1998) and 
both in vitro and in vivo studies o f prion disease suggest that caspases 3, 8 and 12 are activated 
(Jamieson et al., 2001;Siso et al., 2002;Kristiansen et al., 2005;Hetz et al., 2007). Caspase 8 
mediates cell surface death receptor (Fas-L)-induced pathway o f apoptosis, caspase 12 
mediates ER-stress induced pathway and caspase 3 is a common downstream effector of 
apoptosis. Therefore, the vCJD prion-infected differentiated 197 cultures could be analysed for 
the presence of these activated caspases using in vitro assays specific for each caspase 
(Oncogene) or immunoblotting with specific antibodies.
6.2.2.3 Evaluating ubiquitin-proteasome system dysfunction in differentiated 197 cells
Until recently the cause o f prion-mediated neurodegeneration was not known. As for other 
neurodegenerative diseases, evidence is now emerging to suggest the involvement of 
ubiquitin-proteasome system (UPS) dysfunction in prion-induced cell death (Ciechanover and 
Brundin, 2003). The UPS is a cellular protein quality control system responsible for the non- 
lysosomal degradation o f short-lived, mutant and misfolded protein and is involved in many 
cellular functions, including transcriptional regulation, cell cycle control and control of 
apoptosis. Evidence for proteasome impairment in prion-infected neurones is observed in 
mouse prion-propagating cell lines. Mild proteasome inhibition of mouse prion-infected 
neuroblastoma cells results in PrPSc aggresome formation, which triggers caspase-dependent 
cell death (Ciechanover and Brundin, 2003). More recently an intracellular neurotoxic 
mechanism of prions has been proposed, in which oligomers of misfolded prion protein impair 
proteasome function by specifically inhibiting catalytic (3-subunits o f the 26S proteasome 
(Kristiansen et al., 2007). The vCJD prion-propagating differentiated 197 line will be useful in
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establishing whether proteasome impairment is also a feature o f human prion disease 
pathogenesis and specifically whether the vCJD prions inhibit catalytic (3-subunits o f the 26S 
proteasome. Proteasome function could be assessed (as described in Kristiansen et al., 2007) 
using fluorogenic peptide enzyme assays, a proteasome P-subunit activity probe (Berkers et al.,
2005) and a ubiquitinated-GFP-tagged live cell proteasome reporter. Assessment of 
proteasome function over time will allow better understanding of the relationship between 
proteasome dysfunction and neuronal dysfunction following prion infection.
ER stress (caused by accumulation o f protein aggregates or excessive protein traffic in the ER) 
has also been implicated in neuronal death in prion disease (Yoo et al., 2002;Hetz et al., 
2003;Hetz et al., 2005;Hetz et al., 2007). ER stress results in the unfolded protein response 
(UPR) involving three signalling pathways that serve to increase folding capacity o f the ER 
and reduce protein load. UPR induced chaperones are found in the cortex o f sCJD and vCJD 
patients and in mouse prion-infected neuroblastoma cells (Yoo et al., 2002;Hetz et al., 2003). 
Whether the involvement o f the ER-stress in prion disease pathogenesis is primary or 
secondary to UPS dysfunction is unclear at present. Inhibition o f the UPS by prions (as 
described in Kristiansen et al., 2007) may contribute to ER stress because the proteasome is 
essential for normal ER-associated degradation (ERAD) of protein. Therefore, misfolded 
proteins destined for degradation by ERAD may remain in the ER. Alternatively, prion 
infection may directly result in ER stress, the latter o f which is thought to inhibit proteasome 
dysfunction (Menendez-Benito et al., 2005). ER stress can be assessed (as described in Hetz et 
al., 2007) by the detection o f upregulated genes involved in UPR, UPR chaperones and 
markers o f ER stress-induced cell death, such as the transcription factor GADDI 53/CHOP and 
activated caspase-12. A time-course experiment measuring both proteasome function and ER 
stress markers in the vCJD prion-infected 197 cells would clarify the relationship between 
these two cellular pathways and their contribution to neuronal pathogenesis in human prion 
disease.
6.2.2.4 The effect of vCJD prion infection on synaptic function
Electroencephalogram (EEG) abnormalities are a common feature of human prion diseases and 
synaptic dysfunction is believed to be an early pathological event during prion infection 
(Cathala and Baron, 1987). Since uninfected 197 neurones have the capacity to generate action 
potentials (Dr Roberta Donato, UCL, unpublished work), these cells represent a unique system 
on which to study human neurophysiological changes in response to human prion infection, 
prior to neuronal death. Electrophysiology data from hippocampal and cortical neurones from 
scrapie-infected animals, suggest that prion infection increases neuronal membrane excitability 
as a result of reduced potassium conductances (Jefferys et al., 1994;Johnston et al., 
1997;Johnston et al., 1998). Changes in membrane excitability in the vCJD prion-infected 197
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neurones could be determined by measuring resting membrane potential, action potential 
threshold and amplitude. The use of the non-specific potassium channel antagonist, 
tetraethylammonium (TEA) would determine if  membrane potential changes were due to 
potassium conductances (as described in Johnston et al., 1998)). Both prion-infected and PrPc 
knock-out mice exhibit significantly reduced long slow afterhyperpolarisation potentials 
(AHP) (Colling et al., 1996;Johnston et al., 1998;Barrow et al., 1999;Mallucci et al., 2002), 
which are responsible for preventing repetitive action potential firing and are mediated by 
TEA-insensitive calcium-activated potassium channels. Therefore, loss o f the long slow AHP 
could be demonstrated in vCJD prion-infected 197 neurones by repetitive firing o f calcium 
spikes in response to a long depolarising current pulse, which would not be inhibited by TEA. 
The levels o f synaptic proteins, including syntaxin 1 A, SNAP-25, synaptobrevin, synapsin and 
synaptophysin, could also be studied by quantitative immunoblotting o f infected and 
uninfected cells to assess prion-induced changes in synaptic function.
Prion infection causes a number o f changes in neuronal morphology. Prior to neuronal loss, 
synaptic loss and axonal degeneration are observed in scrapie-infected mouse models (Jeffrey 
et al., 2000). Furthermore, increased branching o f basal dendrites has been detected in 
hippocampal CA1 pyramidal cells (Barrow et al., 1999). Therefore, it would be interesting to 
study the ultrastructure o f vCJD prion-infected 197 neurones using transmission electron 
microscopy (described in 2.9). Alterations in neurite morphology (neurite length and 
branches), number o f synapses formed, vesicle trafficking and evidence o f axonal degeneration 
and neuronal vacuolation could all be assessed. The Cellomics™ Arrayscan robotic 
fluorescence microscope may also be useful for these experiments because it can directly 
quantify cell body morphology, neurite length and branching using their neurite outgrowth 
assay.
6.2.3 Screening potential therapeutics for human prion disease
Prion diseases remain incurable and the screening o f potential therapeutics for prion disease 
has been performed on in vivo and in vitro experimental models of non-human prions. 
Therefore, the results o f these studies may not be relevant for the treatment o f human prion 
disease. The human vCJD prion-propagating neuronal 197 line represents a physiologically 
more relevant model on which to specifically assay compounds for potential therapeutic effect 
in vCJD. The vCJD prion-infected cell line would need to be developed for use in a high- 
throughput screening assay. The MRC Prion Unit has a collaboration with GlaxoSmithKline to 
screen the GSK compound library for anti-prion activity. It is anticipated that the human cell 
line will form part o f a tertiary screen to assess 100 potential vCJD therapies.
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6.1 Conclusions
This thesis aimed to develop a cell line that stably propagated human vCJD prions. This 
cellular model is o f critical importance to the future of human prion disease research but is 
currently lacking, despite over forty years o f investigation. To-date, research into human prion 
disease has been undertaken in transgenic mouse models but these possess inherent limitations, 
such as long disease incubation times. A cellular model is needed to provide a cheaper, faster 
assay system for human prions without the ethical constraints associated with animal 
experiments, and to provide a more easily manipulated model for the study of disease 
pathophysiology at the cellular and molecular levels.
In this thesis, mammalian cell lines were investigated for their ability to chronically propagate 
human vCJD prions. Because numerous cell models o f prion disease are derived from tumour 
cell lines, in chapter 3 a panel o f rodent and human tumour cell lines, derived from tissues 
capable o f propagating prions in vivo and in vitro, were screened for susceptibility to human 
vCJD prion infection. It became apparent that expression of human PrPc, which was 
methionine homozygous at codon 129 (to match the PrP^ sequence in the vCJD brain 
homogenate), was insufficient to establish vCJD prion infection in these cell lines. Therefore, 
it can be concluded that cellular susceptibility to human prions is determined by multiple, as 
yet unidentified, factors (discussed in chapter 4). The transient propagation o f human vCJD 
prions observed in one cell line, the rabbit RK13 line expressing human PrPc, was most likely 
due to its ability to transmit prions intercellularly via exosomes (Fevrier et al., 2004). The 
RK13 cell line highlighted that tumour cell lines are not ideal cellular models due to their 
genetic instability, which may indeed have caused the loss o f their vCJD prion susceptible 
phenotype.
In chapter 4, the mouse PK1 cell line was hypothesised to possess factors required for cellular 
prion propagation because it is permissive to RML and 22L mouse prions (Professor 
C.Weissmann, unpublished data and Klohn et al., 2003). Cellular equivalents o f the vCJD 
prion-susceptible transgenic mouse lines were generated. The inhibitory endogenous murine 
PrPc was knocked out and human PrPc overexpressed in PK1 cells. Nonetheless these cells 
were unable to propagate vCJD prions. This and the fact that the PK1 cell line is not 
permissive to mouse MF7 or hamster prions (Dr P.Klohn, unpublished data), suggested that 
cellular prion propagation factors may be prion strain-specific. Alternatively, human prion 
conversion in cell lines may be less efficient than mouse prion conversion to RML and 22L, 
requiring additional cellular factors.
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Given that vCJD is readily transmitted to both wild-type and human PrPc transgenic mice 
(Asante et al., 2002) but vCJD prion propagation was not achieved in either the human PrPc- 
overexpressing PK1 mouse PrP1 knockout lines or the mammalian tumour cell lines, it can be 
concluded that transmission o f vCJD prion infection to cell lines is much more difficult than to 
mice. Indeed, prion strains behave differently in cells than in animals. This is evidenced by the 
fact prion disease incubation times in mice do not influence cellular prion susceptibility; that 
is, short incubation time prion strains do not infect cells more easily than long incubation time 
strains (Vorberg et al., 2004). Therefore the whole organism appears to provide mechanisms to 
facilitate cellular prion uptake and/or propagation that may not be available in the reductionist 
approach o f cell lines. Such mechanisms may include, first, cleavage of PrP^ by digestive 
enzymes. The protease-resistant PrPSc fragments resulting from enzymatic digestion o f PrP^ 
are thought to form complexes with ferritin which results in their endocytosis into epithelial 
cells thus mediating their transport from gut to lymphoid tissue (Mishra et al., 2004). Second, 
complement component, Clq, has been reported to bind PrP^ and therefore may facilitate its 
uptake into complement receptor-expressing cells, such as follicular dendritic cells (Blanquet- 
Grossard et al., 2005). Third, the long incubation times associated with prion disease (a 
clinically silent phase prior to symptom onset) are critical for prion accumulation in non­
dividing cells, such as follicular dendritic cells and neurones. This time period is not available 
in rapidly dividing cell cultures and therefore could be the reason why they cannot achieve 
high enough prion levels to establish infection.
The experiments described in chapter 5 led to the establishment o f chronic, stable vCJD prion 
propagation in a primary human neuronal culture, derived from a foetal neural stem cell line 
(ReNcell 197VM). This is the first known description o f cellular human prion propagation in 
vitro. The fact that the NSC line, 197, was only susceptible to vCJD prion infection in its 
differentiated neuronal state, strongly suggests a neuronal phenotype is a key determinant of 
cellular prion susceptibility. This work demonstrates that it is essential to recapitulate PrPSc 
processing in vivo most faithfully in order to achieve human prion propagation in vitro. The 
development o f a vCJD prion propagating cell line opens up many avenues of investigation to 
further our knowledge o f human prion neurobiology.
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6.2 Future Work
6.2.1 Further development of the vCJD prion-propagating differentiated 197 
cell line
6.2.1.1 Confirmation of infectivity in vCJD prion-infected 197 differentiated cultures
The chronic presence o f protease-resistant PrP (the surrogate marker for prion infection) in the 
differentiated 197 cultures was shown in chapter 5. However, as is standard for prion- 
propagating cell lines, it would be important to demonstrate that the vCJD prion-infected 197 
cells are producing infectious prions by transmission o f infectivity in v itro  and in vivo. This 
could be done by inoculating cell homogenate prepared from vCJD prion-infected 
differentiated 197 cultures into (1) uninfected differentiated 197 cultures and (2) vCJD prion- 
susceptible mice; Tg45 (which overexpress human PrP 129M four-fold) and SJL (wild-type) 
strains (Asante et al., 2002). PrP-Sc would be detected in the cell cultures by the SCA or 
immunoblotting (Milhavet et al., 2006;Cronier et al., 2004). Since vCJD prion-inoculated mice 
do not always develop clinical signs of disease (Asante et al., 2002), prion transmission from 
197 cultures to mice would be assessed by histopathological examination of brain tissue for 
PrPSt and immunoblotting of brain tissue for type 4 PrP^. It would be important to include 
particle monitor cell homogenate in these experiments to control for infectivity from the 
residual inoculum. In some cases, infectivity from prion-propagating cell lines has been 
demonstrated using cell culture supernatant (Schatzl et al., 1997;Fevrier et al., 2004;Cronier et 
al., 2004). This method may also demonstrate the presence o f infectious prions in the vCJD 
prion-infected 197 cultures and additionally show i f  PrP^ is being released into the culture 
medium (perhaps in exosomes). In order to quantify infectivity in the differentiated 197 model, 
vCJD prion-infected cell homogenate from the cultures would need to be titrated against 
dilutions o f vCJD brain homogenate in either the cellular system or the mouse bioassay.
6.2.1.2 Confirmation of de novo production of PrP^ in the vCJD prion-infected 197 
differentiated cultures
Further evidence of de novo PrP^ production in differentiated 197 cultures could be achieved 
by metabolic radiolabelling o f cellular proteins (using methods similar to those described in 
Schatzl et al., 1997;Follet et al., 2002). After vCJD prion infection o f the differentiated 197 
cultures, cells would be incubated for several hours with methionine-free medium 
supplemented with L-[3 S] methionine to allow incorporation o f radiolabelled methionine into 
newly synthesised proteins. This would be followed by protein extraction from the cells and 
PK digestion o f the material (as described in section 2.6.2) and analysis by SDS-PAGE. Newly 
converted PrPSc in the differentiated 197 cultures would be radiolabelled and visualised by 
autoradiography, clearly distinguishing it from the unlabelled PrPSc in the residual vCJD
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inoculum. Assaying 197 cultures at different time-points post-infection would indicate the rate 
o f cellular PrP^ production during the lifespan o f the cultures.
6.2.1.3 Investigation of susceptibility of differentiated 197 cultures to other human
prion strains
Since vCJD differs in its clinicopathological phenotype to sporadic CJD, it would also be 
useful for basic and therapeutic research to have a cellular model o f sCJD. Therefore, it would 
be important to test i f  the differentiated 197 cells could propagate type 1 and type 2 sCJD 
prions (derived from PRNP codon 129 methionine homozygotes), using the methods described 
in chapter 5.
6.2.2 Human PrP^ cell biology
Since the differentiated 197 cells appear to undergo delayed prion-induced cell death, they 
may closely model the effect o f human prions on neurones during in vivo disease, in which 
progressive neuronal dysfunction precedes cell death.
6.2.2.1 Subcellular localisation of human PrP**
It would be important to determine where PrPSc accumulates in the vCJD prion-infected 197 
cells over time so this could be correlated with changes in biological parameters studied. 
Subcellular localisation o f PrP^ is difficult to assess (Taraboulos et al., 1990;Archer et al.,
2004) because the lack o f a PrP^-specific antibody means pre-treatment o f cells with 
denaturants (formic acid, guanidinium thiocyanate or thermolysin) is required to remove PrPc 
and reveal PrP^ epitopes, but this pre-treatment results in poor immunoreactivity. Previous 
work has suggested that PrPSc is localised at the plasma membrane (Caughey and Raymond, 
1991), in the endolysosomal compartment (Arnold et al., 1995) and in the cytosol (in 
perinuclear structures responsible for clearance of cytoplasmic misfolded protein aggregates 
called aggresomes; Kristiansen et al., 2005). Immunofluorescence staining o f the vCJD prion- 
infected differentiated 197 cells may allow the subcellular localisation of human PrP,Sv 
accumulation to be determined and may provide clues to some fundamental unanswered 
questions in the prion field, such as the site o f PrP1*' conversion and intra-cellular trafficking of 
human PrP^. Confocal analysis o f PrP^-stained cells would determine localisation at the cell 
membrane. It would also demonstrate the proportion of the cells in the culture that become 
infected with vCJD prions. Determining the presence of PrPSc in the endolysosomal 
compartment and in the cytosol could be achieved by dual label immunostaining 
demonstrating co-localisation of PrPSc with the endolysosomal marker (LAMP-1) and 
cytosolic marker (Hsc70), respectively. The presence of PrPSc aggresomes could be established 
by demonstrating colocalisation of PrPSc with vimentin, Hsc70, ubiquitin and 20S proteasome 
subunits.
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6.2.2.2 Study of apoptosis in differentiated 197 cultures
Apoptosis is regarded as the principal mechanism of cell death in prion disease as determined 
by in vivo and in vitro studies (Schatzl et al., 1997;Jamieson et al., 2001 ;Siso et al., 2002;Hetz 
and Soto, 2003;Hetz et al., 2003;Cronier et al., 2004;Kristiansen et al., 2005). The work 
presented in chapter 5 shows that vCJD prion infection o f differentiated 197 cultures resulted 
in a delayed cell death, suggestive o f apoptosis. To confirm this mechanism of cell death, the 
simultaneous presence of several apoptotic markers would need to be assessed in vCJD prion- 
infected differentiated 197 cultures at late stage infection (possibly day 45). Apoptotic cells 
exhibit fragmented nuclei (Oberhammer et al., 1993), the presence of which could be 
determined in the vCJD prion infected 197 cultures by nuclear DNA staining with DAPI (4’,6- 
diamidino-2-phenylindole) and subsequent analysis by fluorescence microscopy. Poly (ADP- 
ribose) polymerase (PARP), a nuclear enzyme involved in DNA repair, is cleaved late in the 
apoptotic cascade by caspase 3. The presence of PARP cleavage products could be assessed in 
the vCJD prion infected 197 cultures by immunoblotting with a specific antibody. Apoptosis 
can be initiated through a number o f different pathways (Thomberry and Lazebnik, 1998) and 
both in vitro and in vivo studies o f prion disease suggest that caspases 3, 8 and 12 are activated 
(Jamieson et al., 2001;Siso et al., 2002;Kristiansen et al., 2005;Hetz et al., 2007). Caspase 8 
mediates cell surface death receptor (Fas-L)-induced pathway o f apoptosis, caspase 12 
mediates ER-stress induced pathway and caspase 3 is a common downstream effector of 
apoptosis. Therefore, the vCJD prion-infected differentiated 197 cultures could be analysed for 
the presence of these activated caspases using in vitro assays specific for each caspase 
(Oncogene) or immunoblotting with specific antibodies.
6.2.2.3 Evaluating ubiquitin-proteasome system dysfunction in differentiated 197 cells
Until recently the cause o f prion-mediated neurodegeneration was not known. As for other 
neurodegenerative diseases, evidence is now emerging to suggest the involvement o f 
ubiquitin-proteasome system (UPS) dysfunction in prion-induced cell death (Ciechanover and 
Brundin, 2003). The UPS is a cellular protein quality control system responsible for the non- 
lysosomal degradation o f short-lived, mutant and misfolded protein and is involved in many 
cellular functions, including transcriptional regulation, cell cycle control and control of 
apoptosis. Evidence for proteasome impairment in prion-infected neurones is observed in 
mouse prion-propagating cell lines. Mild proteasome inhibition of mouse prion-infected 
neuroblastoma cells results in PrPSt aggresome formation, which triggers caspase-dependent 
cell death (Ciechanover and Brundin, 2003). More recently an intracellular neurotoxic 
mechanism of prions has been proposed, in which oligomers of misfolded prion protein impair 
proteasome function by specifically inhibiting catalytic P-subunits o f the 26S proteasome 
(Kristiansen et al., 2007). The vCJD prion-propagating differentiated 197 line will be useful in
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establishing whether proteasome impairment is also a feature o f human prion disease 
pathogenesis and specifically whether the vCJD prions inhibit catalytic P-subunits o f the 26S 
proteasome. Proteasome function could be assessed (as described in Kristiansen et al., 2007) 
using fluorogenic peptide enzyme assays, a proteasome P-subunit activity probe (Berkers et al.,
2005) and a ubiquitinated-GFP-tagged live cell proteasome reporter. Assessment of 
proteasome function over time will allow better understanding of the relationship between 
proteasome dysfunction and neuronal dysfunction following prion infection.
ER stress (caused by accumulation of protein aggregates or excessive protein traffic in the ER) 
has also been implicated in neuronal death in prion disease (Yoo et al., 2002;Hetz et al., 
2003;Hetz et al., 2005;Hetz et al., 2007). ER stress results in the unfolded protein response 
(UPR) involving three signalling pathways that serve to increase folding capacity o f the ER 
and reduce protein load. UPR induced chaperones are found in the cortex o f sCJD and vCJD 
patients and in mouse prion-infected neuroblastoma cells (Yoo et al., 2002;Hetz et al., 2003). 
Whether the involvement o f the ER-stress in prion disease pathogenesis is primary or 
secondary to UPS dysfunction is unclear at present. Inhibition o f the UPS by prions (as 
described in Kristiansen et al., 2007) may contribute to ER stress because the proteasome is 
essential for normal ER-associated degradation (ERAD) o f protein. Therefore, misfolded 
proteins destined for degradation by ERAD may remain in the ER. Alternatively, prion 
infection may directly result in ER stress, the latter o f which is thought to inhibit proteasome 
dysfunction (Menendez-Benito et al., 2005). ER stress can be assessed (as described in Hetz et 
al., 2007) by the detection o f upregulated genes involved in UPR, UPR chaperones and 
markers o f ER stress-induced cell death, such as the transcription factor GADDI 53/CHOP and 
activated caspase-12. A time-course experiment measuring both proteasome function and ER 
stress markers in the vCJD prion-infected 197 cells would clarify the relationship between 
these two cellular pathways and their contribution to neuronal pathogenesis in human prion 
disease.
6.2.2.4 The effect of vCJD prion infection on synaptic function
Electroencephalogram (EEG) abnormalities are a common feature of human prion diseases and 
synaptic dysfunction is believed to be an early pathological event during prion infection 
(Cathala and Baron, 1987). Since uninfected 197 neurones have the capacity to generate action 
potentials (Dr Roberta Donato, UCL, unpublished work), these cells represent a unique system 
on which to study human neurophysiological changes in response to human prion infection, 
prior to neuronal death. Electrophysiology data from hippocampal and cortical neurones from 
scrapie-infected animals, suggest that prion infection increases neuronal membrane excitability 
as a result o f reduced potassium conductances (Jefferys et al., 1994;Johnston et al., 
1997;Johnston et al., 1998). Changes in membrane excitability in the vCJD prion-infected 197
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neurones could be determined by measuring resting membrane potential, action potential 
threshold and amplitude. The use of the non-specific potassium channel antagonist, 
tetraethylammonium (TEA) would determine if  membrane potential changes were due to 
potassium conductances (as described in Johnston et al., 1998)). Both prion-infected and PrPc 
knock-out mice exhibit significantly reduced long slow afterhyperpolarisation potentials 
(AHP) (Colling et al., 1996;Johnston et al., 1998;Barrow et al., 1999;Mallucci et al., 2002), 
which are responsible for preventing repetitive action potential firing and are mediated by 
TEA-insensitive calcium-activated potassium channels. Therefore, loss of the long slow AHP 
could be demonstrated in vCJD prion-infected 197 neurones by repetitive firing o f calcium 
spikes in response to a long depolarising current pulse, which would not be inhibited by TEA. 
The levels o f synaptic proteins, including syntaxin 1 A, SNAP-25, synaptobrevin, synapsin and 
synaptophysin, could also be studied by quantitative immunoblotting of infected and 
uninfected cells to assess prion-induced changes in synaptic function.
Prion infection causes a number o f changes in neuronal morphology. Prior to neuronal loss, 
synaptic loss and axonal degeneration are observed in scrapie-infected mouse models (Jeffrey 
et al., 2000). Furthermore, increased branching o f basal dendrites has been detected in 
hippocampal CA1 pyramidal cells (Barrow et al., 1999). Therefore, it would be interesting to 
study the ultrastructure o f vCJD prion-infected 197 neurones using transmission electron 
microscopy (described in 2.9). Alterations in neurite morphology (neurite length and 
branches), number o f synapses formed, vesicle trafficking and evidence o f axonal degeneration 
and neuronal vacuolation could all be assessed. The Cellomics™ Arrayscan robotic 
fluorescence microscope may also be useful for these experiments because it can directly 
quantify cell body morphology, neurite length and branching using their neurite outgrowth 
assay.
6.2.3 Screening potential therapeutics for human prion disease
Prion diseases remain incurable and the screening o f potential therapeutics for prion disease 
has been performed on in vivo and in vitro experimental models of non-human prions. 
Therefore, the results of these studies may not be relevant for the treatment o f human prion 
disease. The human vCJD prion-propagating neuronal 197 line represents a physiologically 
more relevant model on which to specifically assay compounds for potential therapeutic effect 
in vCJD. The vCJD prion-infected cell line would need to be developed for use in a high- 
throughput screening assay. The MRC Prion Unit has a collaboration with GlaxoSmithKline to 
screen the GSK compound library for anti-prion activity. It is anticipated that the human cell 
line will form part o f a tertiary screen to assess 100 potential vCJD therapies.
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1 Appendix - Neural stem cell culture
1.1 Neural stem cell culture medium (500 ml)
483.5 ml DMEM/F12
10 ml 50x B27
5 ml L-Glutamine (200 mM)
lm l Heparin sodium mucous (5000 I.U/ml; CP Pharmaceuticals Ltd.)
0.5 ml Gentamycin (50 mg/ml)
1.2 Growth factors
1.2.1 Epidermal growth factor (EGF; Sigma): 10 pg/ml stock recipe
Aseptically reconstitute 0.2 mg EGF powder with 20 ml filter-sterilised lOmM acetic acid, 
containing 0.1% human serum albumin (HSA; Sigma). Store aliquots at -20°C for 3 
months. Store defrosted aliquots at 4°C for 2 weeks. Use at 20 ng/ml final concentration.
1.2.2 Basic fibroblast growth factor (bFGF; Peprotech): 10 pg/ml stock recipe
Aseptically reconstitute 25 pg bFGF powder in 2.5 ml DMEM/F12 containing 0.1% HSA. 
Store aliquots at -20°C for 3 months. Store defrosted aliquots at 4°C for 2 weeks. Use at 
10 ng/ml final concentration.
1.3 Trituration solution (100ml)
55 mg soybean trypsin inhibitor (Sigma)
3.3 ml 30% HSA (Sigma)
96.7 ml DMEM/F12
Sterilise by passing through 0.2 pm filter
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2 Appendix - Bacterial culture 
2.1 Luria Bertani (LB) medium (1L)
Tryptone lOg
Yeast Extract 5g
NaCl lOg
Gently shake the above ingredients and add
5N NaOH 0.2ml to adjust to pH7
Add ddH20 to a final volume o f 1L (in 2L tlask)
Very briefly and gently stir (at setting 1 on magnetic stirrer) 
Sterilise by autoclaving at 121 °C
2.2 LB agar (1L)
Tryptone lOg
Yeast Extract 5g
NaCl lOg
5N NaOH 0.2ml
Bactoagar 15g
Adjust to 1L with d d ^ O  in a 2L flask
Very briefly and gently stir (at setting 1 on magnetic stirrer)
Autoclave at 121 °C
Put in oven @ 55-60°C to cool but not set 
Add 100 pg/ml ampicillin 
Pour into petri dishes
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3 Appendix - Buffers
3.1 2x SDS-PAGE sample buffer
125mM Tris-HCl
20% (v/v) glycerol
4% SDS
0.025% (w/v) bromophenol blue 
pH 6.8
3.2 Deglycosylation buffer
4m M AEBSF
1.25% Nonidet -P40
Made up in sodium phosphate buffer, pH7 (see appendix 33)
3.3 Sodium phosphate buffer
50mM Na2HP04,
ImM EDTA
pH7
3.4 SDS-PAGE running buffer (National Diagnostics)
25 mM Tris-HCl pH 8.0
192 mM glycine
0.1% SDS
3.5 Electroblotting buffer (National Diagnostics)
25 mM Tris-HCl pH 8.0
192 mM glycine
20% methanol
3.6 TBST
10 mM Tris-HCl, pH 8.0
150 mM NaCl
0.1% Tween 20
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3.7 PBST
lx
0.05%
PBS
Tween 20
3.8 Tropix assay buffer
20mM 
ImM 
pH 9.8
3.9 Lysis buffer
50 mM 
150 mM
0.5%
0.5%
Tris-HCl
MgCl2
Tris.HCl, pH 8 
NaCl
Na deoxycholate 
Triton X-100
Sterilise by passing through a 0.2pm filter for treatment o f brain homogenate prior to cell 
infection
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4 Appendix - Plasmid vectors
4.1 Human PrP expression vectors
Restriction sites used to clone the human PrP ORF into pCDNA 3.1 (A) and pLNCX2 (B) 
are shown in red.
BGHpA
— -PCMV f1 orf
SV40orl
pCDNA3.1(+)
5428 bpAmpicillin
SV40pA
pUC ori
B 5' LTR
AMPr
pLNCX2
6.1 kb
Col E1G418r
PCMVIE r  | 3' LTR
MCS
2926 2936 2946 2956 2966 2976 2986 2996
AGATCTCGAGCTCAAGCTTGTTTGGCCGAGGCGGCCGCTTGTCGACAGGCCTTAATGGCCTAACATCGATA
Xhol Hind III S/i I Sal Sh\ C!a I
Bgl II Not I Stu I
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4.2 siRNA retroviral expression vectors
Restriction sites used to clone shRNA into pSuper.retro (A) and pMSCV (B) are shown in 
red.
pUC ori
5 ’LTR
pSUPER.retro
7195 bp
H1 P ro m o te r
Hind III
Bgl II
5 ’ LTR
A M P r
pMSCV.hyg
6.3 kb
Col E1 
ori
H ygror
3 ’ LTR
1410 1420 1430
*  *  *
AGATCTCTCGAGGTTAACGAATTC
Bgl II Xho I Hpa I EcoR I
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5 Human PRNP primers
Human PRNP DNA and amino acid sequence are shown; forward primers are shown by red 
arrows and reverse primers in blue arrows. For PCR amplification o f genomic human PRNP, 
primers outside the open reading frame, 106 and 46 were used. Primers 3, 10, 122, 33 and 125 
were used for sequencing.
i t t T O A T A C C A T T O C T A T O C A C T C A T T■ ■ ■ ■ I . ■ ■' ----106 103
C A J T A T O C A G  A A A C A T T T A O T A A T T T C  A A C A T A A A T A T < ^< 5 A C T C  TG A C  T T C T C C T C T T<£A‘
10 20
A T O OCG A A C C T T OOC TO C TGG
M e t
1
A l a A s n L e u
7 0
G l y
S
C y s T r p
8 0
TO C A A O AAG CGC CCG A AO
L e u C y s L y s L y s
1 3 0
A?-g
25
P r o L y s
1 4 0
C A P o o c A Q C C C T GGA GGC A AC
G i n G l y S e r t * r o  G l y
45
G l y A s n
1 9 0 2 0 0
C A T P O T G OT QGC TGG OGG CAG
H i s G l y G l y  G l y  T r p
65
G l y G in
2 5 0 2 6 0
TG G OGG CAG C C T C A T G OT OGT
T r p G l y
10
G i n P r o
3 1 0
H is
85
G l y G l y
3 2 0
A AG _ c c p A G T AAG CC A  A A A AC C
L y s P?t> S e r L y s
3 7 0
P r o
105
L y s T h r
3 8 0
Q T O ,O T Q GOG QGC C T T GOC
V a l V a l G i y G l y  L e u  G l y  G l y
125
3 0
10
90
30
150
50
210
70
270
90
40
100
160
220
.TTTTG C A G AG C A G  T C A T T
50 «0
T r p 5 A s p
110
35
55
170
230
3 l y20
120
40
18C
60
240
75
280
r ^ A S S L
80
290 3 0C
A P T  CAQ TQ Q  A A C
95 100
330 340 350 360
A A C  A T O  A A G  C A C  AT ^  G O T O G T O C T  O C A  O CA O C T  OOP O CA
390
4 3 0
T T C  QOC A P T
P h e  G l y  S e r  A s p  T y r
a y  T A T  Q A O g A C _ C O T
 G l u  A s p  A r g  T y r
400 410 420
A T O  AQ C AG O  CCC A T C  A T A  C A T
r  A l a  M e t  S e r  A r g  P r o  l i e  l i e  H i s
135 140
460 470 480
A T O  C A C  C O T  TA G  CCC A A C  C A A
s n  M e t  H i s  A r g  T y r  P r o  A s n  G in
145 150 155 160
4 9 0 5 00 510 520 530 540
O TG T A C T A C AGG CCC A TG O A T GAG T A C A Q C  A AC CAG A A C  A A C t t t ; , g t g C A C  OAC TO C  O TC
V a l T y r T y r A r g P r o M e t A S P G lu T y r S e r  A s n G i n  A s n  A s n P h e  V a l H i s  A s p  C y s V a l
165 170 175 180
5 5 0 560 570 580 590 600
A A T A C A A T C A AG CAG CA C A CG O TC A C C  A C A A C C A C C  A AG GGG GAG A A C  T T C  ACC GAG
A s n l i e  T h r l i e L y s G in H i s T h r V a l T h r  T h r T h r T h r  L y s G l y  G l u  A s n  P h e  T h r G lu
185 190 195 200
6 1 0 6 2 0 630 640 650 660
A C C OAC O T T A AG A TG A TG GAG CGC G TG O T T  GAG C A G A T G  T O T A T C  A C C C AG  T A C ,Q A O AGG
T h r A s p V a l L y s M e t M e t G lu A r g V a l V a l  G lu G i n M e t  C y s l i e  T h r  G in  T y r  G lu A r g
205 210 215 220
6 7 0 6 80 690 700 710 720
G A A T C T CAG GCC T A T T A C CAG A G A GGA T C G  AGO a t g s .O TC C T C T T C  TC C T C T  C C A  C C T
G l u S e r X X X A l a T y r T y r G in X X X G l y S e r  S e r M e t V a l  f f e u P h e  S e r S e r  P r o  P r o V a l,w
225 230 235 240
7 3 0 7 4 0 750 760
A T C C T C CTO A TC T C T T T C C TC A T C T T C C TO  A T A G TG G GA T G A G G A A Q G TC TTC C T C TTTTC A C C A TC T TTC
l i e L e u L e u H e S e r P h e L e u l i e P h e L e u  l i e V a l G l y  E n d
245 250 253
2 T C T T T C T T C T C T C T T T G
TCC CQ G A'iTA Q O C TA A TC A A TA C C C TT O Q C A C TQ A TO O O C A C TQ G A A A A C A TA Q AO TA G AC C TO AQ A TQ C TO Q TC A AG C C
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6 Transmissibilitv of vCJD inoculum (12811) to wild-type SJL mice
Brain section from mouse (SJL strain) infected with 1% 12811 vCJD inoculum 360 days post­
infection.
A Haematoxylin and eosin staining 
B GFAP staining demonstrating widespread gliosis
C Anti-PrP monoclonal antibody (ICSM35) staining demonstrating diffuse PrP^ staining
2 mm
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7 Human PRNP ORF  sequence
Example electropherogram o f  human PRNP ORF construct to demonstrate no
mutations and methionine homozygosity at codon 129 (red box).
n *
m k i m h  h M t l i l
, a a w- ito
t k i t  M k ^ ' f c i  /
<n J tf' *» o t a t
i f a  .iiu
a t  m  r t  *  *a at ; sa as at
m  m  m  *a oo MC «■ «4C <W
fyw?- /iVTfiCTcsx:^ . V  X M
« at SH Ol W MO »•  ^ « «0
JCTA
Codon 129 Met
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